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Abstract
Purinergic P2X7 receptors are ligand-gated ion channels characterized by 
the formation of a membrane pore upon continuous activation. This 
receptor has been shown to be expressed and functional in osteoclasts. 
P2X7 receptor knockout mice studies suggested that this receptor has a 
role in bone formation. The aim of this project was to characterise the 
expression and function of P2X7 receptors in human osteoblasts and to 
investigate the modulation of P2X7 receptor expression and function by 
oestrogen and glucocorticoids. Reverse transcriptase-polymerase chain 
reaction (RT-PCR) and Western blotting were used to study P2X7 
receptor expression at the mRNA and protein levels, respectively. P2X7 
receptor pharmacology was studied using pore formation and YO-PRO 1 
influx in the presence of different agonists and antagonists. The effects of 
P2X7 receptor activation on physiological aspects of osteoblast function, 
namely alkaline phosphatase (ALP) production, interleukin-6  (IL-6 ) and 
IL-lp release and mineralisation, were also studied.
The general findings are:
• Human osteoblasts (cell lines and primary cells) express 
functional P2X7 receptors with higher expression seen in primary 
cells.
• P2X7 receptor protein is expressed in all the osteoblast-like cell 
line samples used (lysate, nuclei, and membranes).
• The functional form of the P2X7 receptor protein appears to 
correspond to the 67 kDa band and not the 85 kDa band as 
suggested by the Western blotting results.
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• The pharmacology of P2X7 receptors in human osteoblasts is 
atypical as evinced by the low affinity of the agonist, benzoyl- 
benzoyl-adenosine triphosphate (DBzATP) and the weak action of 
the antagonists, KN62 and brilliant blue-G (BBG).
•  17p-oestradiol and dexamethasone modulate P2X7 receptor 
function probably by a non-classical, non-genomic mechanism.
•  ALP production and IL-6  release are increased by P2X7 receptor 
activation.
• P2X7 receptor activation appears to decrease mineralisation in 
primary human osteoblasts.
•  In addition to P2X7 receptors, human osteoblasts express P2 X4 
and P2X5 receptors.
These findings suggest that P2X7 receptors play an important role in 
osteoblast bone formation and in osteoblast-osteoclast signalling. 
Targeting P2X7 receptors is a novel approach for the treatment of 
conditions such as osteoporosis and rheumatoid arthritis. However, 
further research is needed to develop selective agonists and antagonists.
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Chapter 1: General 
Introduction
P2X7 Receptors in Osteoblasts
1.1 Adenosine triphosphate
Adenosine triphosphate (ATP) is synthesized in the mitochondria from 
adenosine diphosphate (ADP) and inorganic phosphate under the 
influence of ATP synthase (Schon et al., 2001). ATP synthase consists of 
two segments, F0 and F x (Pedersen et al., 2000; Schon et al., 2001; Senior 
et al., 2002), where the former consists o f at least 7 subunits and the 
latter consists o f 6  subunits (Schon et al., 2001). The F0 segment is found 
in the mitochondrial inner membrane and is responsible for proton 
transport from the intermembrane spaces to the mitochondrial matrix 
(Schon et al., 2001; Senior et al., 2002). The Fi segment is found in the 
matrix and utilizes the protons transported by the F0 segment to convert 
ADP to ATP (Schon et al., 2001). The exact detail of ATP synthesis is 
still not clear, but it is believed to be complicated and involve 
conformational changes and/or rotations of different subunits of ATP 
synthase (Pedersen et al., 2000; Schon et al., 2001; Senior et al., 2002). It 
has been suggested that the pathway of ATP synthesis and hydrolysis is 
common (Pedersen et al., 2000; Schon et al., 2001; Senior et al., 2002; 
Weber and Senior, 2003) and that the Fj segment is responsible for the 
hydrolysis (Pedersen et al., 2000; Weber and Senior, 2003).
The relationship between the different purinergic receptors arises from 
the relationship between their natural ligands such as ATP, which is 
metabolized by ectoenzymes to ADP, then to adenosine monophosphate 
(AMP), and finally to adenosine which is taken up by the cell to 
resynthesize ATP (Lazarowski et al., 2003; Schwiebert and Zsembery, 
2003; B outs et al., 2006) as shown in Figure 1.1.
Due to the role of ATP as the intracellular energy source, it is believed to 
be available in every cell (Bours et al., 2006). The intracellular ATP
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concentration is approximately 3-10 mM, but the extracellular 
concentration is much lower (Schwiebert and Zsembery, 2003; Bours et 
al., 2006). Normal ATP concentrations in the plasma have been reported 
to be 400-700 nM (Bours et al., 2006). Large amounts of ATP are 
released non-lytically (Pellegatti et al., 2005; Ferrari et al., 2006) 
possibly by ATP-binding cassette (ABC) transporters (Schwiebert and 
Zsembery, 2003; Gallagher, 2004). Another pathway of ATP release is 
believed to be by cell lysis following cell injury (Gartland et al., 2003a; 
Ferrari et al., 2006) which causes its release in very high concentrations 
(1-5 mM) resulting in cell apoptosis (Gartland et al., 2003a). In 
osteoblasts intracellular ATP concentration has been reported to be 
approximately 3-5 mM (Gallagher and Buckley, 2002).
Extracellular ATP has been implicated in many functions including 
immunity and inflammation (Bours et al., 2006), as a neurotransmitter 
(Cunha and Ribeiro, 2000; Khakh and North, 2006; Bumstock, 2006b) 
and as a co-neurotransmitter with many other neurotransmitters (Cunha 
and Ribeiro, 2000; Bumstock, 2006b). The modulatory action of ATP on 
inflammatory and immune processes is believed to involve many 
immune cells such as neutrophils, monocytes and macrophages and non- 
immune cells (Bours et al., 2006). The ATP metabolite, adenosine, is 
believed to have similar effects to ATP on inflammatory and immune 
processes (Bours et al., 2006). In the heart, ATP was found to have a 
positive inotropic effect and induced various types of arrhythmias when 
applied rapidly to cells (Vassort, 2001). In epithelial cells, ATP has been 
shown to have many physiological effects. An example of this is in the 
lung, where ATP was found to increase the release of chloride in cystic 
fibrosis patients, which made purinergic receptors a potential approach 
for cystic fibrosis therapy (Schwiebert and Zsembery, 2003). In the ear, 
ATP was found to regulate hearing sensitivity and development and was
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implicated in the treatment o f  Meniere’s disease and tinnitus (Bumstock, 
2006b).
ADP UOP ADO
UMP URID INOS
ATP UTP UDP-glu
receptor
activation
P2Y& PI
nucleotide
release
A
* hydrolysis
e x t r a c e l lu a r
A
ATP
UTP
UDP-sugars
CMPMM
E-NTDPase E-NPP
Figure 1.1: Cellular release and fate of nucleotides
A diagram showing the cellular release of nucleotides, their metabolism, and their 
receptors. Nucleotides are believed to be released via lytical or non-lytical mechanism. 
ATP, UTP, and UDP-sugar stimulate P2Y receptors and ATP stimulates P2X 
receptors. E-NTPDases degrade nucleotides tri-phosphate (NTPs) to nucleotides di­
phosphate (NDPs), and then to nucleotides mono-phosphate (NMPs). Adenosine, 
which is produced from ATP, stimulates adenosine receptors. ADO, adenosine; E- 
NTPDases Ecto-Nucleotidase 5’-Triphosphate Diphosphohydrolase; E-NPP, Ecto- 
phosphodiesterase / Nucleotide Pyrophosphate; UDP-glu, UDP-glucose; URID, 
uridine; INOS, inosine. Adapted from Lazarowski, et al (2003).
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1.2 History of purineraic receptors
The physiological actions of ATP were discovered as early as 1929, 
when ATP and adenosine were found to have an effect on the heart and 
coronary blood vessels (Drury and Szent-Gyorgyi, 1929). The idea of 
ATP as a neurotransmitter started when acetylcholine and noradrenaline 
responses in the smooth muscle of the guinea pig taenia were blocked. 
This block did not cause the expected contractions, but relaxation 
occurred, which led to the conclusion that a non-adrenergic, non- 
cholinergic (NANC) neurotransmitter must be involved (Bumstock et al., 
1963). This NANC neurotransmitter was also reported in cat stomach 
(Martinson and Muren, 1963). After many experiments in a variety of 
animal organs, the NANC neurotransmitter was suggested to be ATP 
(Bumstock et al., 1970). For many years acceptance of ATP as a 
neurotransmitter was met with resistance, although there was very strong 
evidence that this was one of its modes of action (Bumstock, 2006b). 
This resistance was due to the fact that ATP is involved in intracellular 
biochemical processes, and was thought unlikely to have an extracellular 
role (Bumstock, 2007). In addition to acting as a neurotransmitter, ATP 
was suggested to act as a co-neurotransmitter in sympathetic and 
parasympathetic nerves (Bumstock, 1976; Sneddon and Bumstock, 
1984; Cunha and Ribeiro, 2000; Bumstock, 2006b). The proportion of 
ATP and noradrenaline or acetylcholine was found to be tissue- and 
species-dependent (Bumstock, 2006b). ATP was reported to act as a co­
neurotransmitter with many other neurotransmitters including, 5- 
hydroxytryptamine, glutamate, dopamine, and y-aminobutyric acid 
(GABA) (Cunha and Ribeiro, 2000; Bumstock, 2006b).
In 1978 the first description of purinergic receptors and their subdivision 
into two main classes, PI and P2 activated by adenosine and ATP,
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respectively was published (Bumstock, 1978) and then the two P2 
subtypes, X and Y were distinguished (Bumstock and Kennedy, 1985). 
However, distinction of the different purinergic receptors was originally 
based on their pharmacological properties (Bumstock, 2006b). An 
important stage in the history of purinergic receptors was the cloning of 
P2X receptors which occurred in the mid 1990s (Gever et al., 2006). The 
first P2X receptor complementary deoxyribonucleic acid (cDNA) cloned 
was in 1994 (Valera et al., 1994), the P2X4 receptor cDNA in 1996 
(Wang et al., 1996), and the P2X7 receptor cDNA later in 1996 
(Suprenant et al., 1996). Cloning of some of the P2Y members occurred 
in the 1990s (Webb et al., 1993; Tokuyama et al., 1995) and others in the 
early 2000s (Zambon et al., 2000; Zambon et al., 2001). Figure 1.2 
shows the most important stages in the discovery of P2X receptors.
The P2X7 receptor was formerly known as P2Z since it was thought to 
belong to a different family than the P2X (Suprenant et al., 1996). This 
was based mainly on the characteristic pore formation (discussed later in 
Chapter 4) observed first with this receptor and later with other P2X 
receptors namely P2X2 and P2X* (Di Virgilio, 1995).
Nowadays, research is concentrating on the production of more potent 
and selective purinergic agonists and antagonists for effective and safe 
use in humans. For example P2X receptor antagonists are in different 
stages of research in a variety of areas (Stokes et al., 2006; Donnelly- 
Roberts and Jarvis, 2007; King, 2007) such as analgesics (Donnelly- 
Roberts and Jarvis, 2007; King, 2007).
The Al and A2 adenosine (originally called PI) receptors were first 
described in 1979 based on their pharmacology (Van Calker et al., 1979). 
Adenosine receptors were cloned in the late 1980s and early 1990s
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(Ralevic and Bumstock, 1998). For example, the A2a adenosine receptor 
cDNA was cloned in 1989 (Libert et al., 1989) and the Aj adenosine 
receptor cDNA in 1991 (Mahan et al., 1991).
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1.3 P2X Receptors
There are seven purinergic P2X receptors (P2X] -  P2X7) and all are 
ionotropic ligand-gated ion channels (Bumstock, 2007). They are 26 to 
47 % identical in their amino acid sequence and their sizes range from 
379 (P2X*) to 595 amino acids (P2X7) (Khakh et al., 2001b). 
Additionally, the P2X receptor amino acid sequence is species-dependent 
(North and Suprenant, 2000a; Young et al., 2007). The species homology 
is quite variable between the different P2X receptors ranging from 79.7 
% (P2X7 receptor) to 95.6 % (P2 X3 receptor) between human and rat 
(North and Suprenant, 2000a).
Each member of the P2X receptor family consists o f two hydrophobic 
transmembrane domains (TM) (Figure 1.3) attached together by a 
cysteine-rich (about 270 amino acids) hydrophilic extracellular loop. 
This loop contains two disulfide bridges and three N-linked glycosyl 
chains (Bumstock, 2002). The N and C-termini are located intracellularly 
and the length of the C-terminus differs widely between the P2X family 
members; 242 amino acids for the P2X7 receptor, but only 28 amino 
acids for the P2X$ receptor. The length o f the N-terminus is similar for 
all the members and consists o f 28 -  30 amino acids. While other 
ionotropic receptors such as cholinergic and serotonergic receptors 
contain 3 or 4 transmembrane domains, P2X receptors are unique in 
having only 2 (Egan et al., 2004).
The location and identity of the ATP binding site is debatable. However, 
the ATP binding site in P2X receptors is believed to be in the 
extracellular loop adjacent to TM1 and TM2 (Bumstock, 2004; Egan et 
al., 2004; Bumstock, 2007). This ATP binding site could be a positive
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charge loci in the extracellular loop attracting the negative charge o f  the 
phosphate group o f  the agonists (Egan et al., 2004).
cysteine-rich 
loop
ATP
Figure 1.3: General Topology of the P2X receptors
Illustration describing the general topology of P2X receptors showing the N- and C- 
termini, two transmembrane domains attached together by a cysteine-rich (270 amino 
acids) hydrophilic extracellular loop containing disulfide bridges and three N-linked 
glycosyl chains. Adapted from Khakh, et al (2001a) and Bumstock (2002). The ligand 
binding site is believed to be in the extracellular loop adjacent to TM1 and TM2 
(Bumstock, 2004; Egan et al., 2004; Bumstock, 2007).
Although all the P2X receptors show non-selective permeability to small 
cations such as sodium and potassium, som e o f  them have considerable 
permeability to calcium. This feature is more pronounced if  the receptor
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is activated repeatedly or for a prolonged time as is the case with the 
P2 X7 receptor as it becomes permeable to large molecules as big as 900 
Dalton (D) on repetitive activation (North, 2002).
The response of the P2X family members to their natural ligand ATP 
varies widely. While P2Xj and P2X3 receptors have high affinity (EC50 
value: 1 pM), the P2 X2, P2X*, P2 X5, and P2X* receptors have lower 
affinity (EC50 value 10 pM). The P2X7 receptor has a very low affinity 
for ATP (EC50 value 300 pM) (North and Barnard, 1997).
Some P2X receptors such as the P2X2, P2X^ and P2X7 are characterized 
by the effect of monovalent and/or divalent ions on their function. 
Virginio et al (1997) studied the effect of divalent cations (Ca2+, Mg2+, 
Zn2+, and Cu2+) and protons on rat P2X7 receptor function activated by 
2’,3’-0-(4-benzoy 1-benzoyl)-ATP (DBzATP). In this study it was found 
that divalent cations and protons inhibited P2X7 receptor function as 
tested by whole-cell currents and Quinolinium 4-[(3-methyl-2(3H)- 
benzoxazolylidene)methyl]-l-[3-(trimethylammonio) propyl]- diiodide 
(YO-PRO 1) uptake. The order of potency of divalent cations in 
inhibiting P2X7 receptor function was reported to be: Cu2+> Cd2+= Zn2+> 
Ni2+»  Mg2+= Co2+> Mn2+> Ca2+> Ba2+»  Sr2^ Virginio et al., 1997). 
Michel et al (1999) have shown that the response of the P2X7 receptor to 
the agonists ATP and DBzATP was decreased by monovalent and 
divalent cations (Mg2+, Ca2+, Cu2+, and Na+), monovalent anions (Cl ), 
and by changes in pH (Michel et al., 1999). Xiong et al (1999) found that 
Cu2+ and Zn2+ increased ATP-induced currents mediated by P2X2 and 
P2 X4 receptors (Xiong et al., 1999).
One possible explanation for the inhibitory effect of divalent cations on 
P2X receptor activation by agonists such as ATP and DBzATP may be
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that these compounds bind the divalent cations leading to decreased or 
abolished activity of the agonists (Michel et al., 1999). However, this 
may not be correct as Xiong et al (1999) reported that ATP-induced 
currents mediated by P2X2 and P2 X4 receptors increased in the presence
2“F 2"Fof Cu and Zn . Another suggested explanation is that these cations 
have a direct modulatory effect on P2X receptors (Virginio et al., 1997).
Many P2X receptor heteromultimers have been recognised. Examples 
are P2 Xi/2, P2Xi/4, P2Xi/5, P2X2/3, P2 X2/6, and P2X4/6, and it has been 
suggested that these cause the difference in the observed P2X 
pharmacology between transfected and native cells (Bumstock, 2007). 
One of the extensively studied P2X heteromultimers is the P2X2/3 (Ueno 
et al., 1998; Koshimizu et al., 2002) and it has been found to have some 
of the properties of the P2X2 receptor and other properties of the P2X3 
receptor (North, 2002). For example, it was found that the P2X2/3 
receptor is activated by aPmeATP, a property contributed by the P2X3 
subunit, and potentiated by low pH, a property contributed by the P2X2 
subunit (North and Suprenant, 2000a). The P2X2/3 receptor was reported 
to be expressed by some neurons and sympathetic ganglion cells (North, 
2002; Bumstock, 2007). The P2X$ receptor exists only in a 
heteromultimeric form (Bumstock, 2004; Egan et al., 2004; Jacobson et 
al., 2004; Bumstock, 2007). P2X7 receptors were believed not to form 
heteromultimers (Bumstock, 2004; Egan et al., 2004; Jacobson et al., 
2004; Bumstock, 2007) but a recent study reported that P2X7 and P2X» 
receptors might form heteromultimers together (Guo et al., 2007).
P2X receptors are widely distributed and are expressed by many body 
tissues such as neurons, muscles, bones, and epithelia (North, 2002). For 
example, neurons were found to express P2X2, P2X3 and P2 X4 receptors 
(North, 2002; Bumstock, 2007), while smooth muscles were found to
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express P2Xi and P2 X2 receptors (Bumstock, 2007). Heart was found to 
express P2Xi, P2X2, P2X* and P2X5 receptors, while P2 X7 receptor was 
implicated in airway epithelium and salivary glands (North, 2002). The 
distribution and physiological function o f purinergic receptor in bone 
cells will be discussed later in this introduction (Section 1.7).
1.4 P2X7 Receptor
The P2X7 receptor is the largest member of this family (595 amino acids) 
and has the longest C-terminus (242 amino acids) (Khakh, 2001a). It is 
39.2 to 49.8 % identical in its amino acid sequence with other P2X 
receptors (North, 2002). Differences in the P2X7 receptor amino acid 
sequence were observed between different species, where for example 
human and rat receptors have a 79.7 % identical amino acid sequence 
(North and Suprenant, 2000a). This was suggested as an explanation for 
the differences in response to agonists and antagonists between different 
species (Young et al., 2007).
An important characteristic of the P2X7 receptor is the formation of a 
non-selective pore in the cell membrane permeable to molecules as large 
as 900 D after prolonged activation. The characteristics of this P2X7 
receptor pore formation and its physiological effects are discussed in 
detail in Chapters 4 and 5. The P2X7 receptor has been described as a 
death receptor, because cell death by either necrosis or apoptosis 
resulting from its stimulation has been reported in many studies (Di 
Virgilio et al., 1998; Sluyter and Wiley, 2002; Wang et al., 2004a). This 
cell death was found to have the characteristics of both necrosis and 
apoptosis, therefore it is sometimes called “aponecrosis” (Elliott et al.,
2005).
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The P2X7 receptor has been found to play an important role in immune 
and inflammatory responses (Di Virgilio et al., 2001; Bours et al., 2006). 
An important effect of P2X7 receptors on inflammatory process is on 
cytokine release (Di Virgilio et al., 2001; Bulanova et al., 2005; Bours et 
al., 2006; Hughes et al., 2007). The P2X7 receptor was described as the 
cytokine release pore (Ferrari et al., 1997), because its stimulation 
induced the release of many cytokines such as interleukin (IL)-lp, IL-4, 
IL-6 , IL-13, and tumour necrosis factor-a (TNF-a) (Ferrari et al., 1997; 
Bulanova et al., 2005; Di Virgilio, 2007; Hughes et al., 2007; Qu et al., 
2007).
1.4.1 P2Xt receptor agonists
Although ATP is the natural ligand of the P2X receptors, and is the most 
potent o f the nucleotide tri-phosphates (NTPs), the response of the P2X7 
receptor to it is very weak (EC5o= 300 pM) (King and Townsend- 
Nicholson, 2003). In fact DBzATP was reported to be the most potent 
P2X7 agonist (EC5o= 3 pM) (North and Suprenant, 2000a). In addition to 
P2X7 receptors, other P2X receptors are also activated by DBzATP 
namely P2Xj, P2 X2, and P2 X5, with EC50 values of: 3, 30, and >300 pM, 
respectively. As mentioned earlier the presence o f extracellular divalent 
cations affects the activity of the agonists, which makes comparisons of 
agonist potencies between studies difficult (North and Suprenant, 
2 0 0 0 b).
ADP, adenosine 5 !-0-(3-thiotriphosphate) (ATPyS), and 2-methylthio- 
adenosine 5'-triphosphate tetrasodium salt (2Me-S-ATP) when tested 
were found to be less effective compared to ATP, while adenosine, 
apmeATP, pyMethylene adenosine triphosphate (pymeATP), and uridine
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triphosphate (UTP) were found to be ineffective at 300-1000 pM (North 
and Suprenant, 2000b).
1.4.2 P2X^receptor antagonists
One of the most important difficulties in studying the P2X7 receptor is 
the lack of selective antagonists. Many antagonists have been studied, 
but none were found to be selective (North and Suprenant, 2000a). 
Divalent cations such as Ca2+, Mg2+, Zn2+, and Cu2+ were found to have 
an inhibitory effect on P2X7 receptor agonists and hence were regarded 
as blockers (North, 2002).
The suramin analogue, 8,8'-(cari>onylbis(imino-4,l-
phenylenecarbonylimino-4,l-phenylenecarbonylimino)) bis (1,3,5- 
naphthalenetrisulfonic acid) (NF279) was reported to be a highly 
effective antagonist against the human P2Xj receptor, but has moderate 
potency at human P2X7 receptors with IC50 values o f 0.05 pM and 2.8 
pM, respectively (Klapperstuck et al., 2000).
Pyridoxal phosphate-6-azo(benzene-2,4-disulfonic acid) tetrasodium salt 
hydrate (PPADS) and 4-[(2S)-2-[(5-isoquinolinylsulfonyl)methylamino]- 
3-oxo- 3-(4-phenyl-l-piperazinyl)propyl] phenyl isoquinolinesulfonic 
acid ester (KN62) were found to have partially reversible antagonist 
activity, but the effect of adenosine 5'-triphosphate periodate oxidized 
sodium salt (oATP) was irreversible. IC50 values were found to be 30 -  
100 nM for KN62, and 50 pM for PPADS (the PPADS IC 50 value was 
much lower against other P2X receptors) (Humphreys et al., 1998; 
Michel et al., 2000; North and Suprenant, 2000b). Humphreys et al 
(1998) found that the rat P2X7 receptor was not blocked by KN62, while 
it fully blocked the action of ATP on human receptors, but only partially
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that of DBzATP (Humphreys et al., 1998). KN62 was found to be 500- 
fold more selective for human than rat receptors (Hibell et al., 2001b).
In addition to their findings of the substantial species selectivity of the 
P2X7 receptor antagonists, Hibell et al (2001) also documented the effect 
of the experimental conditions on the antagonist’s potency, as they 
studied agonist concentration, temperature, and buffer composition. This 
study found that the activity of oATP, KN62 and Coomassie Brilliant 
Blue G (BBG) on the human P2X7 receptor is reduced at 22°C. 
Additionally PPADS, pyridoxal-5'-phosphate (P5P), oATP and suramin 
were found to have 3- to 10-fold lower activity in sodium chloride 
(NaCl) than in sucrose buffer (Hibell et al., 2001b).
The effect of several antagonists has been compared using whole cell 
patch clamp, and the following rank order of antagonist potency on the 
human P2X receptor was found: KN62 > Calmidazolium > PPADS = 
Cu2+ > Suramin = 5- (N,N -  Hexamethylene) -  Amiloride (HMA) 
(Chessell et al., 1998).
BBG was regarded as a selective antagonist as it succeeded in inhibiting 
the current, YO-PRO 1 uptake, and membrane blebbing resulting from 
P2X7 receptor stimulation at nanomolar concentration (IC50 values: 10 
and 200 nM for rat and human receptors, respectively). P2Xj, P2X2, 
P2X3, P2 X2/3, P2 X4, and P2Xi/5 receptors were tested and BBG was 
found to be either ineffective or much higher concentrations in the 
micromolar range were needed to block activity (Jiang et al., 2000).
Many other new antagonists have been studied utilizing P2X7 receptor 
pore formation, and claimed to be potent such as the 4,5-diarylamines,
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where one compound has an IC50 value of 0.01 pM, but their selectivity 
needs to be established (Alcaraz et al., 2003; Merriman et al., 2005).
1.4.3 Tissue distribution of P2X7 receptors
P2X7 receptors were initially only found in haemopoietic cells but now 
they have been identified in other cells as well (Gartland et al., 2001). 
The P2X7 receptor is often found internally in cells, but tends to become 
externalized in pathological conditions like cancer (Bumstock, 2004).
In human blood the P2X7 receptor was reported to be expressed by the 
following cells: macrophages, dendritic cells, B-lymphocytes, T- 
lymphocytes, polymorphonuclear cells, and erythrocytes (Di Virgilio et 
al., 2001; Volonte et al., 2006). In addition to macrophages, expression 
o f P2X7 receptors in microglia, brain, spinal cord, lung and spleen has 
been reported by some other studies (Suprenant et al., 1996; Chiozzi et 
al., 1997). Collo et al 1997 studied the distribution of P2X7 receptor in 
hemopoietic cells using Northern blotting, in situ hybridization and 
immunohistochemistry. This study showed expression of the P2X7 
receptor in cells derived from myeloid progenitors (granulocytes and 
monocytes). B cells and a subset o f T cells were also found to be positive 
for the receptor ribonucleic acid (RNA) (Collo et al., 1997). Murine mast 
cells were found to express the P2X7 receptor (Bulanova et al., 2005).
To examine the role of the P2X7 receptor in pathological blood cells, 
Zhang et al., (2004) studied its expression in human leukaemic cells. It 
was found that the relative receptor expression levels were significantly 
higher in acute myelogenous leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic myelogenous leukemia (CML), and myelo- 
dysplastic syndrome (MDS) groups compared to the normal group.
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Interestingly, after one induction therapy regimen, the remission rate in 
the high P2X7 expression group was lower than those in negative or low 
expression groups suggesting its involvement in disease pathogenesis 
(Zhang et al., 2004). In chronic lymphocytic leukemia (CLL) a single 
nucleotide polymorphism in the P2X7 receptor gene causes replacement 
of glutamic acid with alanine at amino acid position 496, and results in 
loss of receptor function. It was reported that this polymorphic mutation 
could be inherited and could contribute to the disease pathogenesis, and 
its clinical outcome (Thunberg et al., 2002; Wiley et al., 2002).
In non-haemopoietic cells, expression of P2X7 receptors in epithelial 
tissues (namely airway epithelium, salivary gland, exocrine pancreas, 
anterior pituitary gland, and skin) was shown either at the mRNA level, 
or implied from the pharmacological evidence (North, 2002). Based on 
pharmacological properties, the P2X7 receptor was found to be expressed 
in the toad stomach (North, 2002). In addition, the receptor is expressed 
in human intestinal epithelial carcinoma cells (Coutinho-Silva et al.,
2005), and human epidermal and monocyte-derived Langerhans cells 
(Georgiou et al., 2005).
In addition to hemopoietic cells, Collo et al. (1997) studied the 
expression of the P2X7 receptor in the rat nervous sytem, and found that 
it is expressed in the brain by microglia and ependymal cells. Expression 
of P2X7 receptors in rat neurons was also documented (Deuchars et al., 
2001). Kobayashi et al (2005) reported expression of P2X7 mRNA by 
glial cells in the rat lumbar dorsal root ganglion (Kobayashi et al., 2005).
Additionally, functional receptor was found to be expressed by human 
melanoma cells and receptor activation caused their apoptosis (White et 
al., 2005).
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Human fibroblasts from diabetic patients were found to have enhanced 
P2 X7 receptor responses (Solini et al., 2004). Enhanced receptor 
responses were also found in diabetic retinal microvasculature, and 
suggested to be the mechanism of diabetic retinopathy (Sugiyama et al.,
2004).
Expression of P2X7 receptor on the nucleus and then in the cytoplasm of 
prostate tissue was found to suggest prostate cancer in its early stage. 
The P2X7 receptor labelling was proposed as a method to detect prostate 
cancer and to monitor progression of the disease and its treatment (Slater 
et al., 2005). Similarly, the P2X7 receptor was suggested as a good 
marker for human thyroid cancer (Solini et al., 2008).
The distribution and physiological function of P2X7 receptor in bone 
cells will be discussed later in this introduction (Section 1.7).
1.5 Other purinergic receptors
1.5.1 Adenosine Receptors
The adenosine or Pj receptor family consists of four members (Ai, A 2a, 
A 2b, and A3). They are members of the rhodopsin -  like G protein- 
coupled receptor (GPCR) family (King and Townsend-Nicholson, 2003; 
Bumstock, 2007). Their sizes range between 318 and 412 amino acids 
(Ralevic and Bumstock, 1998; King and Townsend-Nicholson, 2003). 
They are 39-61% identical in amino acid sequence and share 11-18 % 
identity with P2Y receptors (King and Townsend-Nicholson, 2003; 
Bumstock, 2007). Adenosine receptors are coupled mainly to activation 
or inhibition of adenylate cyclase (Bumstock, 2007). Adenosine 
receptors are widely distributed, and have been proven to modulate many
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of the body’s systems, such as the cardiovascular, immune, skeletal and 
central nervous systems (King and Townsend-Nicholson, 2003; Evans et 
al., 2006; Bumstock, 2006b).
1.5.2 P2Y Receptors
These are GPCR composed of seven transmembrane domains. As with 
all GPCRs the ligand binding site is in the N-terminus, and available 
extracellularly, while the C-terminus is available intracellularly (King 
and Townsend-Nicholson, 2003; Bumstock, 2006a; Bumstock, 2007). 
They are 15-65 % identical in their amino acid sequence and their sizes 
range between 328 and 538 amino acids (von Kugelgen and Wetter, 
2000; King and Townsend-Nicholson, 2003). It is believed that several 
amino acids in transmembrane domains 3, 5, 6 , and 7 are involved in 
ligand binding (von Kugelgen and Wetter, 2000).
This family consists of eight members, P2Yi, P2Y2, P2Y4, P2Y6, P2Yn , 
P2 Yj2, P2 Yn, and P2 Yi4 receptors, which are all present in human 
tissues (Sak and Webb, 2002; Hoebertz et al., 2003; Bumstock, 2007). 
P2Yi, P2Y2, P2Y4, and P2Y6 receptors are coupled to phospholipase C 
(PLC) resulting in the formation of inositol triphosphate (IP3). P2Yi2, 
P2Yn, and P2YU receptors are negatively coupled to adenylate cyclase. 
P2Y11 receptor is coupled to both PLC and adenylate cyclase leading to 
increases in cyclic adenosine triphosphate (cAMP) (Volonte et al., 2006).
They are widely distributed in the human body including the heart (P2Yj, 
P2Y2, P2Y6), skeletal muscles (P2Y,, P2Y2), lung (P2Y2, P2Y4, P2Y6), 
and spleen (P2Y2, P2Y6, P2Yn) (von Kugelgen and Wetter, 2000).
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ATP may act either as an agonist or antagonist at the human P2Yj 
receptor. Conversely, it is a pure agonist at the P2Yi receptor in other 
species (Sak and Webb, 2002). Some members are activated by 
nucleotide diphosphates (such as ADP for P2Yi and uridine diphosphate 
(UDP) for P2Y6), while others by nucleoside triphosphates (such as ATP 
and UTP for P2 Y2 and UTP for P2Y4) (von Kugelgen and Wetter, 2000; 
King and Townsend-Nicholson, 2003).
1.6 Bone biotoav
1.6.1 Bone Composition
Bone composition varies according to anatomical site, age, and dietary 
and health status (Bostrom et al., 2000; Sommerfeldt and Rubin, 2001; 
Baron, 2003). Generally bone is composed of 60-70 % mineral or 
inorganic phase, 5-8 % water, and the rest is organic matrix. Collagen 
type I is the main constituent of the organic matrix and accounts for 
about 90 %, while the remainder is non-collagenous protein. Examples 
of non-collagenous proteins found in bone are osteonectin, osteopontin, 
osteocalcin, and bone sialoprotein. Some of these non-collagenous 
proteins may be produced by bone cells, and others may be produced in 
other organs and absorbed by the bone matrix. Hydroxyapatite 
(Caio(P04)6(OH)2) makes up the inorganic phase and may contain some 
impurities such as carbonate, magnesium, and fluoride. These impurities 
can substitute for the calcium, phosphate, or hydroxyl groups of the 
hydroxyapatite leading to a major change in some of its physical 
properties and thus affecting its normal function (Bostrom et al., 2000; 
Sommerfeldt and Rubin, 2001; Baron, 2003). The mineral content o f 
bone provides its mechanical rigidity and load bearing strength, while the
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collagen provides bone elasticity and flexibility (Robey and Boskey,
2006).
Bone can be divided into two types, cortical bone (also called compact 
bone (Seeley et al., 2008a)) representing approximately 80 % of the adult 
skeleton, and cancellous bone (also called trabecular bone (AMA, 2004; 
Slomianka, 2006)) representing approximately 20 % of the adult skeleton 
(Figure 1.4) (Dempster et al., 2006). However, the ratio of cancellous: 
cortical bone is widely variable between different bones (Felsenberg and 
Boonen, 2005; Dempster et al., 2006). It is estimated that this ratio is 
approximately 75:25 in vertebrae, but 50:50 in the femoral head 
(Dempster et al., 2006). The first difference between these two types of 
bones is that cortical bone is dense, solid, and has more bone matrix and 
less space while cancellous bone is spongy and has more space and less 
matrix with a honey comb-like network (Dempster et al., 2006; Zaidi, 
2007; Seeley et al., 2008b). The second difference is in the function of 
the two types of bone. Cancellous bone provides bone scaffolding 
without extra weight and is considered to be more metabolically active 
(Dempster et al., 2006; Seeley et al., 2008a), while cortical bone 
provides support and is involved in mechanical loading (Felsenberg and 
Boonen, 2005; Dempster et al., 2006; Zaidi, 2007; Seeley et al., 2008a). 
However, their functions are believed to be species- and situation- 
dependent (Dempster et al., 2006).
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Figure 1.4: Bone architecture
A diagram showing the two types of bones; cortical (compact), and cancellous 
(trabecular). A adapted from AMA (2004) and B adapted from Slomianka (2006).
1.6.2 Bone Cells
Bone has three major types o f  bone cells; osteoclasts, osteoblasts, and 
osteocytes (Arnett and colleagues, 2004) (Figure 1.5).
Figure 1.5: Bone cells
A diagram showing the three major bone cells; osteoclasts (OC), osteoblasts (OB), 
and osteocytes (OY). Adapted from Arnett and colleagues (2004).
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Human adult bone mass is maintained locally by the balance between 
osteoclasts and osteoblasts which are responsible for the two major 
processes in bone, resorption and formation, respectively (Harada and 
Rodan, 2003; Zaidi, 2007).
A) Osteoclasts
Osteoclasts are the bone cells responsible for resorption (bone 
destruction). Osteoclasts are multinucleated (4 -  20 nuclei) (Figure 1.5) 
and originate from a monocyte / macrophage hemopoietic lineage 
(Teitelbaum, 2000; Baron, 2003; Boyle et al., 2003; Seeley et al., 
2008b). For osteoclastogenesis, osteoblasts or stromal cells secrete 
macrophage colony stimulating factor (M-CSF) and receptor activator 
for nuclear factor kappa-B ligand (RANKL) (Teitelbaum, 2000; Baron, 
2003; Boyle et al., 2003; Teitelbaum, 2007). M-CSF and RANKL act on 
M-CSF receptor and receptor activator for nuclear factor kappa-B 
(RANK), respectively (Zaidi, 2007). Additionally, contact between 
osteoclast precursors and osteoblasts or stromal cells is needed for 
osteoclastogenesis (Teitelbaum, 2000; Baron, 2003; Boyle et al., 2003; 
Teitelbaum, 2007).
The osteoclast starts its function of resorption by adhering to the bone 
surface and forming a sealed extracellular area. Then, across its ruffled 
membrane, the osteoclast secretes protons to acidify the environment, 
and lysosomal enzymes such as cathepsin K, and carbonic anhydrase II 
to dissolve the minerals and degrade the collagenous matrix (Teitelbaum, 
2000; Baron, 2003; Boyle et al., 2003; Zaidi, 2007).
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The action of many anti-osteoporosis agents such as oestrogens and 
bisphosphonates arises from their action on osteoclast apoptosis 
(Teitelbaum, 2000; Zaidi, 2007).
B) Osteoblasts
Osteoblasts are the bone cells responsible for bone formation which is 
‘the synthesis and deposition of the bone extracellular matrix” (Ducy et 
al., 2 0 0 0 ).
Osteoblasts are mononucleated cells derived from local mesenchymal 
stem cells under the influence of local growth factors such as fibroblast 
growth factors, bone morphogenetic proteins and Wnt proteins (Baron, 
2003; Spangler, 2008). The precursor stem cells proliferate into 
preosteoblasts and then into mature osteoblasts (Baron, 2003). 
Osteoblasts never work individually (Baron, 2003). Their plasma 
membrane is rich in alkaline phosphatase (ALP) which is used as an 
index of bone formation (Baron, 2003; Cohen, 2006). Osteoblasts have 
been found to express receptors for parathyroid hormone(Manen et al., 
1998), prostaglandins(Nemoto et al., 1995), oestrogen receptors 
(Penolazzi et al., 2004; Miki et al., 2007), and vitamin D3 (van Leeuwen 
et al., 1992).
Bone formation by osteoblasts is involved in bone growth, mineralisation 
and remodelling (Ducy et al., 2000). A differentiated osteoblast starts 
bone formation by secreting bone matrix proteins (type I collagen and 
other non-collagenous proteins) followed by mineral (hydroxyapatite) 
deposition on the network o f type I collagen (Mackie, 2003). ALP 
contributes to the process o f osteoblast mineralisation (Mackie, 2003).
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After finishing bone formation osteoblasts differentiate into osteocytes or 
bone lining cells or undergo apoptosis (Baron, 2003; Jilka, 2007).
C) Osteocytes
Osteocytes are cells which were originally osteoblasts and became 
trapped in the bone matrix (Baron, 2003; Jilka, 2007; Seeley et al., 
2008b). On osteoclastic bone resorption, osteocytes are phagocytosed 
and digested along with other bone components (Baron, 2003; Jilka, 
2007).
1.6.3 Bone modelling and remodelling
Bone modelling is a formation process that is usually not preceded by 
resorption, and is involved in bone growth. Bone remodelling is a 
continuous physiological process throughout life in which resorption by 
osteoclasts is followed by bone formation by osteoblasts, and is intended 
for the replacement of old bone with new bone, in addition to its role in 
mineral metabolism (Ducy et al., 2000; Sommerfeldt and Rubin, 2001; 
Baron, 2003; Seeley et al., 2008b). Although mechanical load has a 
minor effect on bone modulation, it was found that strenuous sports such 
as tennis make the player’s bones stronger. Conversely, immobilization 
can increase bone loss significantly (Harada and Rodan, 2003). The 
period needed for one full remodelling cycle is 3-6 months, and this 
cycle sequence is called activation—resorption—reversal—formation 
(ARRF) as shown in Figure 1.6. During activation, RANKL, produced 
by osteoblasts and stromal cells, simulates the preosteoclasts to fuse and 
proliferate into mature osteoclasts which migrate to the remodelling site. 
After activation the osteoclasts start to resorb bone in two stages; a rapid 
stage achieved by multinucleated osteoclasts which takes about eight
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days, followed by a slow  stage achieved by mononuclear cells which 
takes about thirty four days. The reversal phase is an intermediate stage 
between resorption and formation where macrophage-like, 
uncharacterized mononuclear cells are observed. In this phase stopping 
resorption and cementing together o f  old and new bone occurs. Lastly, 
formation occurs where the osteoblasts secrete new collagen matrix and 
then mineralise it (Sommerfeldt and Rubin, 2001; Baron, 2003; Prentice,
2007).
Bone Turnover Cycle
Osteoblasts
Bone remodelling unit
Osteoclasts
Activation
O steoclast apoptosis
He*vi»nal
Bone resorption days
C ollagen fo rm a tio n /m in e ra lis a tio n
Resting phase
V
form at ion
Bone formation 3-6 months
-     — ■»
Figure 1.6: Bone remodelling
A diagram showing activation-resorption-reversal-formation (ARRF) in the bone 
remodelling cycle sequence. Adapted from Prentice (2007).
Many hormones are involved in the remodelling process. Some o f  these 
are: oestrogen, testosterone, thyroid, parathyroid and growth hormones 
which are anabolics, but thyroid and parathyroid hormones in excess act 
as pro-resorptive agents (Zaidi, 2007).
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1.7 Purinergic receptors in bone
1.7.1 Osteoclasts
Many studies have confirmed the expression of P2 X7 receptors by 
osteoclasts, and clearly established their function. The first, carried out 
by Hoebertz et al (2000), reported the presence of P2X7 receptors in the 
nuclei of cultured rat osteoclasts using immunocytochemical studies 
(Hoebertz et al., 2000).
Naemsch et al (2001) demonstrated the expression of the P2X7 receptor 
by rabbit osteoclasts using immunocytochemistry, and patch clamp 
techniques. Patch clamp studies showed that inward current developed 
upon activation of the receptor, and was blocked on antagonist 
application. This study proved that the receptor was functional as it 
documented the channel permeability of small cations. Additionally, 
pore formation was ruled out as up to 3 minutes stimulation with 
DBzATP did not permeabilize the cell to N-methyl-D-glucamine 
(NMDG, M.Wt. 196 daltons) (Naemsch et al., 2001). They concluded 
that P2X7 receptor activation results in inhibition of bone resorption, and 
that P2X7 receptor pore formation is species- and cell type-dependent 
(Naemsch et al., 2001).
The involvement of P2X7 receptors in the process o f calcium signalling 
between osteoblasts and osteoclasts was studied by Jorgensen et al 
(2002). This group confirmed that human osteoclasts express P2X7 
receptors using reverse transcriptase-polymerase chain reaction (RT- 
PCR), and proved that the receptor is functional by utilizing Ca2+ uptake 
and pore formation properties. To achieve the objective of the study, 
osteoblast P2X7 receptors were blocked using oATP which led to 
diminished calcium signal propagation to osteoclasts. This demonstrates
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the presence of osteoblast-osteoclast calcium signalling and the 
involvement of the P2X7 receptor in this process (Jorgensen et al., 2002).
Gartland et al (2003b) studied the effect o f blocking the P2X7 receptor on 
the formation of human multinucleated osteoclasts by utilizing the 
receptor pore formation characteristic, in addition to RT-PCR, 
immunohistochemistry, and terminal deoxynucleotidyltransferase- 
mediated dUTP nick-end labelling (TUNEL). This study showed that 
human osteoclasts express the P2X7 receptor and its activation mediates 
pore formation. Additionally, blockade of the receptor prevented the 
formation of multinucleated osteoclasts from human peripheral blood, 
increased osteoclast apoptosis and eventually inhibited osteoclastic 
resorption (Gartland et al., 2003b).
In a study by Ke et al (2003) to find the importance of P2X7 receptors in 
bone resorption, it was revealed that deletion of the receptor in mice 
caused increased resorption proving the significance o f the receptor in 
osteoclast function. An interesting finding in this study is that 
multinucleated osteoclasts can be produced even in the absence of P2X7 
receptors, although electrophysiological studies showed that the P2X7 
receptor is expressed only in the wild-type, but not the knock-out mice 
(Ke et al., 2003). In another study the formation of multinucleated 
osteoclasts from mononuclear precursor cells was not impaired in P2X7 
receptor knockout mice (Gartland et al., 2003c).
Gartland et al (2003b), and Jorgensen et al (2002) showed pore 
formation by osteoclasts, while Naemsch et al (2001) ruled it out. This 
may be due to insufficient time for agonist stimulation as Gartland et al 
(2001) stated that 5 minutes is usually needed for pore formation in 
haemopoietic cells. The above mentioned studies established the vital
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role of the P2X7 receptor in osteoclast formation and function. 
Additionally, P2 X2 and P2 X4 receptors have been identified in 
osteoclasts, and it has been reported that P2X2 receptor stimulation 
increases osteoclast activity (Hoebertz et al., 2003). Expression of P2Xj, 
P2 X 4, P2X5, P2X* and P2X7 receptors has also been reported in 
osteoclasts and ATP was found to play a role in osteoclast activation by 
increasing expression of RANKL (Buckley et al., 2002).
P2Yj, P2Y2, P2Y4, P2Y6, and P2Yn receptors have also been identified 
in human osteoclasts, and it has been claimed that P2Yj receptor 
activation causes stimulation of osteoclast formation and function 
(Buckley et al., 2002; Hoebertz et al., 2003).
1.7.2 Osteoblasts
Expression of P2X7 receptors in osteoblasts has been reported in very 
few studies. The first, carried out by Nakamura et al (2000), showed the 
expression of P2X7 receptors mRNA by human osteoblast-like MG63 
cells (Nakamura et al., 2000).
Gartland et al (2001) studied the expression of P2X7 receptors by two 
human osteosarcoma cell lines (SaOS2 and Te85) and primary human 
bone-derived cells. The first finding in this study was the expression of 
P2X7 receptors by osteosarcoma cells and primary human cells using RT- 
PCR. The immunocytochemical technique showed high expression of the 
receptor in the SaOS2 cells, but no expression was observed in the Te85 
cells, and varying degrees were found in the primary human cells. P2X7 
receptor pore formation upon activation was studied using lactate 
dehydrogenase (LDH) release and ethidium bromide uptake. Both were 
reported in SaOS2 cells, but not in Te85 cells. Pore formation in SaOS2
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cells was confirmed by blocking the receptor using the antagonist 
PPADS. Changes in the morphology of SaOS2 and human primary cells 
were also noticed upon activation which eventually led to apoptosis, and 
again this effect was blocked by the antagonist PPADS. One of the 
interesting findings in this study is that pore formation in osteoblasts 
needed 60 minutes incubation with the agonists, while only 5 minutes is 
usually needed for haemopoietic cells, which led the authors to assume 
an atypical pharmacology of the receptor. This study concluded that the 
P2X7 receptor is functional in osteoblast cells, and its expression is 
dependent on the differentiation o f the osteoblast population (Gartland et 
al., 2 0 0 1 ).
The importance of P2X7 receptors in bone formation was established in 
the study by Ke et al (2003). They compared P2X7 receptor expression 
and function in knockout and wild-type mouse osteoblasts using RT- 
PCR and pore formation studies. It was found that it was only expressed 
and functional in wild-type, but not knockout mice. The authors 
concluded that “Loss of P2X7 receptors increased osteoclastic bone 
resorption, while decreasing osteoblastic bone formation. Thus, P2X7 
receptor agonists may be useful as a combined antiresorptive and 
anabolic therapy in skeletal disorders such as osteoporosis” (Ke et al., 
2003). Additionally, P2X7 receptor expression has been reported in other 
studies (Li et al., 2005; Orriss et al., 2006; Panupinthu et al., 2007). 
Furthermore, P2X5 and P2X6 receptors have been identified in 
osteoblasts (Nakamura et al., 2000; Hoebertz et al., 2003) where P2X5 
receptors were reported to be involved in osteoblast proliferation and 
differentiation (Hoebertz et al., 2003). P2X2 (Hoebertz et al., 2003) and 
P2 X4 receptors (Nakamura et al., 2000) have also been identified in 
osteoblasts.
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P2Yj (Maier et al., 1997; Hoebertz et al., 2000), P2Y2 (Maier et al., 
1997; Hoebertz et al., 2000; Orriss et al., 2007), P2Y4 (Maier et al., 
1997), and P2Y6 (Maier et al., 1997) receptors have been identified in 
osteoblasts. P2Y2 receptor was found to be involved in communication 
between osteoblasts and in inhibiting bone formation (Maier et al., 1997; 
Hoebertz et al., 2000).
Nothing is known about the expression of adenosine receptors by 
osteoclasts. However, adenosine was reported to stimulate osteoblast 
proliferation (Shimegi, 1996). Additionally, human preosteoblastic cells 
were found to express all four adenosine receptors and adenosine 
stimulated IL-6  release from these cells and inhibited osteoprotegerin 
(OPG) expression (Evans et al., 2006). In another study, expression of 
Aj, A2a, and A2b but not A3 was reported in the MG63 cell line (Russell 
et al., 2007). In this study adenosine was found to inhibit IL-6  release, 
therefore it was suggested that adenosine receptors have a role in 
inflammation and osteoclastogenesis (Russell et al., 2007). The 
difference in the findings of Evans et al (2006) and Russell et al (2007) is 
believed to be the cells used, preosteoblastic cells used by the first group 
and mature osteoblasts by the second.
1.7.3 Osteocvtes
Nothing is known about the expression o f purinergic receptors by 
osteocytes.
1.8 Bone diseases
Due to the discovery of their importance in bone biology (Ke et al., 
2003) and cytokine release (Ferrari et al., 1997; Bulanova et al., 2005; Di
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Virgilio, 2007; Hughes et al., 2007; Qu et al., 2007), P2X7 receptors have 
been implicated in bone diseases such as osteoporosis (Ke et al., 2003) 
and rheumatoid arthritis (Ferrari et al., 2006).
1.8.1 Osteoporosis
Osteoporosis is a metabolic bone disease characterized by increased 
skeletal fragility, thus exposing the patients to fractures arising from 
trivial activities (Mackie, 2003; Marie, 2006). Figure 1.7 shows the 
change that occurs in cancellous bone in osteoporosis (Langton, 2000). 
Advanced age, and the menopause are known to be the key risk factors 
for osteoporosis (Manolagas, 2000; Mundy, 2001; Ebeling, 2004; 
Gonzales-Macias et al., 2005; Reginster and Burlet, 2006), in addition to
9 -4-female sex, low Ca diet, Cushing’s syndrome and corticosteroid 
therapy (Manolagas, 2000; Mundy, 2001; Ebeling, 2004; Gonzales- 
Macias et al., 2005; Reginster and Burlet, 2006).
Bone mineral density (BMD) is an approach to measure bone mass and 
to diagnose osteoporosis. The most accurate BMD test is called dual­
energy X-ray absorptiometry (DXA), which compares the patient’s BMD 
to an established standard and gives a score. The score is either a T-score 
(BMD compared to that of a healthy 30 year-old adult), or a Z-score 
(BMD compared to a person of matching age) (NIAMS, 2006).
Pathophysiology
Fractures in osteoporotic patients are most likely to occur in the hip, 
wrist and vertebrae (Mundy, 2001; Ortolani and Vai, 2006) as a result of 
a decrease in BMD (AMA, 2004). The increased bone fragility in 
osteoporosis is due to two types of changes in bone. The first type of
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change is the decrease in bone mass occurring with advanced age, while 
the other type is specific, occurring in the cancellous bone 
microarchitecture of the vertebral bodies and the neck of the femur 
(Mundy, 2001). The advanced age bone mass decrease is thought to be 
related to genetic factors (Mundy, 2001; Sambrook and Cooper, 2006). 
The main gene shown to be involved is the vitamin D receptor gene 
(Mundy, 2001; Sambrook and Cooper, 2006), but other genes have also 
been suggested including those for IL-6  (Mundy, 2001), the oestrogen 
receptor and type-I collagen (Mundy, 2001; Sambrook and Cooper,
2006). Bone loss in females of advanced age is rapid because of the 
abrupt withdrawal of sex hormones after the menopause, but in males it 
is slow because of the gradual decrease in sex hormones.
At the cellular level, a balance between osteoblast and osteoclast activity 
exists in normal adults, but in osteoporosis this balance is negative, as 
osteoclast activity is increased (Mackie, 2003; Meunier et al., 2004; 
Marie, 2006; Sambrook and Cooper, 2006; Teitelbaum, 2007). It has 
been shown that the rates of osteoblast and osteoclast production and 
apoptosis are crucial in physiological bone regeneration (Manolagas, 
2000).
Sex hormone deficiency (oestrogen and androgens) causes increased 
osteoclastogenesis and osteoblastogenesis, but the life span of osteoblasts 
is decreased in contrast to that of osteoclasts which is increased. This is 
translated into increased bone resorption with decreased bone formation. 
The effect of sex hormone loss on bone cells was reported to be due to 
the upregulation of cytokines such as IL-6 , IL-1 and TNF-a which are 
responsible for osteoblastogenesis and osteoclastogenesis. Additionally, 
sex hormone deficiency causes a decrease in osteocyte life span which
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could cause further weakness o f  bone (Manolagas, 2000; Fini et al., 
2004).
Normal Cancellous bone Osteoporotic cancellous bone
Figure 1.7: Change in cancellous Bone in osteoporosis.
A diagram showing normal (A) and osteoporotic (B) cancellous bone. Adapted from 
Langton (2003).
In advanced age, bone formation after each remodelling cycle is 
decreased. This is reflected by a decrease in bone wall thickness, which 
is used as a measure o f  bone formation. The reasons for this were 
reported to be a decrease in osteoblastogenesis and osteoclastogenesis, 
and the life span o f  osteocytes (Manolagas, 2000).
Secondary osteoporosis is a potential complication o f  excess 
glucocorticoids in the body, which may arise from their chronic use or 
from Cushing’s syndrome (Boling, 2004; Gregorio et al., 2006; Kanis et 
al., 2007). The mechanism for bone loss due to excess glucocorticoid is a 
decrease in osteoblastogenesis and osteoclastogenesis, an increase in the 
life span o f  osteoclasts, and a decrease in the life span o f  osteoblasts and 
osteocytes. In addition, bone resorption resulting from 
hyperparathyroidism increases. Hyperparathyroidism in this case results 
because glucocorticoids increase calcium renal excretion and decrease 
intestinal absorption leading to an increase in parathyroid hormone
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(PTH) release (Manolagas, 2000; Boling, 2004; Gregorio et al., 2006; 
Kanis et al., 2007). Another reason for the increased bone resorption 
induced by glucocorticoids is an increase in the production of RANKL 
(Gregorio et al., 2006; Kanis et al., 2007).
Aging, disuse and glucocorticoids may affect the remodelling process by 
slowing down bone formation following resorption resulting in low bone 
turnover (Zaidi, 2007).
Current pharmacological treatment
Calcitonin was the first therapy used for the treatment of osteoporosis. It 
acts through an antiresorptive mechanism by inhibiting the action of 
osteoclasts. It has a rapid action by stopping osteoclasts producing a 
ruffled border, and a long-term action in reducing the number of 
osteoclasts. It has been shown to reduce the risk of vertebral fracture by 
up to 36 % (Zaidi et al., 2002; Mulder et al., 2006). Calcitonin has 
largely been superseded with newer drugs because o f their potency and 
long-acting effect, but it may be considered if the patient can’t tolerate 
other anti-osteoporotic drugs (Zaidi et al., 2002; Cohen and Adachi, 
2004; Gregorio et al., 2006; Mulder et al., 2006).
Bisphosphonates such as etidronate, and zoledronate are widely used 
nowadays for the management o f osteoporosis because of their potent 
effect on reducing bone turnover, increasing bone mass, and decreasing 
fracture risk (Boling, 2004; Gregorio et al., 2006; Mulder et al., 2006). 
The bisphosphonates have a potent antiresorptive action arising from 
inhibition of osteoclast activity, and induction of osteoclast apoptosis 
(Licata, 2005; Mulder et al., 2006). Additionally, bisphosphonates 
decrease the development of osteoclast progenitors (Manolagas, 2000).
36
P2X7 Receptors in Osteoblasts
Based on their intracellular action on osteoclasts, bisphosphonates are 
divided into two classes. Class 1 are those which have no nitrogen atom 
in their chemical structure such as etidronate and acts by inhibiting ATP- 
dependent intracellular enzymes causing induction of osteoclast 
apoptosis. Class 2 bisphosphonates are the nitrogen-containing 
compounds such as zoledronate and act by inhibiting osteoclast activity, 
and inducing their apoptosis (Licata, 2005; Mulder et al., 2006; Zaidi,
2007). Class 2 bisphosphonates are much more potent than class 1 
compounds, for example zoledronate has an antiresorptive relative 
potency at least 10,000-fold higher compared to etidronate (Licata,
2005). Oral bisphosphonates are associated with poor patient compliance 
due to their high incidence of gastro-intestinal side effects and 
complicated dosing requirement (Epstein and Zaidi, 2005; Black et al., 
2007; Cramer et al., 2007; Kanis et al., 2007). Hence, interest is directed 
currently towards the use of long acting and / or parenteral dosage forms 
such as a once-yearly infusion o f zoledronic acid (Mulder et al., 2006; 
Black et al., 2007).
Recombinant human PTH (teriparatide) is the first anti-osteoporotic drug 
which acts by stimulation of bone formation (Quattrocchi and Kourlas, 
2004; Deal, 2005; McClung et al., 2005; Marie, 2006; Chen et al., 2007). 
Teriparatide is composed of the first 34 amino acids of native human 
PTH (Quattrocchi and Kourlas, 2004; Deal, 2005; McClung et al., 2005; 
Marie, 2006; Chen et al., 2007). A constant high dose of teriparatide 
induces resorption (Quattrocchi and Kourlas, 2004; Mulder et al., 2006), 
but an intermittent low dose induces bone formation (Quattrocchi and 
Kourlas, 2004; Mulder et al., 2006; Jilka, 2007). It acts by stimulating 
osteoblast production, and inhibiting osteoblast apoptosis (Quattrocchi 
and Kourlas, 2004; Jilka, 2007). It was reported that bone formation 
markers increase after about 1 month of treatment with teriparatide,
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while bone resorption markers increase after about 6  months of treatment 
indicating an early stimulation o f bone formation and delayed bone 
resorption (Deal, 2005; Jilka, 2007). As a reflection of the increase in 
osteoblast life span, osteocytes in the newly formed bone in mice 
receiving PTH were found to be more numerous, and closely spaced 
(Manolagas, 2000). In a clinical trial, teriparatide reduced the fracture 
rate by 50 % compared to placebo (Davidson, 2003). The fracture 
prevention trial (FPT) study showed that teriparatide significantly 
increased BMD (Chen et al., 2007) and significantly reduced the risk of 
vertebral and non-vertebral fractures by 65 % and 53 %, respectively, in 
osteoporotic postmenopausal women (Mulder et al., 2006; Chen et al., 
2007). Additionally, back pain was reported less frequently in patients 
using teriparatide compared to alendronate (McClung et al., 2005). The 
use of a combination of bisphosphonates and teriparatide would be more 
potent than using a single agent alone, since each one acts by a different 
mechanism (Quattrocchi and Kourlas, 2004; Deal, 2005; Mulder et al.,
2006). However, a study found that bone density responses to 
teriparatide were impaired in patients pretreated with alendronate (Deal, 
2005; Mulder et al., 2006), which led to a recommendation of leaving a 6  
month drug-free period between alendronate and teriparatide (Deal,
2005). This effect has not been reported with any other bisphosphonate 
(Deal, 2005).
Hormone replacement therapy / oestrogen replacement therapy (HRT / 
ERT) is an approach which compensates for the reduction in oestrogen in 
menopausal women, and acts by inhibiting bone resorption (Mackie, 
2003; Zaidi, 2007). Recently a question has been raised about the 
rationale of the indefinite use of HRT, especially after the publication of 
studies which showed that the risks from its long-term use outweigh the 
benefits. These risks include breast cancer, coronary heart disease, and
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deep vein thrombosis (DVT) (Cohen and Adachi, 2004; Mulder et al.,
2006).
SERMs (Selective Oestrogen Receptor Modulators) such as raloxifene 
have a similar action to oestrogen and are used for the prevention of 
breast cancer (Reid, 2002). Studies showed that raloxifene increased 
spinal BMD by 1-3 % and reduced vertebral fractures by 30 %. The 
incidence of DVT with raloxifene is similar to that caused by HRT 
(Reid, 2002; Mulder et al., 2006).
Fluoride acts by increasing osteoblast proliferation (Davidson, 2003). 
Studies showed that it increased BMD by 8 %, but its continuous use in 
high doses leads to osteomalacia (soft bones), which may explain its 
failure in decreasing the fracture rate (Reid, 2002). Studies recommend 
its use as an adjunct therapy with antiresorptive agents in patients with 
severe bone loss (Cohen and Adachi, 2004).
Vitamin D and calcium supplements are not recommended as a sole 
therapy for osteoporosis since the results of the studies done are variable. 
Instead, the combination may be used as an adjunct therapy with other 
anti-osteoporotic agents (Cohen and Adachi, 2004; Sambrook and 
Cooper, 2006; Rizzoli et al., 2008). Additionally, Vitamin D and calcium 
supplements are recommended for patients using corticosteroids to 
prevent bone loss (Gregorio et al., 2006).
One of the most recent treatments for osteoporosis is strontium ranelate. 
Its efficacy and safety were proved by many animal and human studies 
(Fogelman and Blake, 2005; Ammann, 2006; Marie, 2006; Ortolani and 
Vai, 2006; Bonnelye et al., 2008). It acts by stimulating bone formation 
and inhibiting resorption (Meunier et al., 2004; Fogelman and Blake,
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2005; Ortolani and Vai, 2006; Bonnelye et al., 2008), which makes it the 
first agent to have the opposite actions of being antiresorptive and bone- 
forming (Marie, 2006). At the cellular level strontium ranelate was 
found to decrease the differentiation and activity of osteoclasts and 
increase their apoptosis and increase preosteoblastic cell replication and 
collagen synthesis with no effect on bone mineralisation (Marie, 2006). 
Strontium ranelate was found to produce both early and long-term 
reductions in the risk of vertebral fractures (Meunier et al., 2004). The 
treatment of peripheral osteoporosis (TROPOS) and spinal osteoporosis 
therapeutic intervention (SOTI) studies showed that strontium ranelate 
reduced significantly the risk of vertebral and non-vertebral fractures in 
postmenopausal women, and that it was well tolerated (Reginster et al., 
2005; Adami, 2006; Ortolani and Vai, 2006).
Future treatment
Novel PTH derivatives including oral dosage forms are in phase II 
clinical trials (Rosen, 2004).
Another potential treatment approach is through the 
RANK/RANKL/OPG system, which is known to play a major role in 
osteoclastic bone resorption (Theoleyre et al., 2004; Mazziotti et al., 
2006; McClung et al., 2006; Schwarz and Ritchlin, 2007; Teitelbaum, 
2007). OPG inhibits osteoclast formation by inhibiting RANKL which is 
involved in osteoclast differentiation and activity (Davidson, 2003; 
Theoleyre et al., 2004; Teitelbaum, 2007; Zaidi, 2007). Denosumab is a 
human monoclonal antibody that inhibits binding of RANKL to RANK 
and hence inhibits osteoclast differentiation, activation and survival 
(McClung et al., 2006; Schwarz and Ritchlin, 2007). Denosumab was 
found to decrease bone resorption markers (McClung et al., 2006) and is
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in Phase 2 clinical trials for the treatment of osteoporosis (Lewiecki et 
al., 2007). In a clinical study involving postmenopausal women, 
denosumab administered subcutaneously every 3 or 6  months was found 
to increase BMD and decrease bone resorption (McClung et al., 2006) 
and this effect was sustained for up to 2 years (Cramer et al., 2007). 
Many other studies have proved the efficacy and safety of denosumab in 
osteoporosis (Schwarz and Ritchlin, 2007).
Another anabolic approach could involve targeting sclerostin which is 
produced by osteocytes and inhibits bone formation (Mazziotti et al., 
2006; Mulder et al., 2006; Jilka, 2007). Part of the action of PTH on 
bone formation is believed to be via reduction of sclerostin expression in 
osteocytes (Jilka, 2007; Leupin et al., 2007). A monoclonal antibody 
against sclerostin is under development (Zaidi, 2007).
Purinergic receptors, particularly the P2X7 receptor, represent a 
promising new field in the treatment of osteoporosis especially with the 
discovery of their expression by osteoclasts, and role in apoptosis of 
these cells (Hoebertz et al., 2003). Additionally, P2X7 receptor knockout 
mice were found to have low bone formation and high bone resorption 
(Ke et al., 2003), therefore a P2X7 receptor agonist could be a good 
treatment.
Table 1.1 shows some of the other potential agents or targets for the 
treatment of osteoporosis and their mechanism of action.
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Agent or target Mechanism of action
Calcium sensing 
receptor antagonist
Increase endogenous PTH (Mulder et al., 2006)
Integrin antagonist Inhibit osteoclast interaction with extracellular 
matrix (Mulder et al., 2006)
Cathepsin-K
inhibitor
Inhibit bone resorption (Mulder et al., 2006; 
Sambrook and Cooper, 2006; Stoch and Wagner, 
2007)
Statins Stimulation of bone formation (Soubrier and 
Roux, 2006; Zaidi, 2007)
Leptin Stimulation of bone formation (Mackie, 2003; 
Zaidi, 2007)
Cannabinoid
receptors
Stimulation of bone formation and inhibition of 
bone resorption (Pacher et al., 2006; Bab and 
Zimmer, 2008)
Thiazide diuretics Renal calcium reabsorption and reduction of 
osteoclasts activity (O'Neill et al., 2004)
Full length (84 
amino acid) human 
PTH
stimulation of bone formation (Deal, 2005; 
Mulder et al., 2006)
Table 1.1: Some of the potential agents or targets for the treatment o f osteoporosis and their 
mechanism of action.
1.8.2 Rheumatoid Arthritis
“Rheumatoid arthritis (RA) is an inflammatory joint disease 
characterized by inflammation of synovial tissues, often leading to 
destruction of joint cartilage and bone” (Walsh et al., 2005). It is the 
commonest auto-immune and chronic systemic disease affecting a 
patient’s morbidity and mortality (Sacre et al., 2005). It has higher 
prevalence in females compared to males (Lee and Weinblatt, 2001; 
Brooks, 2006) and is more common between the age of 40 and 70 years 
(Lee and Weinblatt, 2001). The disease is progressive, unless treatment 
is started early and aggressively (Kuritzky and Weaver, 2003; Blom and 
van Riel, 2007). Approximately 50 % of patients become too disabled to 
work within 10 years of disease onset (Kuritzky and Weaver, 2003;
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Brooks, 2006). The influence of genetic factors has been implied by 
various studies performed (Lee and Weinblatt, 2001), and it is thought 
that genes are responsible for about 50 % of the risk of developing RA 
(Edwards and Cooper, 2006). Additionally smoking (Brooks, 2006; 
Edwards and Cooper, 2006) and some infectious diseases such as 
tuberculosis (Edwards and Cooper, 2006) were found to play a role in 
developing RA.
Pathophysiology
The initial signs and symptoms of RA are a symmetrical polyarthritis 
targeting many joints such as the metacarpaphalangeal and proximal 
interphalangeal joints of the hands and joints of the feet, wrists, etc 
(Walsh et al., 2005; Brooks, 2006; Combe, 2007). The major target of 
inflammation in RA is the joint synovium, which is infiltrated by 
inflammatory cells, causing expansion of the synovial tissues due to their 
proliferation and accompanied by neovascularisation forming what is 
known as a “pannus” (Walsh et al., 2005). The inflammatory mediators 
released by these inflammatory cells in the synovium contribute to the 
bone and joint destruction (Walsh et al., 2005; Knedla et al., 2007). The 
major inflammatory cells involved in RA pathogenesis include 
monocytes, B-cells, and T-cells (Chaiamnuay and Bridges, 2005; 
Fournier, 2005; Loetscher, 2005; Knedla et al., 2007).
Cytokines such as IL-1 and 6 , RANKL and TNF-a play a major role in 
the RA inflammatory process. They can either act as inflammatory 
mediators contributing to tissue damage, or have direct or indirect effects 
on osteoclast differentiation, activity or survival (Andreakos et al., 2002; 
Boyce et al., 2005; Clark et al., 2005; Walsh et al., 2005). TNF-a was
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found to be directly related to the release of many of the 
proinflammatory cytokines such as IL-1 and 6  (Andreakos et al., 2002).
Chemokines are chemotactic proteins found to be involved in the RA 
inflammatory process by stimulating migration of the inflammatory cells 
to the synovium (Knedla et al., 2007; Smolen et al., 2007; Tayal and 
Kalra, 2008). Additionally, the release of chemokines was found to be 
stimulated by some cytokines such as IL-4 and 13 (Knedla et al., 2007).
Prostaglandins (PG) are potent inflammatory mediators formed from 
arachidonic acid by cyclo-oxygenase type-1 and 2 (COX-1 and 2) to 
form Prostaglandin H2 (PGH2). Prostaglandin E2 (PGE2) is formed 
from PGH2 by PGE synthase. PGE2 is produced by some inflammatory 
cells such as monocytes, and was found to be elevated in RA synovial 
fluid (Walsh et al., 2005).
Effects on osteoblast differentiation, function and survival of many of the 
inflammatory mediators mentioned above have been shown in in vitro 
studies (Walsh et al., 2005). Osteoporosis in RA patients at sites distant 
from the inflamed joints was also reported. Early studies indicated that 
this was due to decreased bone formation, but more recent studies 
reported this to be mainly due to increased bone resorption (Walsh et al.,
2005).
Current Treatment
Due to their analgesic action, NSAIDs (non-steroidal anti-inflammatory 
drugs) such as ibuprofen and diclofenac were and still are the initial 
medications used in RA treatment (Kuritzky and Weaver, 2003; 
Rindfleisch and Muller, 2005; Combe, 2007). They exert their action by
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inhibition of COX responsible for the production of PGs from 
arachidonic acid (Kuritzky and Weaver, 2003; Rindfleisch and Muller, 
2005; Vuolteenaho et al., 2008). The action of NSAIDs is only 
symptomatic, alleviating pain and swelling, but without any effect on the 
disease process and progression. Based on this, the current 
recommendation is that they should not be used alone (Kuritzky and 
Weaver, 2003; Rindfleisch and Muller, 2005; Majithia and Geraci,
2007). NSAIDs carry the risk of gastro-intestinal (GI) adverse effects 
due to inhibition of the COX-1 isoenzyme responsible for production of 
the prostaglandins which provide GI mucosal protection (Scheiman,
2005).
COX-2 inhibitors (or the Coxibs) such as celecoxib and rofecoxib are 
NSAIDs that selectively inhibit the COX-2 isoenzyme responsible for 
the production of the inflammatory PGs, with a minor action on COX-1. 
They have similar efficacy to the non-selective agents, but with a 
significantly lower incidence of GI adverse effects (Kuritzky and 
Weaver, 2003; Scheiman, 2005; Bannwarth, 2006; Combe, 2007). 
Recently, rofecoxib has been withdrawn from the market due to 
increased risk of cardiovascular events (Scheiman, 2005; Bannwarth,
2006). Based on this, restrictions were placed on the use of all the COX- 
2  inhibitors, although it was stated that the risk of cardiovascular side 
effects appears to differ across this class and they should be considered 
only as a second or third line agents (Becker, 2005).
Corticosteroids in low doses (<10 mg/day prednisone or equivalent) play 
a major role in alleviating RA symptoms because of their potent anti­
inflammatory actions (Geletka and St Clair, 2003; Kuritzky and Weaver, 
2003; Rindfleisch and Muller, 2005; Combe, 2007). They are claimed to 
have a degree of disease-modifying action, by slowing the joint damage
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(Geletka and St Clair, 2003; Kuritzky and Weaver, 2003; Srikanth and 
Deighton, 2006; Combe, 2007), but this damage may increase following 
treatment withdrawal (Kuritzky and Weaver, 2003). Corticosteroid 
dosages and duration of treatment should be kept to the minimum to 
minimize the risk of adverse effects which include osteoporosis, 
hypertension, and hyperglycemia (Kuritzky and Weaver, 2003; 
Rindfleisch and Muller, 2005; Combe, 2007). Rheumatic patients on 
corticosteroids are at higher risk of osteoporosis due to the disease 
process and the additional complications o f the drug (Kuritzky and 
Weaver, 2003). Therefore it is recommended that these patients receive 
vitamin D and calcium supplement (Kuritzky and Weaver, 2003; 
Rindfleisch and Muller, 2005; Majithia and Geraci, 2007).
Disease-modifying anti-rheumatic drugs (DMARDs) have been proven 
to reduce joint damage, and delay disease progression (Kuritzky and 
Weaver, 2003; Blom and van Riel, 2007). Studies support their early use 
for all RA patients (Geletka and St Clair, 2003; Kuritzky and Weaver, 
2003; Rindfleisch and Muller, 2005; Uhlig and Kvien, 2005; Combe,
2007). They include gold agents, anti-malarial agents, and methotrexate. 
Anti-malarial agents are the least effective and least toxic, but gold 
agents have moderate efficacy and the highest toxicity of this group. 
Methotrexate is considered the standard to which other DMARDs are 
compared due to its good therapeutic index (Kuritzky and Weaver, 2003; 
Majithia and Geraci, 2007). Studies have proved that the use of 
combination therapy of DMARDs is more beneficial than using a single 
agent (Geletka and St Clair, 2003; Kuritzky and Weaver, 2003; 
Feldmann et al., 2005; Rindfleisch and Muller, 2005; Uhlig and Kvien, 
2005; Blom and van Riel, 2007).
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Biological agents are the most recent and biggest development in the 
management of RA (Brown, 2005; Majithia and Geraci, 2007). Anti- 
TNF-a monoclonal antibodies such as adalimumab and infliximab are 
examples of these agents (Sacre et al., 2005; Haraoui and Keystone, 
2006; Srikanth and Deighton, 2006; Blom and van Riel, 2007; Williams 
et al., 2007). TNF-a was found to be overexpressed in RA, and blockade 
of its actions caused a reduction in the release of the proinflammatory 
cytokines (Feldmann et al., 2005). These agents are indicated for severe 
RA not controlled by the conventional DMARDs (Kuritzky and Weaver, 
2003; Feldmann et al., 2005). They have proved to be highly effective 
(Kuritzky and Weaver, 2003; Blom and van Riel, 2007), but a minority 
of patients do not respond, therefore methotrexate is added, which 
improves efficacy significantly (Feldmann et al., 2005; Blom and van 
Riel, 2007). These agents carry a risk of infection (Feldmann et al., 2005; 
Rindfleisch and Muller, 2005; Park and Pillinger, 2007), and malignancy 
(Feldmann et al., 2005; Park and Pillinger, 2007).
Other biological agents are, anakinra which is an IL-1 receptor 
antagonist (Rindfleisch and Muller, 2005; Smolen et al., 2007; Williams 
et al., 2007; Tayal and Kalra, 2008) and rituximab which is a monoclonal 
antibody initiated recently for the treatment of RA acting by inducing B- 
cell apoptosis (Brown, 2005; Rindfleisch and Muller, 2005; Sacre et al., 
2005; Blom and van Riel, 2007; Majithia and Geraci, 2007). Rituximab 
was used previously for the treatment of non-Hodgkin’s lymphoma 
(Smolen et al., 2007). Abatacept is another new biological agent acting 
by inhibiting T-cell activation (Blom and van Riel, 2007; Majithia and 
Geraci, 2007; Smolen et al., 2007).
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Future Treatment
Many new agents are in different stages of study, most of which target 
different cytokines such as IL-8 , IL-12, and IL-15 (Sacre et al., 2005; 
Smolen et al., 2007; Williams et al., 2007; Tayal and Kalra, 2008). 
Tocilizumab is a monoclonal antibody against the IL-6  receptor 
(Abramson and Yazici, 2006; Park and Pillinger, 2007; Smolen et al.,
2007), which is in Phase III clinical trials for the treatment of RA (Park 
and Pillinger, 2007; Smolen et al., 2007; Tayal and Kalra, 2008).
Other treatment approaches are through targeting chemokine receptors 
(CCR) such as CCR1 (Loetscher, 2005; Knedla et al., 2007; Smolen et 
al., 2007) T-cell depletion which plays a major role in RA pathogenesis 
(Brown, 2005), and P38 mitogen-activated protein kinases (MAPK) 
(Knedla et al., 2007).
Denosumab, which is undergoing clinical trials for the treatment of 
osteoporosis, is also under consideration to slow joint destruction 
resulting from RA (Smolen et al., 2007). Many other therapeutic 
approaches for the treatment of RA are in different phases of research, 
and some of them (e.g. cathepsin K) are also being considered for the 
treatment of osteoporosis (Smolen et al., 2007).
A novel approach in the treatment of RA is targeting the Epstein-Barr 
virus (EB V) which was found in the synovial tissue of RA patients. The 
remission of patients with active RA when treated with anti-herpes 
medication represents further support for the involvement of EBV in RA 
(Sawada et al., 2007).
Targeting the P2X7 receptor represents a promising area in RA 
management especially with the discovery of its expression by
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osteoclasts (Hoebertz et al., 2003) and that its stimulation causes the 
release of cytokines, namely IL-4, IL-6 , IL-13, and TNF-a, from mast 
cells (Bulanova et al., 2005) and IL-lp from macrophages (Ferrari et al., 
1997; Labasi et al., 2002).
Expression of functional P2X7 receptors by human osteoclasts has been 
shown by many studies, but its expression by osteoblasts was only 
reported in very few studies. Additionally, the exact role of the P2X7 
receptor on bone formation has not been identified, although low bone 
formation was observed in P2X7 receptor knockout mice. Since the P2X7 
receptor is implicated in bone cell function and novel potent therapies for 
osteoporosis are needed, it is important to answer the question “could the 
P2X7 receptor be the next drug target?” To answer this question, it is 
necessary first to know more about P2X7 receptors in human osteoblasts. 
Hence my project was aimed at the characterisation of the expression and 
function of P2X7 receptors in human osteoblasts and the investigation of 
the modulation of receptor expression and function by oestrogen and 
glucocorticoids.
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1.9 General aims
• To study the expression of P2X7 receptors by osteoblast-like 
osteosarcoma cell lines (MG63 and SaOS2).
• To investigate the pharmacology of P2X7 receptors in human 
osteoblast-like cells using P2X receptor agonists and antagonists.
• To study the effects of P2X7 receptor activation and inhibition on 
aspects of osteoblast function.
• To study the effects of glucocorticoids and oestrogen, known to 
affect bone formation, on P2X7 receptor function.
•  To characterise P2X7 receptor expression and function in primary 
human osteoblasts (HOB).
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Chapter 2: Materials and
Methods
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2.1 Materials
All chemicals were purchased from Sigma-Aldrich (Gillingham, UK) or 
Fisher Scientific UK Ltd (Leicester, UK), unless otherwise stated.
2.2 Cell culture
MG63 and SaOS2 human osteosarcoma cells were obtained from 
European Collection of Cell Cultures (ECACC). The cells were grown in 
25 cm2 flasks (Nunc, Fisher Scientific, Loughborough, UK) at 
approximately passages 14 - 34, or on glass coverslips coated with 3- 
aminopropyl triethoxy silane for immunocytochemistry, in Dulbecco’s 
modified Eagle’s medium (DMEM; Cambrex, Berks, UK) supplemented 
with 5 % foetal calf serum (FCS; Invitrogen, Paisley, UK), 2 mM 
glutamine, 4500 mg/1 glucose, 50 U/ml penicillin G sodium and 50 
pg/ml streptomycin sulfate. This medium will be referred to as DMEM 
throughout this thesis. To routinely passage the cells in 25 cm flasks, 
350 pi trypsin - ethylenediaminetetraacetic acid disodium salt (EDTA) 
(0.025 % trypsin, Lome Laboratories, Reading, UK, 0.025 % EDTA) 
was added, and incubated at 37°C for 5 minutes, and then the cells were 
split in a ratio of 1:5. The cells were maintained at 37°C in a humidified 
atmosphere of 95 % air and 5 % C 02, and the medium changed every 
three or four days.
Human embryonic kidney cells (HEK293) stably transfected with the 
P2X7 receptor (Hibell et al., 2000) were used as a positive control and 
referred to as HEK7 in this thesis.
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2.3 Preparation of cell Ivsate
Medium was removed from the flask where cells had been grown to 
confluence. 1 ml of lysis buffer (Tris base 50 mM, l,2-di(2-l 
aminoethoxy)ehane-N,N,N ’ ,N ’ -tetra-acetic acid disodium salt [EGTA] 5 
mM, sodium chloride 150 mM, Triton 1 %, sodium vanadate 0.4 mM, 
sodium fluoride 50 mM, phenylmethylsulfonyl fluoride [PMSF] 1 mM, 
phenylarsine oxide 20 pM, sodium molybdate 10 mM, leupeptin 10 
pg/ml, aprotinin 10 pg/ml) was added, and the flask incubated on ice for 
15 minutes. Cells were removed from the bottom of the flask using a 
scraper, centrifuged at 15,306g (centrifuge: Sanyo Harrier 18/80) at 4°C 
for 15 minutes, and the supernatant was kept in aliquots at -20°C until 
used.
2.4 Isolation of nuclei
The medium was removed from the flask where cells had been grown to 
confluence, and 1 ml trypsin-EDTA was added, and incubated at 37°C 
for 10 minutes. 1 ml of growing medium was added and the cells were 
resuspended. The cells were centrifuged at 500 g at 4°C for 5 minutes. 
The pellet was gently loosened by vortexing and resuspended in 4 ml 
NP-40 lysis buffer (10 mM Tris base, 10 mM sodium chloride, 5 mM 
magnesium chloride, 0.5 % tergitol (NP-40), pH 7.4) and incubated on 
ice for 5 minutes. The lysed cells were centrifuged at 500 g at 4°C for 5 
minutes, and the pellet resuspended in 4 ml lysis buffer, vortexed well, 
and centrifuged as above. The pellet containing the nuclei was 
resuspended in 150 pi 2:1 50 mM Tris pH 7.4: 3x Laemmli sample 
buffer (9.4 mM Tris base, 20.8 mM sodium doedcyl sulphate [SDS], 30 
% glycerol, 15 % p-mercaptoethanol, 3 % bromophenol blue [1 mg/ml], 
(Laemmli, 1970)) by gentle vortexing and stored at -20°C until needed.
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2.5 Cell membrane preparation
The media was removed from cells grown to confluence. The cells were 
collected with a scraper in Dulbecco’s phosphate-buffered saline (PBS), 
and centrifuged at l,000g at 4°C for 5 minutes. The pellet was 
resuspended in 20 ml ice-cold buffer containing: Tris base 50 mM, 
sodium chloride 150 mM, EDTA 1 mM, 4-(2-Aminoethyl)- 
bezenesulfonylfluoride.HCl (AEBSF) ImM, bacitracin 0.1 mg/ml. The 
pellet was homogenised with a Polytron homogenizer (3x10 seconds) 
and centrifuged at 500g at 4°C for 10 minutes to pellet nuclei. The 
supernatant was kept on ice, and the pellet resuspended in 10 ml buffer 
with a Polytron homogeniser as above and centrifuged again as above. 
The supernatant was combined with the earlier one and centrifuged at 
48,000g at 4°C for 15 minute. The final pellet was resuspended in 15 ml 
of the above buffer by vortexing and centrifuged as above. The pellet 
was resuspended in 1 ml buffer without peptidase inhibitors (bacitracin 
& AEBSF), using a syringe and a fine gauge needle. Membrane aliquots 
were stored at -80 °C until needed.
2.6 Protein assay
Serial dilutions of a standard bovine serum albumin 2 mg/ml (Pierce, 
Perbio Science UK Ltd. Cramlington, Northumberland, UK) were 
prepared. 25 pi of each standard dilution and 5 pi of the samples were 
used to determine the protein concentration using BCA™ assay reagents 
A and B (Pierce) according to the manufacturer’s instructions. The 
samples were incubated at 37°C for 30 minutes, and then allowed to cool 
at room temperature for 5 minutes. The optical densities (OD) of the 
standards and the samples were measured at 540 nm using an MRX 
microplate reader-MRXTC Revelation (Dynex Technologies Limited,
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Worthing, West Sussex, UK). A standard curve was produced from 
which the protein concentration of the samples was calculated using the 
Prism 4.0 programme (Graphpad software, San Diego, USA). The 
BCA™ protein assay method is based on a reduction reaction of Cu2+ to 
Cu,+ by protein in an alkaline medium. The Cu,+ ion formed is detected 
colorimetrically after its chelation by bicinchoninic acid forming a water 
soluble complex. This complex shows linear absorbance with increasing 
protein concentrations (manufacturer’s instructions).
2.7 Primary Antibodies
Two anti-P2X7 receptor primary antibodies were used in this thesis. One 
was a rabbit polyclonal anti-P2X7 receptor antibody (Caltag-Medsystems 
Ltd., Buckingham, Bucks, UK) with antigeneic sequence 
(KIRKEFPKTQGQYSGFKYPY) corresponding to residues 576 -  595 
of the rat P2X7 receptor. This antibody recognises the human receptor 
and is referred to as the rP2X7 antibody. A monoclonal anti-human P2X7 
receptor antibody (L4, (Buell et al., 1998)) and referred to as the L4 
antibody in this thesis was also used. Other primary antibodies used were 
rabbit polyclonal C-terminal anti-P2X2 and anti-P2 X4 receptor antibodies 
(Caltag-Medsystems Ltd., Buckingham, Bucks, UK), referred to as 
rP2X2, and rP2X4 antibodies, respectively. Primary antibodies for 
housekeeping gene protein (P-actin (anti-p-actin antibody, Sigma- 
Aldrich) and glyceraldehyde-3-phosphate dehydrogenase [GAPDH] 
(anti-GAPDH antibody, Ambion, Huntingdon, UK) were used.
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2.8 Western Blotting
Samples were boiled at 95°C for 5 minutes, and then loaded onto 10 % 
polyacrylamide gels (acrylamide 10 %, Tris.HCL 375 mM, SDS 0.1 %, 
ammonium persulfate [APS] 0.005 %, N,N,N',N'-
Tetramethylethylenediamine [TEMED] 0.05 %). A Precision Plus 
protein standards marker (Bio-Rad Laboratories Ltd. 
Bio-Rad House, Hertfordshire, UK) was loaded onto the gel to help in 
determining the size of the separated proteins. Membrane samples of 
HEK7 cells were used as a positive control (Michel et al., 1999). Tank 
buffer (Tris base 2.5 mM, glycine 19 mM, SDS 0.005 %, pH 8.3) was 
used to run the gel. Then the gels were blotted on to 0.2 pm 
nitrocellulose membranes (Amersham Biosciences, Little Chalfont, UK) 
using a semi-dry blotter (Pharmacia Biotech, St. Albans, UK) at 0.8 
mA/cm2 for one hour, in blotting buffer (Tris base 42.9 mM, glycine 
38.9 mM, SDS 0.038 %, methanol 20 %).
After blotting, the membranes were washed in Tris-buffered saline with 
Tween-20 (TBST, Tris base 2 mM, sodium chloride 15 mM, Tween-20 
0.1 %, pH 7.5), and then blocked at room temperature for one hour in 5 
% weight/volume fat-free dried milk (Blotto; Marvel, Premier 
International Ltd., Spalding, UK) in TBST. The membranes were then 
incubated in the primary antibody (at a concentration of 1 : 1000  in 1 % 
w/v Blotto) at 4°C overnight. For readsorption of the primary antibody 
with the peptide used to raise it, the peptide was incubated at 4°C 
overnight with the antibody in 1 % w/v Blotto before use. Control 
antibody was incubated without peptide.
After incubation with the primary antibody, the membranes were washed 
twice for 5 minutes in TBST, and once for 15 minutes, then incubated for
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60 minutes at room temperature in the secondary antibody anti-rabbit 
immunoglobulin G (IgG) (Vector, Burlingame, California) conjugated to 
horseradish peroxidase (HRP) at 1:20,000 in 1 % w/v Blotto. The 
membranes were washed as above in TBST, the bands visualized using 
Enhanced Chemiluminiscent detection (Super Signal®, West Dura, 
Pierce), and the membranes exposed to chemiluminiscent X-ray film 
(Amersham Biosciences). Films were scanned using a Lexmark X I180 
scanner.
2.9 Immunocvtochemistrv
Cells were grown on 13 mm coverslips treated with 2 % 3- 
aminopropyltriethoxy silane in acetone. The media was removed from 
the coverslips, and the cells rinsed three times with 0.1 M PBS (0.145 M 
sodium chloride, 0.0964 M sodium hydrogen orthophosphate, 0.0215 M 
sodium dihydrogen orthophosphate, pH 7.4). The cells were fixed for 15 
minutes with 2 % formaldehyde in 0.1 M PBS, and then washed three 
times (5 minutes apart) with 0.1 M PBS and stored in this buffer until use 
in a sealed plate.
On the day of use, the cells were washed again as above. The cells were 
blocked for 30 minutes with 400 pi PBS containing 3 % serum from the 
animal used to raise the secondary antibody (horse for anti-mouse 
secondary or goat for anti-rabbit secondary), 1 % bovine serum albumin, 
and 0.1 % Triton X-100® to permeabilise the cells if needed. The cells 
were then incubated in 400 pi blocking solution containing the primary 
antibody (1:600 for the L4 antibody (personal communication, E.J. 
Kidd), and 1:1000 for the rP2X7 antibody) for 24-72 hours at 4°C. The 
blocking solution alone was used as a control. To confirm the labelling 
seen when using the polyclonal rP2X7 receptor antibody, it was
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preincubated for 48 hours in PBS containing 3 % goat serum with 0.8 pg 
of the peptide used to raise it.
After incubation, the cells were washed three times (5 minutes apart) 
with 0.1 M PBS, and incubated in 400 pi blocking solution containing 
the relevant secondary antibody conjugated to Cy3 at 1:800 (anti-rabbit: 
Millipore, Watford, UK and Anti-Mouse: Amersham Biosciences) for 1 
hour at room temperature in the dark. The cells were washed again as 
above, then the coverslips dipped in distilled water to remove buffer salts 
and left to dry in the dark. Dry coverslips were mounted on glass slides, 
rinsed with 100 % ethanol using an anti-fade agent (Fluorescent 
mounting medium, DAKO UK Ltd, Cambridge House, Cambridgeshire, 
UK) and stored in the dark in the fridge until examination under the 
fluorescent microscope (Leica DMRA2, Wetzlar, Germany). Images 
were recorded using a digital camera (Leica DC 500, Wetzlar, Germany) 
and the Leica FW 4000 software (Wetzlar, Germany). Images were 
processed using Adobe Photoshop 6.0 (Adobe, USA).
2.10 RT-PCR
RNA was extracted from the cells using the MIDAS RNA extraction kit 
(Biogene, Cambridge, UK) according to the manufacturer’s instructions, 
and then the RNA samples were treated with a DNase kit (Applied 
Biosystems, Lingley House, Warrington, UK). The RNA content in the 
samples was measured at 260 nm and 280 nm using a Genesys 10 UV 
spectrophotometer (Fisher Scientific UK Ltd). 1 OD unit measured at 
260 nm corresponds to 40 pg of RNA/ml. The ratio of A260/A28o of pure 
RNA acid is 2.0, and a ratio of 1.8-2.0 corresponds to 90-100% pure 
RNA acid (manufacturer’s instructions). The A260/A280 ratios obtained 
for the samples were in this range.
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RT reactions were carried out to prepare cDNA from the RNA in a 40 pi 
RT reaction (MgCl2 25 mM, reverse transcription lOx buffer 2 pi, 
deoxynucleotides triphosphate (dNTP) mixture 10 mM, Recombinant 
RNasin® Ribonuclease inhibitor 0.5 pi, high concentration avian 
myeloblastosis virus (AMV) RT 15 U, oligo (dt)j5 Primer 0.5 pg, RNA 1 
pg, nuclease free water to a final volume of 40 pi). The RT kit was from 
Promega (Promega UK, Southampton, UK). Another 20 pi RT reaction 
was done with the concentrations as above, but without AMV. RT 
reactions were incubated in a Perkin Elmer 480 Thermal Cycler (Global 
Medical Instruments, Minnesota, USA) at 42°C for 1 hour, then at 99°C 
for 5 minutes to inactivate the AMV enzyme. cDNA samples were stored 
at -20°C until needed.
A PCR master-mix for each of the samples, and 1 blank, was prepared: 
lOx buffer 2.5 pi (Promega UK), PCR nucleotide mix 0.5 pi (Promega 
UK), sense primer 10 pmol, anti-sense primer 10 pmol, MgCl2 1.5 pi 
(Promega UK), Taq DNA Polymerase 0.2 pi (Promega UK), sterile 
water to 25 pi. 1 pi of the cDNA for each sample was added to 24 pi of 
the master mix and 1 pi of distilled water added to the blank. The PCR 
reactions were run in a Perkin Elmer 480 Thermal Cycler, and the 
conditions were: 94°C for 3 minutes, 60°C for 1 minute, 72°C for 1 
minute, and then 35 cycles at: 94°C for 30 seconds, 60°C for 1 minute, 
72°C for 1 minute. The conditions were based on previous PCR 
experience in our laboratory and were the same for all the receptors. 
Details of all the primers pairs used are presented in Chapter 3.
lx TBE Buffer (Tris base 90 mM, boric acid 90 mM, EDTA 2.5 mM) 
was used to prepare 1.5 % agarose gels and 1.27 pM ethidium bromide 
was added. Ethidium bromide fluoresces on binding to the DNA and thus
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allows visualization of the bands. The marker ladder (0.3 jig/lane, New 
England Biolabs, Herts, UK), and 18 pi samples were loaded into the 
gel, and run at 100 V for about 50-60 minutes. The gel was observed 
under a transilluminator (Fotodyne Incorporated, New Berlin, USA), and 
a photograph taken using a Polaroid MP-4 land camera. To confirm the 
identity of the bands obtained, they were excised from the gels, 
incubated in 50 pi sterile water, kept in the fridge for 48 hours, and the 
cDNA eluted into the water sequenced using the Big Dye® Terminator V 
3.1 Cycle Sequencing kit (Applied Biosystems, Warrington, UK). The 
sequencing was performed by the Central Biotechnology Services 
available on site at Cardiff University.
2.11 Quantitative real-time RT- PCR
Standard curves for the human P2X7 and p-actin (house-keeping gene) 
primer pairs and cDNA prepared from HEK7 cells were prepared to 
confirm that the expression of these two genes can be compared against 
each other, reflected by the standard curve efficiency (has to be 
100± 10%). “ 100  % reaction efficiency indicates occurrence of a 
doubling of product for every reaction cycle. Reaction efficiencies < 
80% indicate inhibition of amplification, poor primer or probe binding or 
loss of linearity at high concentrations in the standard curve. Reaction 
efficiency > 1 1 5 %  can indicate amplification of more than one product, 
template-independent probe degradation or loss of linearity at low 
concentrations” (Stratagene, personal communication). For these 
standard curves, serial dilutions of cDNA from HEK7 cells were 
prepared in triplicate. PCR reactions (25 pi) containing: 12.5 pi 2x 
Brilliant® SYBR Green quantitative PCR (QPCR) Mastermix 
(Stratagene, Texas, USA), 10 pmol sense primer, 10 pmol antisense 
primer, 9.5 pi sterile water, and 1 pi cDNA were prepared for each
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standard sample. The reactions were run in an MX 3000P-Multiplex 
QPCR System (Stratagene, Texas, USA), and the conditions were: 94°C 
for 3 minutes, 60°C for 1 minute, 72°C for 1 minute, and then 40 cycles 
at: 94°C for 30 seconds, 60°C for 1 minute, 72°C for 1 minute. The 
master mix contained SYBR® Green which is a dye freely available in 
the reaction solution which fluoresces on binding to the double-stranded 
DNA produced during the PCR reaction. This fluorescence is monitored 
on a real-time basis as the PCR product is generated over the PCR 
cycles. However, fluorescence may result from non-specific product such 
as primer-dimers. To check for primer-dimers, melting curves were 
checked to make sure that there was only one peak at a high temperature 
with each pair of primers used. In addition, samples were also run on 
agarose gels and gave the expected bands. The fluorescence signal 
produced is monitored in real-time and can be displayed as amplification 
plots, which shows the change in fluorescence during the PCR cycles, 
and can be used to quantitate the threshold cycle (Ct), which is defined 
as ctthe cycle at which fluorescence is determined to be statistically 
significant above background” (manufacturer’s instructions).
2.12 YO-PRO 1 assay
YO-PRO 1 is a dye that fluoresces on binding to nucleic acids. The YO- 
PRO 1 uptake method used has been described previously by Michel et 
al. (1999) to study P2X7 receptor activation.
Cells were grown in 25 cm2 flasks until confluent, then the medium was 
removed and cells were collected using trypsin-EDTA. The cells were 
resuspended in 1 ml of growing medium and centrifuged at 2 0 0 g at room 
temperature for 5 minutes. The cell pellet was then resuspended in 10 ml 
Dulbecco’s PBS, the cells were counted with a haemocytometer and
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centrifuged again at 200g for 5 min at room temperature. The cell pellet 
was resuspended in 10 ml ice-cold assay buffer pH 7.4 (KC1 5 mM, 
CaCl2 0.5 mM, glucose 10 mM, 2-[4-(2-hydroxyethyl)-l-piperazinyl] 
ethane sulfonic acid (HEPES) 10 mM, N-methy-D-glucamine 10 mM, 
and sucrose 280 mM) and centrifuged at 200 g for 5 min at room 
temperature and resuspended again in 37°C assay buffer. Cells were 
added to Greiner 96-well black plates (Greiner Bio-One Ltd., 
Stonehouse, Gloucestershire, UK) (100,000 cells/well for MG63 and 
SaOS2 cells) containing agonist and 1 pM YO-PRO 1 in assay buffer, 
and then the plate was incubated at 37°C. YO-PRO 1 fluorescence was 
monitored in a 96-well plate reader (Fluostar Optima, BMG 
Labtechnologies Ltd., Aylesbury, UK) using an excitation wavelength of 
485 nm, and an emission wavelength of 520 nm. Data were expressed as 
% of maximum uptake for each agonist.
To determine the best incubation time for YO-PRO 1 uptake, MG63 and 
SaOS2 cells were incubated with ATP 8x1 O'4 M for different periods (5- 
30 minutes) and then the uptake was monitored. Another experiment was 
carried out to find the best assay buffer for YO-PRO 1 uptake in MG63 
and SaOS2 cells. Five different buffers were studied, and these are 
shown in Table 2.1.
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Buffer Ingredient
Buffer-A KC1 5 mM, CaCl2 0.5 mM, glucose 10 mM, HEPES 10 
mM, NMDG 10 mM, and sucrose 280 mM
Buffer-B KC1 5 mM, CaCl2 0.1 mM, glucose 10 mM, HEPES 10 
mM, NMDG 10 mM, and sucrose 280 mM
Buffer-C KC1 5 mM, EDTA 0.1 mM, glucose 10 mM, HEPES 10 
mM, NMDG 10 mM, and sucrose 280 mM
Buffer-D Dulbecco’s PBS
Buffer-E KC1 125 mM, EDTA 1 mM, glucose 5 mM, and HEPES 
20 mM, pH 7.4 (Gartland et al., 2001)
Table 2.1: Buffers tested to find the best assay buffer for YO-PRO 1 uptake in 
MG 63 and SaOS2 cells.
All other experiments (outlined below) with YO-PRO 1 were carried out 
for 5 minutes and in buffer-A.
Different P2X receptor antagonists were studied to investigate whether 
they could block pore formation induced by ATP and DBzATP. For this 
purpose cells were pre-incubated with different concentrations of the 
antagonists for one hour in the presence of 1 pM YO-PRO 1 in assay 
buffer-A at 37°C, then ATP or DBzATP was added and the assay 
performed as above in assay buffer-A and an incubation time of 5 
minutes. The antagonist pre-incubation period was based on an earlier 
experiment to determine the best incubation time for the antagonists to 
inhibit YO-PRO 1 uptake (details are given in Chapter 4). Data were 
expressed as % of maximum uptake of each agonist and EC50 values of 
the agonists were calculated using GraphPad Prism 4.0 programme 
(Graphpad software, San Diego, USA).
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Experiments were also performed to investigate receptor desensitization 
and/or the involvement of other pore forming purinergic receptors 
(namely P2X2 and P2 X4). In this experiment flasks of MG63 or SaOS2 
cells were incubated with or without ATP 3x1 O' 3 M at 37°C for 20 
minutes. Following this, the YO-PRO 1 uptake assay was carried out 
using assay buffer-A and an incubation time o f 5 minutes.
To study the effect of cell density and cell culture period on P2X7 
receptor-induced pore formation, experiments were carried out as 
described in Chapter 4.
2.13 ALP assay
MG63 or SaOS2 cells were grown in 25 cm flasks until confluent, then 
the growing medium was removed and cells were collected using 
trypsin-EDTA. The cells were resuspended in 1 ml of medium and 
centrifuged at 522 g at room temperature for 3 minutes. The cell pellet 
was then resuspended in 7 ml medium and the cells counted as before. 
The cells were added to 96 well plates at 1,500 cells per well and 
incubated overnight. For each experiment 2 plates were set up, and for 
control wells and each concentration of ATP, twelve replicates per plate 
were set up. Next day (day 0) the medium was removed and ATP- 
containing medium was added. In the control wells the ATP was 
replaced with an equal volume of water (ATP vehicle). The cells were 
treated again with ATP or water on days 2 and 5.
ALP assays were performed on days 2, 5, and 7. The medium was 
removed from wells in one plate of each pair and cells were washed with 
100 pi Dulbecco’s PBS per well, and then treated with 50 pi freshly
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mixed equal volumes ( 1 :1) of alkaline buffer solution (2 -amino-2 - 
methyl-1-propanol 1.5 M, pH 10.3) and phosphatase substrate (4 mg/ml 
p-nitrophenylphosphate, disodium). In the case of the SaOS2 cells (based 
on previous experiments by B. Evans, personal communication) a ratio 
of alkaline buffer solution to phosphatase substrate of 9:1 was used. The 
treated cells were incubated at 37°C and the absorbance was then read at 
20, 30, 40, and 50 minutes in a Packard Spectracount plate reader 
(Coningen, Netherlands) at 405 nm. The lowest sensitivity of the assay is 
0.4 Sigma unit/ml (approximately 0.06 OD). A blank well (i.e. no cells) 
was included in each assay.
The second plate from each pair was used to assess cell number on each 
assay day using a Cell Titer 96® Aqueous One Solution Cell Proliferation 
assay (Promega, Southampton, UK). According to the manufacturer’s 
instructions, 2 0  pi of the reagent was added to each well, the plate 
incubated at 37°C for one hour and the absorbance read at 490 nm in the 
above plate reader. Appropriate blank wells were always included. The 
results were expressed as OD mean ± the standard error of the mean 
(SEM).
Following an ALP assay and cell number assay on any set of 2 plates, the 
ALP data was corrected for cell number by correcting the ALP data to 
the equivalent of an OD of 10 in the cell number assay.
In addition to investigating the effect of ATP on ALP activity, 
experiments were performed to determine the effect of DBzATP on 
ALP. The cells were treated with DBzATP 24 hours after plating, and 
ALP activity and cell number were measured after 2 days of treatment. 
The results were expressed as ALP activity corrected for cell number as 
described above.
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2.14 IL-6 and IL-1B ELISA
Human IL-6  and IL-ip enzyme linked immunosorbent assay (ELISA) 
Ready-SET-Go sets (eBioscience, Insight Biotechnology Limited, 
Wembley, UK) were used to measure IL-6  and IL-lp concentrations in 
cell culture medium. The manufacturer’s instructions were followe, and 
the assay sensitivities for IL-6  and IL-ip were 2 pg/ml and 4 pg/ml, 
respectively.
A NUNC Maxisorp 96 well ELISA plate was coated with 100 pl/well of 
capture antibody in coating buffer, and the plate was sealed and 
incubated overnight at 4°C. Next day, the wells were washed 5 times 
with >250 pl/well of Dulbecco’s PBS with 0.05 % Tween (PBST), 
allowing about 1 minute for soaking during each wash step, then the 
plate was blotted on absorbent paper to remove any residual buffer. In 
the case of the IL-6  ELISA, the number of washes in this step was 3. 
Next, wells were blocked with 200 pl/well of assay diluent, and 
incubated at room temperature for 1 hour, then washed as before 5 times. 
In the next step 100 pl/well of each standard and sample was added, and 
the plate sealed.
After incubation at room temperature for 2 hours, wells were washed 5 
times as before. Then, 100 pl/well of detection antibody was added, the 
plate sealed and incubated at room temperature for 1 hour, followed by 5 
washes as before. Next, 100 pl/well of Avidin-HRP was added, the plate 
sealed and incubated at room temperature for 30 minutes, followed by 7 
washes with 1-2 minutes soaking during each wash step. Then 100 
pl/well of Substrate Solution (Tetramethylbenzidine) was added to each 
well, and the plate incubated at room temperature for 15 minutes. In the 
last step, 50 pi of Stop Solution (2N sulphuric acid) was added to each
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well, and the plate read at 450 and 570 nm. The 570 nm values represent 
the background and were subtracted from those at 450 nm. A standard 
curve was produced from which the concentration of the samples was 
calculated using the Prism 4.0 programme (Graphpad software, San 
Diego, USA). Protein concentrations were measured for each well using 
the BCA™ method described previously and the data were expressed as 
pg/mg protein.
For collecting cells for protein assay, medium was removed and cells 
washed with Dulbecco’s PBS and fixed with 100 % methanol for 1 
minute, and then the methanol was removed and cells allowed to dry. 
Next, cells were solubilised with 0.5 M sodium hydroxide (NaOH) for 30 
minutes, and the solubilised cells transferred to 1.5 ml tubes and stored at 
-20°C. The method used for protein estimation is described in this 
Chapter (section 2.6).
2.15 Mineralisation
SaOS2 cells were seeded into 6  well plates at 500,000 cells per well and 
incubated overnight. For each experiment 2 plates were set up, one for 
the mineralisation assay and another one for protein assay. The next day, 
the DMEM was changed to one containing ascorbic acid (50 pg/ml). On 
the next day, DMEM was changed to one containing ascorbic acid (50 
pg/ml) and p-glycerophosphate (8  mM), and different treatments. This 
treatment was repeated twice weekly until day 15, when cells were 
stained with freshly prepared 1 % alizarin red S in water as follows.
On the day of staining, the medium was removed and cells were washed 
with approximately 1.5 ml Dulbecco’s PBS per well. Then, the PBS was 
removed and the cells fixed in 1 ml per well with formaldehyde in saline
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(5 ml formaldehyde 40 % solution + 45 ml Dulbecco’s PBS) for 15 
minutes. Next, the formaldehyde in saline was removed and the cells 
washed in 1.5 ml per well with distilled water. The distilled water was 
then removed and the cells were stained with 1 ml per well of alizarin red 
S for 5 minutes. Next, the stain was removed and the cells were washed 
5 times with approximately 2 ml per well of 50 % ethanol leaving the 
last wash on the cells for 15 minutes, and then the ethanol was removed 
and the cells left to air dry. The plates were then scanned using an Epson 
Perfection 4990 photo flatbed scanner, and the alizarin red S stain OD of 
the scans was analyzed using Image-pro plus version 6.1 (Media 
Cybernetics, UK).
2.16 Statistical analysis
Results were analysed using one-way analysis of variance (ANOVA). 
Multiple comparisons were then made using Newman-Keuls post-hoc 
tests in Prism 4.0 programme (Graphpad software, San Diego, USA). If 
two groups of samples were analysed, Student’s t-Test was used. P- 
values less than 0.05 were considered to be significant. All results are 
expressed as the mean ± SEM.
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Chapter 3: Expression of 
the P2X7 receptor by 
human osteoblasts
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3.1 Introduction
3.1.1 Tissue distribution of P2X? ReceDtorsm m m m m _ _ ——^ ^ —i—^ M ——
The P2X7 receptor (initially known as P2Z) is widely distributed in the 
body. P2X7 receptors were initially found in haemopoietic cells only but 
now they have been identified in other cells as well. In human blood the 
P2X7 receptor has been reported to be expressed by the following cells: 
macrophages, dendritic cells, B-lymphocytes, T-lymphocytes, 
polymorphonuclear cells, and erythrocytes (Di Virgilio et al., 2001; 
Volonte et al., 2006). P2X7 receptor were also found in cells derived 
from myeloid progenitors (granulocytes and monocytes), B cells and a 
subset of T cells (Collo et al., 1997) and murine mast cells (Bulanova et 
al., 2005). In pathological blood cells, expression of the P2X7 receptor 
has been reported in human leukaemic cells (Thunberg et al., 2002; 
Wiley et al., 2002; Zhang et al., 2004).
In non-haemopoietic cells, expression of P2X7 receptors in epithelial 
tissues (namely airway epithelium, salivary gland, exocrine pancreas, 
anterior pituitary gland, and skin) has been demonstrated (North, 2002). 
Additionally, P2X7 receptor has been found in toad stomach (North,
2002), human intestinal epithelial carcinoma cells (Coutinho-Silva et al., 
2005), and human epidermal and monocyte-derived Langerhans cells 
(Georgiou et al., 2005). In the nervous system, P2X7 receptors were 
reported in the rat brain in microglia and ependymal cells (Collo et al., 
1997), rat neurons (Deuchars et al., 2001) and glial cells in the rat lumbar 
dorsal root ganglion (Kobayashi et al., 2005).
P2X7 receptor expression has also been shown in many other cells such 
as human melanoma cells (White et al., 2005), fibroblasts from diabetic
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patients’ (Solini et al., 2004; Sugiyama et al., 2004) and prostate cancer 
(Slater et al., 2005).
A more detailed discussion of the tissue distribution of P2X7 receptors is 
presented in Chapter 1.
3.1.2 P2 X7 receptors in bone
The expression and function of P2X7 receptors in osteoclasts is well 
established in the literature (Hoebertz et al., 2000; Naemsch et al., 2001; 
Jorgensen et al., 2002; Ke et al., 2003; Gartland et al., 2003b). in 
contrast, at the beginning of my Ph.D., expression of P2X7 receptor in 
osteoblasts had been reported in few studies only (Nakamura et al., 2000; 
Gartland et al., 2001; Ke et al., 2003). More details of the distribution of 
P2X7 receptors in bone is presented in Chapter 1.
Since P2X7 receptors appear to be involved in bone formation as 
revealed from the work with P2X7 receptor knockout mice (Ke et al.,
2003), and so little was known about their expression in osteoblasts, the 
work in this chapter aimed to characterise these receptors more fully in 
two human osteoblast-like cell lines, MG63 and SaOS2, which are at 
different stages of development of the osteoblast phenotype (Hughes and 
Aubin, 1998). The MG63 cells are early osteoblasts, whilst the SaOS2 
cells are at a much later stage of osteoblast differentiation.
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3.2 Aims
To study the expression of P2X7 receptors by osteoblast-like 
osteosarcoma cell lines (MG63 and SaOS2) and to show the subcellular 
localization of the receptor in these cells. More specifically :
A. To investigate receptor expression at the mRNA level using RT- 
PCR. Additionally, QPCR was used to study the effect of cell 
density on receptor expression.
B. To investigate receptor expression at the protein level using 
Western blotting. Additionally, this technique was used to 
determine the subcellular localisation of the receptor using 
samples of cell membranes, lysate, and nuclei. Furthermore, the 
effect of receptor deglycosylation was studied.
C. To investigate the effect of cell density on receptor expression at 
the protein level using Western blotting.
D. To confirm receptor expression at the protein level using 
immunocytochemistry, and to show the subcellular localization of 
the receptor in these cells.
E. To study the expression of other purinergic pore-forming 
receptors, P2X2, P2 X4, and P2X5.
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3.3 Experimental protocols
The protocols used to study the expression of P2X7 receptors in 
osteoblasts were described in detail in Chapter 2.
3.3.1 RT-PCR
Specific primers for the human P2X2, P2 X4, P2X5, and P2X7 receptors 
and p-actin and their product sizes are shown in table 3.1. All primers 
were obtained from Invitrogen (Paisley, UK) and were checked against 
Genbank for specificity.
Gene Primers (5’- 3 ’) Product 
Size (bp)
P2X2
Receptor
Sense-CCCAAATTCCACTTCTCCAA 204
Antisense-GTCCAGGTCACAGTCCCAGT
P2X4
Receptor
Sense- ACCGTGCTGTGTGACATCAT 190
Antisense- TGAGTGCTTGTGGAGTGGAG
P2XS
Receptor
Sense - AGCTGGAAACGGAGTGAAGA 2 1 2
Antisense- CCTTGACGTCCATCACATTG
P2X7
Receptor
Sense -GTTCCTCTGACCGAGGTT 100
Antisense-CAGGTCTTCTGGTTCCCT
p-actin Sense - CCCAGCCATGTACGTTGCTA 126
Antisense- GGGCATACCCCTCGTAGATG
Table 3.1: Gene primers for the human P2X*  P2X* P2X& and P2X7 receptors and 
P-actin used in this project and their product sizes. bp=base pairs.
Human pancreas cell (BON-1) cDNA, used as a positive control for 
P2X2 receptors was obtained from Dr. J. Ham, School of Medicine, 
Cardiff University.
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3.3.2 Western Blotting
To study the expression of P2X7 receptors at the protein level, Western 
blotting was carried out using the method and antibodies described in 
Chapter 2. Membranes of HEK7 cells were used as a positive control.
P2XZ receptor deqlvcosvlation
Deglycosylation of the P2X7 receptor in MG63 and SaOS2 cell 
membranes was studied using a Glycoprotein Deglycosylation kit 
(Merck chemicals Ltd., Nottingham, UK). According to the 
manufacturer’s instructions, samples were centrifuged at 15,306 g at 4°C 
for 15 minutes, and the pellet resuspended in 30 pi deionized water. The 
sample was divided into two tubes (15 pi each), 5 pi of 5x reaction 
buffer (250 mM sodium phosphate buffer, pH 7.0) and 1.25 pi 
denaturation solution (2 % SDS, 1 M p-mercaptoethanol) were added to 
each tube and mixed gently. Both tubes were heated at 100°C for 5 
minutes, and cooled to room temperature. 1.25 pi Triton X-100® solution 
was added to each tube and mixed gently. 0.5 pi each of: N-glycosidase 
F, a2-3,6,8,9-neuroaminidase, and Endo- a-N-acetylgalactosaminidase 
was added to the deglycosylated tube, and 1.5 pi distilled water added to 
the non-deglycosylated tube. Both tubes were incubated for 3 hours at 
37°C, half the volume of 3x sample buffer added, and they were then 
stored at -20°C until use. The samples were separated on 10 % 
polyacrylamide gels (as described in Chapter 2).
3.3.3 Immunocvtochemistrv
Immunocytochemistry was used to confirm the expression of P2X7 
receptors in the osteoblast-like cells (MG63 and SaOS2) at the protein 
level, and to show the subcellular localization of the receptor in these
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cells. The monoclonal L4 antibody and the polyclonal rP2X7 receptor 
were used for this purpose. Details of the methodology can be found in 
Chapter 2.
3.3.4 Effect of cell density on P2X7 receptor expression
a) mRNA level
To investigate the effect of cell density on P2X7 receptor expression at 
the mRNA level, different cell densities (2xl05, 4xl05, lx l0 6, and 3xl06 
cells per flask) of both cell lines (MG63 and SaOS2) were prepared, 
maintained in culture medium for 24 hours, and then the RNA extracted. 
The RNA preparations were treated with DNAse before undertaking RT 
and QPCR for the P2X7 receptor and p-actin genes. The QPCR system 
software produced a relative quantity chart comparing the receptor 
expression of the samples (i.e. comparing expression of the P2X7 
receptor and p-actin genes). A detailed discussion of the QPCR is 
presented in Chapter 2.
b) Protein level
To study the effect of cell density on P2X7 receptor protein expression, 
cells (MG63 and SaOS2) were seeded at different densities (2xl05, 
4xl05, lxlO6, and 3x106 cells per 25 cm2 flask) in medium, incubated for 
24 hours, lysed and Western blotting performed. The densities of the 
bands were compared to a housekeeping gene protein (P-actin or 
GAPDH).
Additionally, Mg63 and SaOS2 cells at densities of 4xl05, and lxlO6
'y
cells per 25 cm flask were maintained in culture for one and seven days,
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lysed, and Western blotting performed. The densities of the bands were 
compared to a housekeeping gene protein (p-actin or GAPDH).
3.4 Results
3.4.1 Expression at the mRNA level
RT-PCR for P2 X4 receptors (Figure 3.IB), P2X5 receptors (Figure 3.1C), 
and P2X7 receptors (Figure 3.ID), in MG63 and SAOS2 cell mRNA 
samples gave bands of the expected size (200 bp for the P2 X4, and P2X5 
and 100 bp for the P2X7 receptor). Control samples (water or no AMV in 
the RT reaction) did not show any bands. To confirm these results 
sequencing was carried on the bands excised from the gel and the 
expected sequence of nucleotides was obtained in the DNA fragments 
(Figures 3.3, 3.4, and 3.5). No bands were seen using the P2X2 receptor 
primers in either cell line (Figure 3.1 A). Human pancreatic cell line 
mRNA (BON-1 cells) was used as a positive control to demonstrate that 
the primers did amplify the expected product (200bp, Figure 3.1 A) 
which was sequenced to confirm the expected sequence of nucleotides 
(Figure 3.2).
3.4.2 Expression at the protein level
a) Western Blotting:
Membranes of HEK7 cells were used as positive controls. Using the 
rP2X7 receptor antibody, bands were seen in the positive control, SaOS2 
and MG63 cell membranes, lysate, and nuclei at 89.1±0.7 kDa (n=10) 
and 67.9±0.8 kDa (n=10) (figure 3.6). The 89 kDa band was absent in 
some of the membrane samples. A representative example with bands at 
91.7 and 73 kDa (SaOS2) and 106.6 and 71.4 kDa (MG63) is shown in
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Figure 3.6C. Bands larger than 100 kDa were also seen in the SaOS2 
and MG63 lysate and nuclei (data not shown). A band at 55 kDa was 
also seen in some of the samples. Following pre-incubation of the rP2X7 
receptor antibody with the peptide used to raise it, all of the bands in the 
positive control, SaOS2 and MG63 membranes, lysate and nuclei were 
greatly reduced or disappeared.
Additionally, Western blotting was performed to investigate the 
expression of other pore-forming P2X receptors (P2X2 and P2 X4). Rat 
brain cell membranes were used as a positive control. Figure 3.7 shows 
bands in the positive control, and MG63 and SaOS2 cell lysate samples 
at 59 kDa (61.3±0.6 kDa; n=5) for the P2X4 receptor. Following pre- 
incubation of the rP2 X4 receptor antibody with the peptide used to raise 
it, this band in the positive control, and MG63 and SaOS2 cell lysates 
disappeared. Using the anti-P2X2 receptor antibody, bands at 56.5±1.0 
kDa (n=7) and 65.7±1.0 kDa (n=7) were seen in all samples but, 
following pre-incubation of the rP2X2 receptor antibody with the peptide 
used to raise it, only the positive control band disappeared (figure 3.8).
Deglycosylation of MG63 and SaOS2 cell membranes reduced the 
apparent molecular weight of the P2X7 receptor from 6 8  kDa±1.7 to 
60kDa ±2 (n=3) and from 70 kDa±1.9 to 61 kDa±2 (n=3) in MG63 and 
SaOS2 cells, respectively (figure 3.9).
b) Immunocvtochemistrv
Localization of the P2XZ receptor with the L4 antibody
The L4 monoclonal antibody binds to an external epitope on the P2X7 
receptor (Buell et al., 1998), and therefore it is not necessary to 
permeabilize the cell to see staining. To observe the effect of
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permeabilizing the cell and allowing the antibody to enter inside the cell, 
a surfactant, Triton X-100® was also used. The blocking solution in 
which the antibody was diluted was used either in the presence or 
absence of Triton X-100®. Figures 3.10 and 3.11 show MG63 and 
SaOS2 cells incubated with the L4 antibody in the presence and absence 
of Triton X-100®. In the presence of Triton X-100®, the labelling was 
seen throughout the cell, but in its absence, only the cell membrane was 
labelled. C and D in Figures 3.10 and 3.11 show MG63 and SaOS2 
control cells in which the blocking solution was used alone (without 
addition of antibody) plus or minus Triton X-100®. As can be seen, only 
very faint labelling of the cells was present compared to the cells 
incubated with the antibody.
Localization of the P2Xt receptor with the rP2Xz receptor 
antibody
Since the epitope to which the rP2X7 receptor antibody binds is located 
intracellularly on the C-termini of the receptor, Triton X-100® was 
always added to the blocking solution used to dilute the antibody. In 
Figure 3.12 A and C MG63 and SaOS2 cells were incubated with the 
rP2X7 antibody, and showed much more intense labelling of the nuclei 
compared to the cytoplasm. No labelling was seen in the control cells 
incubated with the blocking solution in the absence of the antibody (data 
not shown).
To confirm that the labelling seen with the polyclonal rP2X7 receptor 
antibody was specific, it was incubated for 48 hours with the peptide 
used to raise it, and thus the antibody would no longer be available to 
recognise and bind to the receptor. Following pre-adsorption the 
labelling disappeared or was much weaker (Figure 3.12 B and D).
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3.4.3 Effect of cell density on P2Xt receptor expression
a) Quantitative real-time RT-PCR
Standard curves for the P2X7 receptor and p-actin cDNA were generated 
by preparing serial dilutions of the cDNAs. These are shown in Figure 
3.13 (A and B). The standard curves for P-actin and P2X7 receptor 
cDNAs gave efficiencies of 105.7%, and 95.6% respectively. To confirm 
that the fluorescence resulted from the P2X7 receptor cDNA and not 
from non-specific product such as primer-dimers, the final PCR reaction 
samples were run on an agarose gel and only gave bands of the expected 
size (100 bp) (data not shown). In addition melting curves showed one 
peak only (data not shown).
To determine the influence of cell density on receptor mRNA expression, 
QPCR was carried out on RNA prepared from cells at different densities 
(2xl05, 4xl05, lxlO6, and 3xl06 cells per flask). The relative quantity of 
the receptor expression based on the mRNA level for all the cell 
densities of both cell lines is shown in Figure 3.14. In this figure the 
software built in the system compared P2X7 receptor expression to that 
of p-actin in SaOS2 and MG63 cells. In each cell line the ratio of P2X7 
receptor: p-actin expression in 2x105 cells per flask was set at 1.0. P2X7 
receptor expression in the 3xl06 SaOS2 cells per flask was found to be 
significantly higher than for 2xl05 cells per flask. Expression of p-actin 
did not change with cell density (data not shown).
b) Western blotting
To find the effect of cell density and days in culture on the P2X7 receptor 
protein expression, cell lysate samples of MG63 and SaOS2 cells at 
4xl05 and lxlO6 cells per 25 cm2 flask and cultured for 1 or 7 days were 
separated on 10 % gels. Membranes of HEK7 cells were used as positive
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control. In all experiments the P2X7 receptor band was seen at 69 kDa ± 
1.35 (n=2), as was a band for P-actin at 42.7 kDa±0.42 (n=2) (Figure 
3.15). An 88kDa±0.9 (n=2) band was seen in the MG63 4xl05 sample 
cultured for 1 day, and 4xl05 and lx l0 6 samples cultured for 7 days. 
Other bands (75, 70, 52, and 36 kDa) were also seen in some samples. 
The band intensity was similar for all samples of the P2X7 receptor (69 
kDa band) while the 85 kDa band was stronger in the higher cell density 
and longer growth time. However, the P-actin band intensity varied with 
cell number.
In other experiments, to find the effect of cell density on the P2X7 
receptor expression, cell lysate samples of MG63 and SaOS2 cells at 
2xl05, 4xl05, lxlO6 and 3xl06 cells per 25 cm2 flask grown for one day 
were separated on 10% gels. Membranes of HEK7 cells were used as 
positive controls. The P2X7 receptor band was seen at 60.1 kDa±3.6 for 
MG63 and 61.7 kDa±3.1 for SaOS2 and a band for p-actin at 39.8 
kDa±1.3 for MG63 and 40.4 kDa±l for SaOS2. In addition, a band at
88.1 kDa±l was seen in all the samples except the positive control, and 
another 92.8 kDa band was seen in the MG63 4xl05, lxlO6, 3xl06, and 
SaOS2 lxlO6 and 3xl06 samples (Figure 3.16). Other smaller band in 
some samples was also seen at 23 kDa (data not shown). The intensity of 
the P2X7 receptor at 60 kDa band was not altered by cell density, but the 
intensity of the 88  kDa and p-actin bands increased as the cell density 
increased.
Since the intensity of the P-actin band was shown to increase with 
increasing cell density, an experiment was performed to examine another 
housekeeping gene protein, GAPDH. In both experiments the positive 
control gave a band at 72-72.5 kDa (P2X7 receptor protein) and 34.1- 
35.3 kDa (GAPDH protein), but other samples gave strong bands at 61-
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65.2 kDa and 35.3-35.6 kDa (Figure 3.17). A band of 86.2-105.8 kDa 
size was seen in the lx l0 6 and 3xl06 samples. Other smaller band in 
some samples was also seen at 25 kDa (data not shown). The intensity of 
the P2X7 receptor did not alter with increasing cell density but the 
intensity of the 86 kDa and GAPDH bands increased as the cell density 
increased.
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Figure 3.1: Representative example of RT-PCR of P2X2, P2X4, P2X5, and P2X7 
receptor mRNA in MG63 and SaOS2 samples.
RT-PCR was performed on RNA extracted from MG63 and SaOS2 cells using primers 
for the human P2X2 (A), P2X* (B), P2X5 (C) and P2X7 (D) receptors. In A the marker 
ladder is shown in lane 6 , and human pancreas cell cDNA used as a positive control 
showed a band of 200 bp in lane 7, while no band was seen in all other samples. In B, 
C, and D the marker ladder is shown in lane 1, and in lanes 2 and 4 200 bp (or 100 
bp) bands were seen for MG63 and SaOS2 samples, respectively, corresponding to 
P2 X4 and P2X5 (or P2X7 ) receptors; lanes 3, 5, and 6 , no bands were seen when 
MG63 (lane 3) and SaOS2 (lane 5) sam ples were incubated without the RT enzyme or 
when sterile water was used in the PCR reaction instead of the RT reaction (lane 6 ). 
[n=2-5]
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Figure 3.2: Sequencing of the excised BON-1 cell band for the P2X2 receptor.
The human pancreatic cell line (BON-1) was used as a positive control to demonstrate 
that the P2X2 receptor primers did amplify the expected product. The band was 
excised and sequencing was performed and the expected sequence of nucleotides 
was obtained in the DNA fragment. [n=1]
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Figure 3.3: Sequencing of the excised SaOS2 and MG63 bands for the P2X4 
receptor.
Sequencing of the excised SaOS2 (A) and MG63 (B) sample bands for the P2 X4 
receptor was performed and the expected sequence of nucleotides was obtained in 
the DNA fragments. [n=1]
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Figure 3.4: Sequencing of the excised SaOS2 and MG63 bands for the P2XS 
receptor.
Sequencing of the excised SaOS2 (A) and MG63 (B) sample bands for the P2X5 
receptor was performed and the expected sequence of nucleotides was obtained in 
the DNA fragment. [n=1]
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Figure 3.5: Sequencing of the excised SaOS2 and MG63 bands for the P2X7 
receptor.
Sequencing of the excised SaOS2 (A) and MG63 (B) sample bands for the P2X7 
receptor was performed and the expected sequence of nucleotides was obtained in 
the DNA fragment. [n=1]
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Figure 3.6: Representative example of P2X7 receptor Western blotting in SaOS2 
and MG63 cells with and without preadsorption of the antibody with its cognate 
peptide.
Positive control (10 pg of HEK7 cell membrane in lane 1), and 25 |jg of SaOS2 (A and 
B) or MG63 (C and D) cell membranes (lane 2), lysate (lane 3), and nuclei (lane 4) 
were separated on 10 % gels and probed after prior incubation of the rP2X7 receptor 
antibody (1:1000) with (B & D) or without (A & C) the peptide (1.2 pg) used to raise it. 
Bands were seen at at 73 kDa and 91.7 kDa in SaOS2 cells (A) and at 71.4 kDa in 
MG63 cells (C). All these bands were greatly reduced or disappeared after 
preincubation with the peptide (B & D). [n=10]
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Figure 3.7: Representative example of P2X4 receptor Western blotting in SaOS2 
and MG63 cells with and without preadsorption of the antibody with its cognate 
peptide.
Positive control (60 pg of rat brain lane 1 A and B), and 12.5 pg of MG63 (lanes 2 A 
and B) and SaOS2 (lane 3 A and B) cell lysate were separated on 10 % gels and 
probed after prior incubation of the rP2X4 receptor antibody (1:1000) with (B) or 
without (A) the peptide (3.2 pg) used to raise it. A band was seen in all the samples at 
59 kDa (A), which disappeared after preincubation with the cognate peptide (B). [n=5]
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Figure 3.8: Representative example of P2X2 receptor Western blotting in SaOS2 
and MG63 cells with and without preadsorption of the antibody with its cognate 
peptide.
Positive control, 60 pg of rat brain (lane 1 A and B), 12.5 pg of MG63 (lane 2 A and B), 
and SaOS2 (lane 3 A and B) cell lysate were separated on 10 % gels and probed after 
prior incubation of the rP2X2 receptor antibody (1:1000) with (B) or without (A) 4 pg of 
the peptide used to raise it. The positive control gave two bands at 67.3, 61.9, 57 and 
52 kDa, MG63 and SaOS2 cell lysate sam ples gave bands at 61.9 and 52 kDa, but 
only the positive control bands (lane 1 in B) disappeared following preincubation with 
the cognate peptide. [n=7]
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Figure 3.9: Representative example of Western blotting of the effect of 
deglycosylation on MG63 and SaOS2 cell membranes.
Positive control (5 pg of HEK7 cell membranes in lane 1), and 100 pg of non­
deglycosylated MG63 (lane 2) and SaOS2 (4) cell membranes, deglycosylated MG63 
(lane 3) and SaOS2 (lane 5) cell membranes. The nitrocellulose membrane was 
probed with the rP2X7 antibody (1:2000). The positive control gave a band at 66.6 
kDa, non-deglycosylated MG63 cell membranes at 68 kDa, deglycosylated MG63 cell 
membranes at 59.6 kDa, non-deglycosylated SaOS2 cell m em branes at 69.4 kDa, 
and deglycosylated SaOS2 cell membranes at 50.7 kDa. [n=3]
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Figure 3.10: Representative example of immunocytochemistry in MG63 cells 
using the L4 antibody.
MG63 cells were incubated in the presence (A & B) and absence (C & D) of the L4 
antibody (1:600) and in the presence (A & C) and absence (B & D) of Triton X-100® 
and detected with an anti-mouse secondary antibody conjugated to CY3 (1:800). In A 
labelling was seen throughout the cells, but in B the staining was located at the cell 
membrane. C and D are control images and show very little labelling of the cells 
compared to (A) and (B). Scale bar=10 pm. [n=3]
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Figure 3.11: Representative example of im mu nocytochemistry in SaOS2 cells 
using the L4 antibody.
SaOS2 cells were incubated in the presence (A & B) and absence (C & D) of the L4 
antibody (1:600) and in the presence (A & C) and absence (B & D) of Triton X-100® 
and detected with an anti-mouse secondary antibody conjugated to CY3 (1:800). In A 
labelling was seen throughout the cells, but in B the staining was located at the cell 
membranes. C and D are control images and show very little labelling of the cells 
compared to (A) and (B). Scale bar=10 pm in (A & C) and 20 pm in (B & D). [n=3]
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Figure 3.12: Representative example of immunocytochemistry in MG63 and 
SaOS2 cells using the rP2X7 receptor antibody in the presence and absence of 
peptide.
MG63 (A and B) and SaOS2 cells (C and D) were incubated with the rP2X7 receptor 
antibody (1:1000) after prior incubation with (B and D) or without (A and C) the peptide 
used to raise it (0.8 pg) and detected with an anti-rabbit secondary antibody 
conjugated to Cy3 (1:800). A and C showed intense staining in the nuclei compared to 
the cytoplasm, while in B and D the staining disappeared or was much weaker. Scale 
bar=10 pm in (A & B) and 20 pm in (C & D) [n=3].
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Figure 3.13: Standard curve for p-actin and P2X7 receptor cDNAs.
An efficiency of 105.7% for p-actin (A) and 95.6% for P2X7 (B) cDNAs was achieved. 
Ct: threshold cycle; “the cycle at which fluorescence is determined to be statistically 
above background"(Manual). [n=1]
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Figure 3.14: Relative expression of the P2X7 receptor mRNA for both cell lines.
2x105, 4x105, 1x106, and 3x10® SaOS2 (A) or MG63 (B) cells per flask were grown 
overnight, and the next day the RNA was extracted, and RT reactions followed by 
qPCR were performed. The system assum es the 2x10s cells/flask = 1. Statistical 
analyses were performed using one-way ANOVA with Newman-Keuls post-hoc test. 
*P<0.05 vs. 4x10s cells per flask. [n=3]
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Figure 3.15: Representative example of Western blotting of the effect of days 
cells in growth on P2X7 receptor expression
Positive control (10 pg of membrane of HEK7 cells) in lane 1, and 11 pg of cell lysate 
of MG63 (lanes 2, 3, 6, and 7) and SaOS2 (lanes 4, 5, 8, and 9) 4x105 cells (lanes 2, 
4, 6, and 8) and 1x106 (lanes 3, 5, 7, and 9) grown for 1 (lanes 2 -5) or 7 days (lanes 
6-9). The nitrocellulose membrane was probed with rP2X7 antibody (1:2000) and p- 
actin antibody (1:10,000). The positive control gave a band at 67 kDa (P2X7 receptor 
protein) and 40 kDa (p-actin protein), but other samples gave strong bands at 60 kDa 
and 41.9 kDa (except lane 8; SaOS2 4x105 cultured for 7 days). A band of 85 kDa 
size was seen in the following samples. MG63 1x106 cultured for 1 day, and 4x105 and 
1x106 cultured for 7 days. Other bands (75, 70, 52, and 36 kDa) in some samples 
were also seen. [n=2]
92 .8
87.1  
77.3
71.2
43
Figure 3.16: Representative example of Western blotting of the effect of cell 
density on P2X7 receptor expression
Positive control (10 pg of membrane of HEK7 cells) in lane 1, and 10 pg of cell lysate 
of MG63 (lanes 2, 3, 4, and 5) and SaOS2 (lanes 6, 7, 8, and 9) 2x105 cells (Lanes 2 
and 6) 4x105 cells (lanes 3 and 7), 1x10® cells (lanes 4 and 8) and 3x106 cells (lanes 5 
and 9). The nitrocellulose membrane was probed with rP2X7 antibody (1:2000) and p- 
actin antibody (1:10,000). The positive control gave a band at 77.3 kDa (P2X7 receptor 
protein) and 43 kDa (p-actin protein), but other samples gave strong bands at 71.2 
kDa and 43 kDa. A band of 87.1 kDa was seen in all the samples except the positive 
control, and another 92.8 kDa band was seen in the following samples: MG63 4x105, 
1x106, 3x10®, SaOS2 1x10®, and 3x10®. [n=5]
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Figure 3.17: Representative example of Western blotting of the effect of cell 
density on P2X7 receptor expression
Positive control (10 pg of membrane of HEK7 cells) in lane 1, and 10 pg of cell lysate 
of MG63 (lanes 2, 3, 4, and 5) and SaOS2 (lanes 6, 7, 8, and 9), 2x105 cells (Lanes 2 
and 6), 4x105 cells (lanes 3 and 7), 1x10® cells (lanes 4 and 8) and 3x10® cells (lanes 
5 and 9) The nitrocellulose membrane was probed with rP2X7 antibody (1:2000) and 
GAPDH antibody (1:4000). The positive control gave a band at 72 kDa (P2X7 receptor 
protein) and 34.1 kDa (GAPDH protein), but other sam ples gave strong bands at 65 2 
kDa and 35.6 kDa A band of 105.8 kDa size was seen in the 1x10® and 3x10® 
samples (n=2]
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3.5 Discussion
This chapter investigated the expression of P2X7 receptors by human 
osteoblasts at the mRNA and protein levels. Additionally, the subcellular 
localisation of the receptor and its deglycosylation was studied.
RT-PCR was utilized to confirm the expression of the P2X7 receptor at 
the mRNA level in both cell lines. This was confirmed by sequencing the 
bands excised from the gel and the expected sequence of nucleotides was 
attained in the cDNA fragments.
Since P2X2 and P2 X4 receptors can both form pores (Virginio et al., 
1999; Gever et al., 2006), the expression of these receptors was 
investigated in both cell lines. Neither P2X2 receptor mRNA nor protein 
were detected in MG63 or SaOS2 cells suggesting that the receptor is not 
expressed or present in very low amounts in these cells. Positive controls 
for the PCR primers and antibody demonstrated that the P2X2 receptor 
mRNA or protein could be detected by both methods. However, P2 X4 
receptor mRNA and protein were identified in both cell lines. Therefore, 
MG63 and SaOS2 cells express P2 X4 and P2X7 receptors. Another study 
reported pore formation with P2X5 receptors (Bo et al., 2003). Hence, its 
expression was also examined using RT-PCR, and the presence of its 
mRNA was identified. Previous studies reported expression of P2 X4 
receptor (Nakamura et al., 2000) and P2X5 receptor (Hoebertz et al., 
2000; Nakamura et al., 2000; Orriss et al., 2006). Therefore, MG63 and 
SaOS2 cells express three potential pore-forming purinergic receptors, 
P2 X4, P2X5 and P2X7.
Initial results demonstrated that the labelling seen with antibodies in 
Western blotting and immunocytochemsitry was specific for the P2X7
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receptor. This was proved by prior overnight incubation of the primary 
antibody (rP2X7 receptor antibody) with the peptide used to raise it. This 
incubation allows the antibody to recognise the immobilized peptide and 
bind to it. The peptide and the antibody are then removed and the 
antibody is no longer available to recognise and bind to the receptor. 
This preincubation caused the relevant labelling to disappear, which 
suggests that it is caused by the anti-P2X7 receptor antibody.
It was found that the receptor is expressed in all the samples used (lysate, 
nuclei, and membrane), but apparently at different levels which suggests 
that the level of expression of the receptor is different between the cell 
parts. The Western blotting results revealed in this study are consistent 
with those of Wang et al. (2005), as the band sizes are similar. They 
carried out their experiments on human cervical epithelial cells and 
reported a band of 85 kDa which they claimed to be the mature and 
functional form of the receptor, and another band of 65 kDa, believed to 
be a deglycosylated form, which was proved by deglycosylating the 
receptor. A previous study described only a band of approximately 70 
kDa in human primary fibroblast lysate (Solini et al., 1999). Wang et al. 
(2005) described another band of 18 kDa which was believed to be a 
degradation product of the receptor. My experiments showed similar 
bands of 67.9±5.4 kDa, and 89.1±3.4 kDa. The 18 kDa band couldn’t be 
seen in my study possibly due to longer gel running time, but I observed 
a band around 24 kDa, and other slightly larger bands (up to 55 kDa) in 
some experiments especially in the nuclei, which could be receptor 
deglycosylated forms. In the majority of my experiments, the 85 kDa 
receptor form, which was described by Feng et al (2005) and Wang et al 
(2005) in human cervical epithelial cells to be the mature and functional 
form of the receptor was either faint or absent in the membrane samples 
and the positive control (membranes of HEK7 cells). This may be
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because the membrane is expressing the receptor at a lower level 
compared to the cytoplasm and the nuclei. However, this is unlikely 
because, if this is the functional form of the receptor, it would be 
expected to be strongly expressed at the membrane where the natural 
ligand (ATP) will activate it. Feng et al (2005) studied transfected 
HEK293 and CasKi (human cervical epithelial cells) cell membrane 
expression of the P2X7 receptor and reported the three bands that were 
seen by Wang et al. (2005) and suggested also that the 85 kDa receptor 
was the functional form of the receptor. A possible reason for the 
difference between the results of this group and our results is that the 
method used to extract the cell membranes in our laboratory is highly 
efficient with no other cellular components available in the sample. To 
prove this a lysate sample of the HEK7 cells was run and it gave a band 
of 91.7 kDa, which may correspond to the 85 kDa band reported by Feng 
et al. (2005). An alternative explanation is that the 85 kDa is not the 
functional form of the receptor in our cells. To determine if the receptor 
in osteoblasts follows the same pattern as the epithelial cells, receptor 
deglycosylation was done.
P2X7 receptor deglycosylation of membrane samples showed that the 
size of the P2X7 receptor band decreased by approximately 9 kDa in the 
deglycosylated samples in both cell lines. North (2002) proposed that the 
glycosylated form of the P2X receptor is functional. My results suggest 
that the 67 kDa band possibly represents the functional form of the 
receptor in these cells (as it is the glycosylated form) and not the 85 kDa 
band claimed in epithelial cells (Wang et al., 2004a; Wang et al., 2004b; 
Wang et al., 2005; Feng et al., 2005b). An explanation of the difference 
of the functional receptor size is that it might differ from one cell type to 
another, and that it is approximately 67 kDa in osteoblasts. Another 
explanation is that there is more than one fully glycosylated form of the
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receptor, but they are not all found in the membrane fraction. I have seen 
previously that the 85 kDa form of the receptor was either absent in 
membrane samples or only gave a faint band. The above groups used cell 
lysate samples and not membranes for their deglycosylation experiments. 
Efforts to deglycosylate P2X7 receptors in my lysate samples were not 
successful probably due to the expression level of the receptor.
From the immunocytochemistry results I can conclude that the receptor 
is strongly expressed in intact cells of both the MG63 and SaOS2 cell 
lines. To investigate the receptor expression using this technique, 
immunolabelling using two different antibodies was carried out. The first 
antibody was the L4 monoclonal antibody, which binds to an external 
epitope of the receptor (Buell et al., 1998), therefore Triton X-100® is not 
needed for it to work. The other antibody was the P2X7 receptor 
polyclonal antibody, which binds to an epitope located intracellularly on 
the C-terminus of the receptor (Manufacturer’s Instructions), therefore 
Triton X-100® was needed to permeabilize the cells. The cell labelling 
with the L4 antibody was compared in the presence and absence of 
Triton X-100® which permeabilizes the cell allowing the antibody to 
enter. The purpose of this was to determine intracellular L4 antibody 
labelling, and to compare this labelling with non-permeabilized cells. On 
permeabilizing the cells with Triton X-100®, the staining was seen 
throughout the cells and found to be weak. In contrast, in the absence of 
Triton X-100®, the labelling was slightly stronger (same antibody 
concentration and exposure), and located at the cell membrane. For 
labelling with the polyclonal P2X7 receptor antibody, Triton X-100® was 
used for all the experiments. In both cell lines I observed that the 
labelling was stronger in the nuclei compared to the membrane and the 
cytoplasm. Therefore the results show that the receptor is expressed 
strongly in the nuclei compared to the cytoplasm. This difference in
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staining between the two antibodies raises a question as to whether the 
polyclonal antibody is labelling only the P2X7 receptor or other proteins 
in addition. To help answer this question, the antibody was incubated for 
48 hours with the peptide used to raise it. This preincubation resulted in 
little or no immunolabelling, thus confirming it was due to the antibody. 
The strong nuclear labelling may be seen because the receptor is strongly 
expressed in the nuclei, especially given that Western blotting of some of 
the nuclei samples showed stronger bands compared to lysate and 
membrane samples (around 70 kDa, 85 kDa and other smaller bands) 
that disappeared on incubation of the antibody with the peptide used to 
raise it. In support of this, a previous study found strong nuclear 
expression of the P2X7 receptor in guinea pig smooth muscle cells, 
(Menzies et al., 2003). An explanation might be that die P2X7 receptors 
have a role in calcium transport into the nuclear envelope, especially as 
the intracellular ATP concentration is sufficient to activate the receptor. 
Previous results from my laboratory have identified labelling on THP-1 
monocyte nuclei (Kidd, G. J., unpublished data). The difference in 
labelling between the L4 antibody and the P2X7 receptor antibody may 
be due to the contributions of the tertiary or quaternary structures of the 
receptor to the external epitope to which the L4 antibody binds.
QPCR showed that there is a tendency for an increase in receptor 
expression with increasing cell density in both cell lines. The significant 
difference was seen only in 3xl06 SaOS2 cells/flask compared to 4xl05 
cells/flask. A possible reason for this effect may be that an increase in 
cell density represents a stress for the cells, and stress has been shown to 
induce nucleotide release via a non-lytic mechanism (Gartland et al., 
2001), causing upregulation of the receptor. The most important 
nucleotide here is the P2X7 receptor natural ligand (ATP) itself, 
especially as IJTP proved to be ineffective on this receptor (Gartland et
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al., 2001). Feng et al (2005) found that ATP affected the expression of 
the three main receptor bands (85, 65, and 18 kDa) in Western blotting 
experiments and stimulated expression o f the functional 85 kD form of 
the receptor. Another possible reason for my finding is inter-cellular 
communication, which has been reported to increase with an increase in 
the density of some cells (Long et al., 2002). In my case, ATP may be 
involved resulting in receptor mRNA upregulation. Wang et al. (2005) 
studied human cervical epithelia cells and found that the band intensity 
in Western blotting differed according to the number of days the cells 
were grown for (studied on days 2 and 6 ). They found that the receptor 
expression and function was greater on day 6  compared to day 2. The 
difference between day 6  and day 2  cell growth would be the cell 
density. To my knowledge this is the first evidence demonstrating an 
increase in receptor mRNA expression with an increase in cell density.
To determine if there was any effect of cell density on receptor 
expression at the protein level, Western blotting was performed using a 
range of cell densities. The results show that cell density does not affect 
expression of the receptor protein, as all the samples had approximately 
the same intensity of the 67 kDa band. The only difference seen involved 
the 85 kDa band which appeared only in the higher cell densities (lxlO6 
and 3x106 cells/flask) and die longer growth period o f the cells (7 days) 
especially in the MG63 cell line. This 85 kDa form of the receptor was 
claimed by Wang et al (2005) to be the functional form, and found to 
give a stronger band on day 6  of incubation compared to day 2. Again 
the differences between the results could be due to the availability of 
more than one functional form of the receptor, 67 and 85 kDa. Hence, it 
appears that the influence of cell density on receptor expression is seen at 
the mRNA level only, possibly because this mRNA is not translated into 
protein. To try and quantify P2X7 receptor expression seen in Western
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blotting, two house-keeping proteins were examined (p-actin and 
GAPDH) based on previous studies in other cell lines (Park et al., 2002; 
Wang et al., 2004a; Wang et al., 2004b). An interesting and unexpected 
finding in my experiments was that the house-keeping proteins used (P- 
actin and GAPDH) gave bands of increasing intensity with the increase 
in cell density, although they are generally thought to be expressed to the 
same levels in different cell samples. This may be due to their 
modulation by stress caused by cell density, which might be a 
phenomenon of these cell lines only. A previous study found that 
GAPDH expression was altered by mechanical stimulation (Saunders et 
al., 2006). Since the band intensity of the house-keeping proteins used 
increased with cell density, comparison with the data for P2X7 receptor 
expression was not possible, and hence no quantification was done.
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3.6 Conclusion
The expression of the P2X7 receptor in human osteoblast-like cell lines 
(MG63 and SaOS2 osteosarcoma cell lines) was demonstrated at the 
mRNA and protein levels. It was observed that the relative receptor 
expression at mRNA level is significantly higher at the highest SaOS2 
cell density. Efforts to prove this concept at the protein level failed due 
to the effect of cell density on the housekeeping protein used. With 
immunocytochemistry, the immunolabelling of the P2X7 receptor 
antibody was found to be stronger on the nuclei compared to the L4 
antibody. In addition, immunolabelling of the L4 antibody was spread 
throughout the cell when the cells were permeabilized. In Western 
blotting, receptor deglycosylation in cell membranes was performed and 
the results suggested that the fully functional form of the receptor is that 
giving a band at approximately 67 kDa. However, the intensity of the 
band of the 85 kDa form of the receptor (claimed to be the functional 
form by some studies) appeared to be increased by increasing cell 
density. Additionally, expression of other pore-forming purinergic 
receptors was investigated in both cell lines. Only expression of P2 X4 
and P2X5 receptors mRNA and protein was demonstrated. No evidence 
was obtained for P2X2 receptor expression. Since the expression of P2X7 
receptor was shown, its functionality needed to be investigated.
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Chapter 4: Effect of P2X7 
receptor agonists and 
antagonists on YO-PRO
1 uptake
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4.1 introduction
One characteristic of the P2X7 receptor is the formation of a non- 
selective pore in the cell membrane permeable to molecules as large as 
900 D (North, 2002; Liang and Schwiebert, 2005; Gever et al., 2006; 
Donnelly-Roberts and Jarvis, 2007; King, 2007). However, not all P2X7 
receptor-expressing cells form a pore (Donnelly-Roberts and Jarvis, 
2007).
Steinberg et al (1987) documented that the mouse macrophage plasma 
membrane was permeable to compounds as large as 831 daltons upon 
activation by ATP. This effect was found to be inhibited in the presence 
of divalent cations (Mg2+ and Ca2+) (Steinberg et al., 1987). At that time 
the P2X7 receptor was still not identified, but the effect of the divalent 
cations on cell permeabilization allows us to conclude that it is due to 
this receptor.
This was also documented by Chessell et al (1997) who showed that 
prolonged activation of P2X7 receptors using ATP led to the uptake of 
ethidium bromide (M.Wt: 314 D) (Chessell et al., 1997). Other studies 
have documented the formation of this pore using larger molecules such 
as YO-PRO 1 (M.Wt.: 629 D for the di-iodide salt, 375 D for fiee base) 
(Hibell et al., 2000).
Dyes reported in the literature for the pharmacological study of P2X7 
receptor-induced pore formation are either ethidium bromide 
(dimensions 1.4xl.lx 0.52 nm) or YO-PRO 1 (dimensions 1.9x1.0x0.55 
nm) (North, 2002). The molecular weight of YO-PRO 1 is higher than 
that of ethidium bromide (see above). It has been reported that uptake of 
ethidium bromide is faster than YO-PRO 1 (North, 2002). However, a
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study on osteoblasts found that an hour is needed for the uptake of 
ethidium bromide (Gartland et al., 2001). This delay in uptake is unusual 
and led the authors to speculate that there was an atypical pharmacology 
of P2X7 receptors in human osteoblasts.
Although pore formation has been observed in cells expressing P2X2, 
P2 X4, and P2X7 receptors, only in the case of P2X7 receptors does this 
lead to cell lysis (Virginio et al., 1999; Gever et al., 2006). Another study 
reported pore formation with the P2X5 receptor (Bo et al., 2003). Since 
the pore formed by all of these receptors is permeable to large cations, 
NMDG, ethidium bromide, and YO-PRO 1, the size of the pore the 
receptors are forming is probably similar.
It is believed that pore formation is induced mainly by the long C- 
terminus of the P2X7 receptor. This was concluded when the receptor 
was truncated to 418 amino acids, which resulted in a significant 
decrease in intracellular YO-PRO 1 uptake (Suprenant et al., 1996). 
However, P2X2, P2 X4, and P2X5 receptors have shorter C-termini, but 
still form pores so this can not be the only factor involved.
Gu et al (2001) reported that P2X7 receptor is expressed by human 
leukocytes, but it lost its function (pore formation) upon mutation of 
adenine to cytosine at position 1513 of the cDNA, causing the 
replacement of alanine with glutamic acid at amino acid position 496 
(Gu et al., 2001).
North (2002) suggested two mechanisms for the progressive 
permeability of the P2X7 receptor to cations and larger molecules on 
activation (Figure 4.1). The first mechanism is the dilation hypothesis, 
where several units of the receptor are involved to form the pore. This
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pore forms upon binding of ATP and dilates progressively by undergoing 
conformational change. In the beginning the pore is permeable to small 
cations, but later it becomes permeable to larger compounds (-900 
daltons) (North, 2002). It is believed that the subunits are arranged where 
the first transmembrane domain o f one subunit is located in close 
proximity to the second (Jiang et al., 2003). The second mechanism is 
the extra protein hypothesis, where a special channel protein is involved. 
Binding of ATP causes permeability of small cations. After activation, 
the receptor interacts with this special protein causing opening of the 
channel protein which is permeable to larger compounds (North, 2002). 
Based on recent studies, the extra protein hypothesis looks more likely 
(Donnelly-Roberts and Jarvis, 2007).
The pore has been reported to be up to approximately 4 nm in size, and it 
may be due to a homomultimer consisting of 2 or 3 molecules of the 
receptor (Ziganshin et al., 2002; Bumstock, 2004).
A second messenger was reported to be needed for P2X7 receptor pore 
formation (Faria et al., 2005; Liang and Schwiebert, 2005). This was 
suggested to be Ca2+ and MAPK in the 2BH4 mouse thymic epithelial 
cell line (Faria et al., 2005). Another study reported that MAPK and 
caspase signalling pathways are required for P2X7 receptor pore 
formation in the THP-1 human monocytic cell line (Donnelly-Roberts et 
al., 2004). The difference in the messenger might be due to differences in 
cell type.
108
P2X7 Receptors in Osteoblasts
ATP
Separate pore 
Hypothesis
Dyes 4001>
Figure 4.1: P2X7 receptor pore formation
A diagram showing two suggested mechanisms for P2X7 receptor pore formation. This 
pore forms upon binding of ATP and dilates progressively by undergoing a 
conformational change. Brief activation of the receptor forms a channel permeable to 
small cations such as sodium and calcium. Prolonged activation of receptors results 
in formation of a pore permeable to larger compounds (~900 daltons). Two suggested 
hypotheses for the pore formation are shown here, the separate pore and the dilation 
hypothesis. Adapted from North (2002); Liang et al (2005).
The other characteristic o f  the P2X7 receptor is its very low affinity for 
ATP (EC50 value 300 pM) compared to other P2X family members 
(North and Barnard, 1997; Gever et al., 2006; Donnelly-Roberts and 
Jarvis, 2007). Additionally, DBzATP is reported to be the most potent 
agonist, though it is not selective (North, 2002; Gever et al., 2006).
Since osteoblast-like cell lines have been shown to express P2X7 and 
other pore forming P2X receptors, the next step was to characterise them 
pharmacologically. For pharmacological study o f  these receptors, pore
m m
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formation can be tested either by electrophysiological or by dye-uptake 
methods. Dye-uptake was reported to be a good technique for 
pharmacological characterization of the P2X7 receptor (Michel et al., 
1999), therefore I chose to utilize it in my study.
4.2 Aims
To investigate the functionality of P2X7 receptors in human osteoblasts 
pharmacologically:
A. To study pore formation upon activation using the YO-PRO 1 
assay.
B. To study the effect of different receptor agonists and antagonists 
on pore formation.
C. To study the involvement of other P2X7 pore-forming receptors in 
YO-PRO 1 uptake.
D. To determine the effect o f cell density and cell culture period on 
pore formation and P2X7 receptor expression.
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4.3 Experimental protocols
To study the function of the P2X7 receptor, the pore formation 
characteristic was utilized. For this purpose, the YO-PRO 1 uptake 
method was used.
To determine the best incubation time for YO-PRO 1 uptake, MG63 and 
SaOS2 cells were incubated with ATP 8x1 O'4 M for different periods (5- 
30 minutes) and then the uptake was monitored. This experiment was 
performed in assay buffer-A pH 7.4 (KC1 5 mM, CaCl2 0.5 mM, glucose 
10 mM, HEPES 10 mM, NMDG 10 mM, and sucrose 280 mM). For 
details see Chapter 2.
To find the best assay buffer for YO-PRO 1 uptake in MG63 and SaOS2 
cells, five different buffers were studied as described in Chapter 2.
4.3,1 Effect of P2Xt receptor agonists on YO-PRO 1 
uptake
The effects of different P2X agonists were tested using the YO-PRO 1 
uptake method. The agonists used were: ATP, DBzATP, ATPyS, and 
2Me-S-ATP.
Experiments were also performed to investigate receptor desensitization 
and/or the involvement of other pore-forming purinergic receptors 
(namely P2X2, P2 X4 and P2X5) as described in Chapter 2.
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4.3.2 Effect off P2X? receptor antagonists on YO-PRO 1 
uptake induced bv agonists
Since there is no agreement in the literature on the pre-incubation period 
with antagonists, an experiment was performed to determine the best 
incubation time for the antagonists to inhibit YO-PRO 1 uptake. MG63 
and SaOS2 cells were incubated in Greiner 96-well black plates with 
ATP 8X10"4 M in the presence of different antagonists for different 
periods (30-60 minutes) and then the uptake was monitored. The 
antagonists used were: BBG, KN62, oATP, and PPADS. The antagonist 
concentrations used were adapted from the literature (Michel et al., 
2000).
4.3.3 Effect of cell density on YO-PRO 1 uptake induced 
bv agonists
To study the effect of cell density and cell culture period on P2X7 
receptor-induced pore formation, MG63 and SaOS2 cells were seeded at 
different densities (lxlO6, 2xl06, and 3xl06 cells per flask) in medium, 
incubated for 1 or 3 days, and YO-PRO 1 uptake was determined. 
Another experiment was performed to find the effect of time cells were 
in culture on receptor function, where lxlO6 cells per 25 cm2 flask were 
grown for 1, 3, or 6  days, then the YO-PRO 1 uptake was determined. In 
each case cells were treated with ATP (5x1 O'4 M or lxlO-4 M) or 
DBzATP (5x1 O'4 M or lxlO'4 M) for 5 minutes prior to the YO-PRO 1 
assay.
4.3.4 Effect of ATP on P2Xt receptor expression
Since it is possible that ATP modulates the expression of the P2X7 
receptor, an experiment was performed to find the effect of incubating
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cells with ATP on receptor expression using Western blotting (described 
in Chapter 2). In this experiment SaOS2 cells were incubated with 
medium containing ATP 3 * 10“3 M or water (ATP vehicle) at 37°C for 
30 minutes, then trypsinised and lysed. Lysate samples were separated 
on 10 % gels (as described in Chapter 2). The films were scanned using a 
Lexmark scanner, and the bands produced quantified by densitometry 
using NIH Image software by comparing their OD to those for the house­
keeping protein, p-actin. This experiment was performed in conjunction 
with Veronica Thiongo (Final year MPharm undergaduate project 
student).
4.4 Results
To find the best conditions for the YO-PRO 1 uptake method in MG63 
and SaOS2 cells, different incubation times with ATP (5-30 minutes) and 
different buffers were studied (see Methods section). Figure 4.2 shows 
the effect of incubation time with ATP on YO-PRO 1 uptake in MG63 
and SaOS2 cells. In the MG63 cell line the 5 minute incubation time 
gave the same or 3.6 - 19 % higher uptake compared to other incubation 
times. In the case of the SaOS2 cells, the uptake was 6 .6  - 41.2 % higher 
at 5 minutes compared to other incubation times. In SaOS2 cells the 
uptake was found to be significantly higher after 5 minute compared to 
20 and 30 minutes incubation, while no significant difference was seen 
in case of MG63 cells. Therefore 5 minutes incubation was used for 
further studies in both cell lines. Figure 4.3 shows the effect of different 
assay buffers on YO-PRO 1 uptake in MG63 and SaOS2 cells. It was 
found that the assay buffer-A gave the best YO-PRO 1 uptake in both 
cell lines and was therefore used in all experiments. No uptake was seen 
with buffer-C, buffer-D or buffer-E (for details of buffers see Chapter 2).
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Additionally, preliminaiy results showed that no uptake was seen with 
buffer-E when the cells were incubated for 60 minutes (data not shown).
4.4.1 Effect of P2Xt agonists on YO-PRO 1 uptake
All the agonists used, ATP, DBzATP, ATPyS, and 2 Me-S-ATP were 
found to induce YO-PRO 1 uptake in SaOS2 cells and their 
concentration-effect curves (Figure 4.4) gave EC50 values of 0.43 
mM±0.02, 0.36 mM±0.04, 0.6 mM±0.05 and 0.42 mM±0.04, 
respectively. In MG63 cells the agonist concentration-effect curves 
(Figure 4.5) gave EC50 values of 0.36 mM±0.03 and 0.5 mM±0.04 for 
ATP and DBzATP, respectively. YO-PRO 1 uptake induced by ATP and 
2Me-S-ATP (in the case of the SaOS2 cells) at concentrations higher 
than lxlO' 3 M was less than that induced by lxlO' 3 M.
Table 4.1 compares the EC50 values of the above mentioned agonists 
obtained in this project with those reported in the literature for human 
P2X2, P2 X4, and P2X7 receptors.
To compare the results obtained in this project with those reported by 
Gartland et al (2001), Figure 4.6 shows the YO-PRO 1 uptake obtained 
using the same concentrations, 0.5 and 1 mM ATP and DBzATP, in 
MG63 and SaOS2 cells. There were small variations between the same 
concentrations of ATP and DBzATP in both cell lines, but none showed 
significant difference.
In the receptor desensitization experiment in MG63 and SaOS2 cells, the 
concentration-effect curve for ATP was identical in the ATP-treated cells 
compared to the control cells (Figure 4.7). The ATP EC50 values of the 
treated and control MG63 cells were 0.43 mM±0.07 and 0.44 mM±0.02,
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respectively, while in SaOS2 cells the EC50 value was 0.58 mM±0.05 in 
both treated and control cells.
4.4.2 Effect of P2Xt antagonists on YO-PRO 1 uptake 
induced bv agonists
One hour was found to be the best incubation time for the antagonists to 
inhibit YO-PRO 1 uptake induced by ATP (data not shown), therefore 
this incubation period was used for further studies in both cell lines.
Figures 4.8, 4.9, 4.10, and 4.11 show the concentration-effect curves for 
ATP in the presence of different concentrations of BBG, KN62, PPADS, 
and oATP, respectively in MG63 cells. Figures 4.12, 4.13, 4.14, and 4.15 
show the concentration-effect curves for ATP in the presence of different 
concentrations of the above mentioned antagonists in SaOS2 cells. 
Figures 4.16 and 4.17 show the concentration-effect curves for DBzATP 
in the presence of different concentrations of BBG and KN62 in SaOS2 
cells.
In MG63 cells BBG at a concentration of 5 pM significantly reduced the 
maximum YO-PRO 1 uptake induced by ATP by approximately 20 %, 
but at 0.2 mM it significantly increased the uptake induced by ATP 3x 
10' 5 M and lx 10"4 M (Figure 4.8). KN62 reduced the maximum YO- 
PRO 1 uptake induced by ATP in a concentration-related manner but this 
was not significant (Figure 4.9). PPADS at concentrations of 3x1 O' 7 M 
and 3x1 O' 8 M significantly decreased the maximum uptake by 
approximately 17 and 11 %, respectively (Figure 4.10). oATP was found 
to have little or no effect on YO-PRO 1 uptake (Figure 4.11).
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In SaOS2 cells BBG at a concentration of 5 pM reduced the maximum 
YO-PRO 1 uptake induced by ATP by approximately 33 % but this was 
not significant (Figure 4.12). KN62 at concentration of 10 pM 
significantly reduced the maximum YO-PRO 1 uptake induced by ATP 
by approximately 11 % (Figure 4.13). PPADS and oATP potentiated 
YO-PRO 1 uptake at the lower concentrations of ATP, but decreased it at 
the higher concentrations but these changes were not significant (Figures 
4.14 and 4.15). In the case of DBzATP, BBG and KN62 were found to 
have some effect on blocking YO-PRO 1 uptake, but this was not 
significant (Figure 4.16 and 4.17). EC50 values for ATP and DBzATP 
were not significantly altered by any of the antagonists used. The EC50 
values obtained in the presence of the highest antagonist concentration 
used are shown in Table 4.2.
4.4.3 Effect of cell density on YO-PRO 1 uptake induced 
bv agonists
YO-PRO 1 uptake was determined in MG63 and SaOS2 cells grown at 
different cell densities (Figures 4.18 and 4.19) or following one cell 
density (lxlO6 per 25 cm2 flask) maintained for different numbers of 
days in culture (Figures 4.20 and 4.21). This experiment was performed 
to identify the effect of the cell density and days cells in culture on the 
receptor function.
In MG63 cells, it was found that the cell density and days cells in culture 
inversely affected YO-PRO 1 uptake induced by both ATP and DBzATP 
(Figures 4.18 and 4.20). The effect of the number of days MG63 cells 
were kept in culture was found to be significant with ATP and DBzATP 
lxlO"4 M. In SaOS2 cells, there was a tendency to increase YO-PRO 1 
uptake with the increase in cell density, but a decrease in uptake with
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increasing days cells in culture for both ATP and DBzATP. None of 
these changes were significant (Figures 4.19 and 4.21).
4.4.4 Effect of ATP on P2X7 receptor expression 
assessed bv Western blotting
Western blotting was carried out with cells pre-treated with ATP 3x1 O'3 
M for 30 minutes in order to determine whether the band pattern 
obtained would be different to that described in Chapter 3. Figure 4.22A 
shows a representative example of the effect of ATP on P2X7 receptor 
protein expression. Bands were seen for the P2X7 receptor at 60 and 67 
kDa, while the (5-actin band was seen at 39 kDa. In order to quantify 
P2X7 receptor expression, it was compared to labelling for p-actin using 
densitometric analysis as seen in Figure 4.22B. ATP did not have a 
significant effect on P2X7 receptor expression. Quantification of the 85 
kDa band could not be performed because this band was not seen in all 
the samples used (data not shown).
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Figure 4.2: Effect of incubation time with ATP on YO-PRO 1 uptake in MG63 and 
SaOS2 cells.
MG63 and SaOS2 cells (approximately 100,000 cells/well) were incubated with ATP 
8x1c4 M and 1 pm YO-PRO 1 in the assay buffer at 37°C for 5-30 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. In MG63 cells the YO-PRO 1 
uptake at 5 minutes incubation time was the sam e or higher than other incubation 
times, but in SaOS2 cells it was higher at 5 minutes compared to all other incubation 
times. (n=4], RFU: relative fluorescence unit. Statistical analyses were performed 
using one-way ANOVA with Newman-Keuls post-hoc test. *P<0.05 and # P<0.001 vs. 
5 minutes incubation.
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Figure 4.3: Effect of assay buffer on YO-PRO 1 uptake in MG63 and SaOS2 cells.
MG63 and SaOS2 cells (approximately 100,000 cells/well) were incubated with ATP 
8x10^ M and 1 pM YO-PRO 1 in different assay  buffers (described in Chapter 2) at 
37°C for 5 minutes. YO-PRO 1 fluorescence was monitored in a 96-well plate reader 
using an excitation wavelength of 485 nm, and an emission wavelength of 520 nm. In 
both cell lines the YO-PRO 1 uptake was greatest in the 0.5 mM calcium chloride- 
containing buffer. [n=2]. RFU: relative fluorescence unit.
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Figure 4.4: Concentration-effect curves for ATP, DBzATP, ATPyS, and 2Me-S- 
A TP in SaOS2 cells.
SaOS2 cells (approximately 100,000 cells/well) were incubated with each agonist and 
1 pM YO-PRO 1 in assay buffer-A at 37°C for 5 minutes. YO-PRO 1 fluorescence was 
monitored in a  96-well plate reader using an excitation wavelength of 485 nm, and an 
emission wavelength of 520 nm. Data were plotted as % maximum YO-PRO 1 uptake 
for each agonist. [n= 4],
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Figure 4.5: Concentration-effect curves of ATP and DBzATP in MG63 cells.
MG63 cells (approximately 100,000 cells/well) were incubated with each agonist and 1 
pM YO-PRO 1 in 0.5 mM assay buffer-A at 37°C for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data were plotted as  % maximum 
YO-PRO 1 uptake for each agonist [n=6-15].
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Aaonist MG63 SaOS2 hP2X, hP2XA hP2X7
fmMI ± rMl ±SEM (mM) (mM) (mM)
SEM Lynch etal, 1999 Bianchi et al, 1999 Bianchi et al, 1999
ATP 0.36 ± 
0.03
0.43 ±0.04 0.001 0.0005 0.095
DBzATP 0.5 ±0.04 0.36± 0.04 0.0004 0.0005 0.0047
ATPyS 0.6± 0.05 0.0014 0.011 >0.1
2Me-S-
ATP
0.42±
0.04
0.0008 0.002 >0.1
Table 4.1: ECso values for ATP, DBzATP, ATPyS, and 2Me-S-ATP.
The first two columns shows EC50 values obtained in this project. The EC50 values of 
these agonists for increasing intracellular calcium were reported in human 
astrocytoma cells transfected with hP2X2 (Lynch et al., 1999) or hP2 X4 or hP2X7 
(Bianchi et al., 1999) receptors.
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Figure 4.6: Comparison of the data obtained by Gartland et al (2001) with the 
results of this study.
A shows the results obtained by Gartland et al (2001) using ethidium bromide and an 
hour incubation with 0.5 and 1mM ATP and DBzATP. YO-PRO 1 uptake in MG63 (B) 
or SaOS2 (C) cells induced by 5 minutes incubation with 0.5 and 1mM ATP and 
DBzATP. Data are expressed as % of control. Statistical analyses were performed 
using Student’s t-Test between each concentration of ATP and DBzATP. [n= 6  - 45]. A 
adapted from Gartland et al (2001).
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Figure 4.7: P2X7 receptor desensitization in MG63 and SaOS2 cells.
SaOS2 and MG63 cells (approximately 100,000 cells/well) were incubated with ATP 
3x10'3 M or Dulbecco’s PBS for 20 minutes at 37°C and were then incubated with ATP 
and 1 pM YO-PRO 1 at 37°C for 5 minutes. YO-PRO 1 fluorescence was monitored in 
a 96-well plate reader using an excitation wavelength of 485 nm, and an emission 
wavelength of 520 nm. [n=3]
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Figure 4.8: ATP concentration-effect curve in MG63 cells in the presence of 
BBG.
MG63 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 in 
the assay buffer in the presence of water (vehicle for BBG), 2x1 O'7 M, 1x1 O'6 M, or 
5x1 O'6 M of BBG at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. Statistical analyses were 
performed using one-way ANOVA with Newman-Keuls post-hoc test. *P<0.05 vs. 
control. [n=3]
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Figure 4.9: ATP concentration-effect curve in MG63 cells in the presence of 
KN62.
MG63 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 in 
the assay buffer in the presence of DMSO (vehicle for KN62), 1x1 O^M, 5x1 O'7 M, or 
1x10‘5M of KN62 at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. [n=3]
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Figure 4.10: ATP concentration-effect curve in MG63 cells in the presence of 
PPADS.
MG63 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 in 
the assay buffer in the presence of water (vehicle for PPADS),3x1 O^M, 1x1 O'7 M, or 
3x10 ?M of PPADS at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. Statistical analyses were 
performed using one-way ANOVA with Newman-Keuls post-hoc test. *P<0.05 and # 
P<0.001 vs. control. (n=3)
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Figure 4.11: ATP concentration-effect curve in MG63 cells in the presence of 
oATP.
MG63 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 in 
the assay buffer in the presence of water (vehicle for oATP), 1x10'5M, 3x10‘5 M, or 
1x1 O^M of oATP at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. [n=3]
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Figure 4.12: ATP concentration-effect curve in SaOS2 cells in the presence of 
BBG.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of water (vehicle for BBG), 2x10"7M, 1x1 O^M, or 
5 x 1 0 ^  of BBG at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. [n=4]
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Figure 4.13: ATP concentration-effect curve in SaOS2 cells in the presence of 
KN62.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of DMSO (vehicle for KN62), IxlO^M, 5x10'7M, or 
1x10‘5M of KN62 at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. Statistical analyses were 
performed using one-way ANOVA with Newman-Keuls post-hoc test. *P<0.05 vs. 
control. [n=3]
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Figure 4.14: ATP concentration-effect curve in SaOS2 cells in the presence of 
PPADS.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of water (vehicle for PPADS), 3x10‘8M, 1x10'7M, or 
3x10’?M of PPADS at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. [n=3]
131
P2X7 Receptors in Osteoblasts
120
100
<o
TO
CL
-5.2 -4.2 -3.7-4.7 -3.2 -2.7
ATP Log (M)
-20 J
-♦“ ATP -*-+oATP(1e-5 M) - a -  +oATP (3e-5 M) +oATP(1e-4 M)
Figure 4.15: ATP concentration-effect curve in SaOS2 cells in the presence of 
oATP.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of water (vehicle for oATP), 1x10'5M, 3x10'5M, or 
1x1 O^M of oATP at 37°C for 1 hour followed by ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the presence of the vehicle. [n=3]
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Figure 4.16: DBzATP concentration-effect curve in SaOS2 cells in the presence 
ofBBG.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of water (vehicle for BBG), 2x10'7M, 1x1 O^M, or 
5x10"®M of BBG at 37°C for 1 hour followed by DBzATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of DBzATP in the presence of the vehicle. [n=4]
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Figure 4.17: DBzATP concentration-effect curve in SaOS2 cells in the presence 
of KN62.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of DMSO (vehicle for KN62), 1x1 O^M, 5x10'7M, or 
1x10'5M of KN62 at 37°C for 1 hour followed by DBzATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of DBzATP in the presence of the vehicle. [n=4]
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MG63 (mM) SaOS2(mM)
ATP 0.28 0.29
ATP  +  BBG 5x10*M 0.28 0.29
ATP 0.17 0.19
ATP + KN62 1x10*M 0.13 0.16
ATP 0.18 0.29
ATP  + oATP 1x10*14 0.12 0.11
ATP 0.26 0.17
ATP  + PPADS 3x1Cr7M 0.16 0.15
DBzATP ND 0.34
DBzATP + BBG 5x10*11/1 ND 0.44
DBzATP ND 0.26
DBzATP + KN62 1x10*M ND 0.23
Table 4.2: EC« values for ATP and DBzATP in the presence or absence of 
different antagonists.
MG63 or SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 |iM
YO-PRO 1 in the assay buffer in the presence of water or DMSO (vehicle), or BBG, 
KN62, oATP, or PPADS at 37°C for 1 hour followed by ATP or DBzATP for 5 minutes. 
YO-PRO 1 fluorescence was monitored in a 96-well plate reader using an excitation 
wavelength of 485 nm, and an emission wavelength of 520 nm. ECso values were 
calculated using Prism. The ECso values obtained with the highest antagonist 
concentration used are shown here. No significant differences were seen with any of 
the concentrations used. ND= not done. n=3-4
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Figure 4.18: Effect of cell density on YO-PRO 1 uptake in MG63 cells.
Cells at different cell densities (1x108t 2x106, and 3x106 cells/25 cm3 flask) were grown 
overnight and were then incubated (approximately 100,000 cells/well) with ATP (A) or 
DBzATP (B) and 1 pM YO-PRO 1 at 37°C for 5 minutes. YO-PRO 1 fluorescence was 
monitored in a 96-well plate reader using an excitation wavelength of 485 nm, and an 
emission wavelength of 520 nm. Data are expressed as  % of control in the presence 
of vehicle. Statistical analyses were performed using one-way ANOVA with Newman- 
Keuls post-hoc test, but no significant differences were seen. [n=3J.
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Figure 4.19: Effect of cell density on YO-PRO 1 uptake in SaOS2 cells.
Cells at different cell densities (1x106, 2x106, and 3x106 cells/ cm3 flask) were grown 
overnight and were then incubated (approximately 100,000 cells/well) with ATP (A) or 
DBzATP (B) and 1 pM YO-PRO 1 at 37°C for 5 minutes. YO-PRO 1 fluorescence was 
monitored in a 96-well plate reader using an excitation wavelength of 485 nm, and an 
emission wavelength of 520 nm. Data are expressed as % of control in the presence 
of vehicle. Statistical analyses were performed using one-way ANOVA with Newman- 
Keuls post-hoc test, but no significant differences were seen. [n=3].
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Figure 4.20: Effect of days cells in growth on YO-PRO 1 uptake in MG63 cells.
Cells at 1x108 cells/flask were grown for 1, 3, or 6 days and were then incubated 
(approximately 100,000 cells/well) with ATP (A) or DBzATP (B) and 1 pM YO-PRO 1 
at 37°C for 5 minutes. YO-PRO 1 fluorescence was monitored in a 96-well plate 
reader using an excitation wavelength of 485 nm, and an emission wavelength of 520 
nm. Data are expressed as % of control in the presence vehicle. Statistical analyses 
were performed using one-way ANOVA with Newman-Keuls post-hoc test. * P<0.05, 
#<0.01 [n=3-4].
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Figure 4.21: Effect of days cells in growth on YO-PRO 1 uptake in SaOS2 cells.
Cells at 1x106cells/flask) were grown for 1, 3, or 6 days and were then incubated 
(approximately 100,000 cells/well) with ATP and DBzATP and 1 pM YO-PRO 1 at 
37°C for 5 minutes. YO-PRO 1 fluorescence was monitored in a 96-well plate reader 
using an excitation wavelength of 485 nm, and an emission wavelength of 520 nm. 
Data are expressed as % of control in the presence vehicle. Statistical analyses were 
performed using one-way ANOVA with Newman-Keuls post-hoc test, but no significant 
differences were seen. [n=3-4J.
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Figure 4.22: Representative example of Western blotting of the effect of 
incubating SaOS2 cells with ATP for 30 minutes on P2X7 receptor expression. 
SaOS2 cells were incubated with medium containing ATP 3  x 10‘3 M or water (ATP 
vehicle) at 37°C for 30 minutes, then trypsinized and lysed. Positive control (10 pg of 
HEK7 cell membrane in lane 1), and 25 pg of SaOS2 cell lysates from 3 different 
passages were separated on 10 % gels. A shows P2X7 receptor labelling. Bands were 
seen at 60 and 67 kDa, while the P-actin band was seen at 39 kDa. B shows P2X7 
receptor: p-actin ratio quantified using densitometric analysis. Statistical analyses 
were performed using Student’s t-Test, but no difference was seen [n=3]
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4.5 Discussion
This chapter investigated the functionality of P2X7 receptors in human 
osteoblast pharmacologically. This was performed by utilizing the pore 
formation characteristic upon receptor activation. The effect of different 
antagonists on the agonist-induced pore formation was also studied. 
Additionally, the effect of cell density, and the number of days cells had 
been in culture, on pore formation and the effect of ATP on receptor 
expression were studied.
4.5.1 Effect of P2Xt agonists on YO-PRO 1 uptake
YO-PRO 1 uptake after 5 minutes incubation was found to be 
significantly higher compared to 20 and 30 minute periods (Figure 4.2) 
in SaOS2 cells. This might be due to the fact that the P2X7 receptor on 
which ATP acts, is a death receptor (Di Virgilio et al., 1998; Sluyter and 
Wiley, 2002; Wang et al., 2004a), and that the cells were thus starting to 
die. In addition, it needs to be taken into consideration that the cells 
themselves are releasing ATP, thus this ATP would increase as cell 
number increase (Buckley et al., 2003). Another explanation, might be 
that the ATP is being broken down as it has been reported that the ATP 
added to SaOS2 cells was degraded completely within 120 minutes 
(Buckley et al., 2003).
Different agonists were used, to compare their potency on the P2X7 
receptor. Additionally, this comparison was useful to confirm that the 
P2X7 receptor is mainly responsible for the pore formation upon 
activation. The results demonstrated that all the agonists used were weak 
(EC50 values in the millimolar level), although DBzATP was slightly 
more potent than the others. These results are consistent with those 
obtained by Gartland et al 2001 where ATP and DBzATP showed
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similar effects in opening the pore in SaOS2 cells (Figure 4.5). DBzATP 
was not more potent than ATP, unlike results from experiments with 
cells containing transfected receptors (Chessell et al., 1998; Michel et al., 
1999; Lee et al., 2006). However, other studies in native cells have 
demonstrated DBzATP to be equipotent to ATP (Hickman et al., 1994; 
Gartland et al., 2001) or to be inactive in opening the pore when used at 
concentrations up to 100 pM (Cario-Toumaniantz et al., 1998). Another 
study found that ATP and DBzATP had comparable potency in inducing 
apoptosis in cells with endogenous receptors (Coutinho-Silva et al., 
1999). Therefore, it is possible that ATP and DBzATP are equipotent in 
cells expressing endogenous P2X7 receptors and/or that the high receptor 
number in transfected cells affects potency.
Comparison of agonist potencies for P2X2, P2 X4, and P2X7 receptors 
suggested that P2X7 receptors are most likely to be involved in my pore 
formation assay. This agrees with the results from the RT-PCR and 
Western blotting for the P2X2 receptor (described in Chapter 3). 
Although P2 X4 receptors are expressed in these cells (described in 
Chapter 3), the agonist potencies results suggest that they do not 
contribute significantly to pore formation. Also, the lack of receptor 
desensitization supports the involvement of the P2X7 receptor, rather 
than P2X2 or P2X* receptors as the latter desensitize upon long exposure 
(seconds in electophysiological studies) to agonists (North and Barnard, 
1997; North, 2002; Fountain and North, 2006; Sperlagh et al., 2006). 
P2X5 receptor has been shown to have little desensitization (North, 
2002). Direct comparison of the agonist potencies for P2X5 to that for 
P2 X4 and P2X7 receptors could not be done as the studies performed on 
P2X5 receptors utilized electrophysiological assays (Collo et al., 19%; Le 
et al., 1999). However, the study that reported pore formation with P2 X5 
receptor showed that YO-PRO 1 uptake occurred with 10 and 100 pM
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ATP and DBzATP, respectively (Bo et al., 2003). Additionally, they 
reported that the YO-PRO 1 uptake occurred after 60 seconds of agonist 
application and that divalent cations had no effect on the uptake (Bo et 
al., 2003).
Interestingly, ATP and 2Me-S-ATP at concentrations higher than 1 mM 
were found to reduce YO-PRO 1 uptake, an effect observed on inducing 
ethidium uptake by ATP in HEK7 cells (Humphreys et al., 1998; Lee et 
al., 2006). This may be due to the agonists binding to the calcium 
available in the buffer (Dweck et al., 2005; Saris and Carafoli, 2005) thus 
reducing the effective concentration. Another explanation may be that 
these agents are exposed to more breakdown at their higher 
concentrations. It was reported in the literature that ATP and 2Me-S- 
ATP potency was decreased by 100-1000 fold by breakdown (Kennedy 
and Leff, 1995). Another, more likely explanation, given the low 
concentration of calcium used in the current study, is that concentrations 
higher than lx l0 ‘3 M cause dephosphorylation of the P2X7 receptor on 
tyrosine-343. A similar effect was seen with repeated application of 
DBzATP (100 pM) on rat P2X7 receptors, where a decline in current 
recorded was observed (Kim et al., 2001). This dephosphorylation might 
cause either a change in channel conformation, or disrupt the protein- 
protein interactions needed for pore formation. Receptor desensitization 
can be ruled out as an explanation as it was not shown in the experiments 
performed on the MG63 and SaOS2 cells and is not reported by other 
studies.
In osteoblasts, Gartland et al 2001 found that one hour incubation with 
agonists was needed for pore formation. In contrast, in my study, a 5 
minute period was found to give maximal pore formation. This 
discrepancy might be due to methodological differences in the buffer and
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dye used (ethidium bromide used by Gartland et al. (2001)). Different 
times were found to be needed by others for the uptake of ethidium 
bromide and YO-PRO 1 through P2X7 receptor-induced pores (Dixon, J, 
Personal communication) which might be due to the dimensions of these 
dyes (See chapter 4). Based on the hour incubation period needed for 
pore formation, Gartland et al (2001) suggested that the P2X7 receptors 
have atypical pharmacology in osteoblasts. Atypical pharmacology is 
also seen in my study, but is based on the low potency of DBzATP 
compared to ATP as pore formation was seen within 5 minutes.
4.5.2 Effect of PZKt antagonists on YO-PRO 1 uptake 
induced bv agonists
Different P2X antagonists (BBG, KN62, PPADS, and oATP) were 
studied to investigate their effect on blocking the pore formation induced 
by the agonists (ATP and DBzATP) and reflected by the YO-PRO 1 
uptake.
An experiment was performed to determine the best pre-incubation 
period for the antagonists to inhibit YO-PRO 1 uptake and one hour was 
found to be the best pre-incubation time (data not shown). Pre-incubation 
period of P2X receptor antagonists was found to vary from one study to 
another. A pre-incubation period of 30 minutes with PPADS, oATP and 
KN62 was found to be enough to study the antagonist effect of these 
compunds on DBzATP-induced YO-PRO 1 uptake in HEK7 cells 
(Michel et al., 2000). Additionally, this study reported that 60 minutes 
pre-incubation did not increase these compounds antagonist effect 
(Michel et al., 2000). Another study used 20 minutes pre-incubation 
period for KN62 in DBzATP-induced YO-PRO 1 uptake assay (White et 
al., 2005). A pre-incubation period of one hour with PPADS was used to
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block DBzATP-induced blebbing in human osteoblasts (Gartland et al., 
2001).
Efforts to generate concentration-effect curves of all of the above 
mentioned antagonists with one concentration of agonist failed, which 
may be due to the atypical pharmacology of the receptor in these cells. 
Therefore, concentration-effect curves of the agonists in the presence of 
different concentrations of the antagonists were studied. The 
concentration-effect curves showed that the main action of the 
antagonists, BBG, KN62 and PPADS, was to reduce the maximum YO- 
PRO 1 uptake induced by ATP and DBzATP. There was no shift in the 
EC50 values. oATP had no effect on YO-PRO 1 uptake in either cell 
lines.
The antagonists were found to behave in a similar non-competitive 
manner in human osteoblasts compared to data reported in the literature 
in other cell-lines (Michel et al., 2000). BBG was reported to be more 
potent at P2X7 receptors compared to other receptors (IC50 values in the 
nanomolar range (Hibell et al., 2000; Jiang et al., 2000; Khakh et al., 
2001b; Sperlagh et al., 2006)), and the effect found here is probably on 
the P2X7 receptor. KN62 is reported in the literature to be the most 
potent P2X7 receptor antagonist with an IC50 value in the nanomolar 
range (Sperlagh et al., 2006). However, that was not found here. The 
reason for this difference is not clear, but may be related to the atypical 
pharmacology of the receptor in the human osteoblasts. Another 
explanation for these results may be the involvement of the P2X4 and/or 
P2X5 receptor in pore formation, but this is unlikely due to affinities of 
the agonists and the reported higher potency of PPADS on P2X5 
compared to P2X7 receptors (North and Suprenant, 2000a; Gever et al.,
2006), but it was found to be weakly active in this study. Alternatively,
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the P2X7 receptor may form a heterodimer with P2 X4 receptor, a 
possibility that very recently has been reported in other cells (Guo et al.,
2007). A heterodimer would probably have different affinities for 
agonists and antagonists compared to homomeric receptors.
4.5.3 Effect of cell density on YO-PRO 1 uptake induced 
bv agonists
The effect of cell density, and the days cells had been maintained in 
culture, on YO-PRO 1 uptake were studied in relation to P2X7 receptor 
protein expression. The purpose of these experiments was to find if cell 
density and the days cells had been kept in culture affected the receptor 
pore formation, and if the functional form of the receptor in osteoblasts is 
the 85 kDa band reported in the literature. It needs to be taken into 
consideration that RT-PCR illustrated that receptor mRNA expression 
was significantly higher at the highest SaOS2 cell density used (see 
Chapter 3).
Although most of the results obtained were not significant, a trend was 
observed in the modulation of the receptor function by cell density and 
the days of cells in culture as reflected by YO-PRO 1 uptake. It was 
observed here that there is an inverse relationship between cell density 
and days of culture and the YO-PRO 1 uptake in MG63 cells, but this 
relationship was less clear in SaOS2 cells. The effect of ATP and 
DBzATP on YO-PRO 1 uptake supports earlier data suggesting that the 
85 kDa form of the P2X7 receptor might not be the functional form (see 
Chapter 3). This is based on the observation that the intensity of this 
band increased as the cell density and the days in culture increased, while 
the YO-PRO 1 uptake was observed to decrease with increasing cell 
density and days of cells in culture, especially in the MG63 cells. The
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reason for the effect of cell density and days of cells in culture on the 
receptor function is not known, but other pore-forming purinergic 
receptors (P2 X4 and P2X5) may be involved, or the P2 X7/P2 X4 
heteromer may exist (Guo et al., 2007).
4.6 Conclusion
Both the MG63 and SaOS2 cells were found to form a pore upon 
activation with ATP and DBzATP using the YO-PRO 1 uptake method. 
My results suggest that the P2X7 receptor is likely to be mainly 
responsible for YO-PRO 1 uptake in these two osteoblast cell lines, 
although the P2 X4 and P2X5 receptors might also be involved, although 
unlikely. This is based on the affinities of the four agonists used to 
induce pore formation and the lack of receptor desensitisation. The 
unexpectedly low affinity of DBzATP, reported to be more potent than 
ATP in the literature, and the weak action of the antagonists confirms 
earlier studies showing the atypical pharmacology of the P2X7 receptor 
in osteoblast cells. Additionally, the observed effects of cell density and 
days of culture on YO-PRO 1 uptake supports earlier findings with 
Western blotting that the 85 kDa form is not the functional form of the 
P2X7 receptor in human osteoblasts.
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Chapter 5: Effect of P2X7 
activation on osteoblast 
function
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5.1 Introduction
5.1.1 Bone metabolism markers
Bone metabolism is an active process that includes bone modelling and 
remodelling, and in the normal situation results in a balance between 
bone resorption and formation (Christenson, 1997) (see detailed section 
in Chapter 1). Biochemical markers are used for monitoring bone 
metabolism and diagnosing diseases. Some of these markers are related 
to osteoblastic bone formation such as ALP and others are related to 
osteoclastic bone resorption such as hydroxyproline (Bikle, 1997; 
Christenson, 1997; Weisman and Matkovic, 2005; Hannon and Eastell, 
2006).
ALP
ALP is the most commonly used osteoblastic bone formation marker 
(Bikle, 1997). It is a plasma membrane enzyme released extracellularly. 
Although its exact function is not clear, it is thought to be involved in the 
shift of some substances (such as inorganic phosphate and calcium) from 
the intracellular to the extracellular region (Christenson, 1997). Four 
widely distributed isoenzymes exist One specific isoenzyme is 
associated with liver, bone, placental and intestinal tissues (Whyte, 1994; 
Christenson, 1997; Balcerzak et al., 2003).
Bone ALP is found in the plasma membrane of osteoblasts, and is 
released in large amounts during bone formation, therefore it is a good 
marker of bone formation (Bikle, 1997; Christenson, 1997). Its 
importance in bone formation was proven by its deficiency in 
hypophosphatasia which causes bone diseases such as rickets (Whyte, 
1994; Bikle, 1997; Wennberg et al., 2000). Interestingly, it was found
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that osteoblasts from ALP-knockout mice can differentiate normally, but 
their initiation of mineralisation in vitro was impaired (Wennberg et al., 
2000). In bone, ALP has been suggested to be involved in the transport 
of inorganic phosphate extracellularly and its increase locally, cellular 
uptake of calcium, and destruction of inhibitors of hydroxyapatite crystal 
growth (Whyte, 1994).
In addition to its role in the diagnosis and monitoring of metabolic bone 
diseases such as osteoporosis, bone ALP can be used in the diagnosis of 
bone metastases (Bikle, 1997; Hannon and Eastell, 2006).
ALP contribution from other tissues is problematic in the accurate 
measurement of bone-ALP, but sensitive immunoassay kits that can 
identify the bone ALP isoenzyme have been developed (Bikle, 1997; 
Christenson, 1997; Hannon and Eastell, 2006). However, this is not a 
problem in experiments such as mine on osteoblasts in cell culture.
5.1.2 Cvtokine release and bone
Many cytokines are involved in bone metabolism (Lowik, 1992; 
Roodman, 1993) and the pathogenesis of some of bone diseases such as 
osteoporosis (Lowik, 1992; Roodman, 1993; Manolagas, 2000; Fini et 
al., 2004) and RA (Lowik, 1992; Roodman, 1993; Andreakos et al., 
2002; Boyce et al., 2005; Clark et al., 2005; Walsh et al., 2005). Two of 
the cytokines which have been studied extensively and demonstrated to 
play a major role in bone metabolism and diseases are IL-6 and IL-1 (a 
and p). IL-6 is produced by osteoblasts and acts as a signalling pathway 
for the stimulation of osteoclastic bone resorption (Canalis et al., 1991; 
Lowik, 1992; Manolagas, 2000; Fini et al., 2004). The action of IL-6 on 
resorption is believed to be via stimulation of osteoclast differentiation
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and activity (Lowik, 1992; Roodman, 1993; Connell and Mclnnes, 
2006). High levels of IL-6 have been detected in the serum and synovial 
fluid of RA patients (Abramson and Yazici, 2006; Connell and Mclnnes,
2006). Additionally, many cytokines including IL-6 are released by 
osteoclasts and stimulate the growth of multiple myeloma cells 
(Hideshima et al., 2005). IL-1 is also involved in bone resorption and 
levels are increased in some forms of osteoporosis (Canalis et al., 1991; 
Roodman, 1993). IL-1 was found to be involved in the inflammatory 
process of RA and in the release of IL-6. Both IL-1 and 6 have been 
reported to modulate expression of RANKL which is involved in 
ostoeclast bone resorption (Theoleyre et al., 2004; Feng, 2005a).
5.1,3 P2Xt receptor-induced cytokine release
The P2X7 receptor has been found to be important in immune and 
inflammatory responses, such as cytokine release (Di Virgilio et al., 
2001; Bours et al., 2006). Ferrari et al., (1997) reported release of IL-1 p 
by microglial cells stimulated with bacterial endotoxin. This effect was 
inhibited by the P2X7 antagonist oATP which led to the receptor being 
described as the cytokine release pore (Ferrari et al., 1997). To prove the 
importance of the P2X7 receptor in IL-lp release and signalling, P2X7 
receptor knockout mice were studied. In these mice, macrophages 
activated with ATP were unable to release IL-ip, and consequently the 
cytokine signalling cascade was impaired (Solle et al., 2001). A similar 
finding was reported by Labasi et al., (2002), who found that leukocytes 
from P2X7 receptor-deficient mice lost their function including IL-lp 
production, and concluded that the receptor has an important role in 
inflammatory processes (Labasi et al., 2002). Furthermore, IL-lp release 
from macrophages stimulated with lipopolysaccharide (LPS) or 
lipopeptide was found to be lOOx faster when ATP was added (Qu et al.,
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2007). Additionally, P2X7 receptors were found to be involved in the 
release of the anti-inflammatory protein, intracellular interleukin-1 
receptor antagonist type-1 (icIL-lra) from both macrophages and 
endothelium (Wilson et al., 2004). In addition to its release as a 
consequence of P2X7 receptor stimulation, IL-lp may change P2X7 
receptor expression. In human fetal brain astrocytes, it was found to
i
increase P2X7 receptor-mediated Ca influx and pore formation induced 
by the agonist, DBzATP (Narcisse et al., 2005).
Ferrari et al (2006) described the P2X7 receptor as a key player in the 
release of the IL-1 family members (Ferrari et al., 2006). Short 
stimulation of P2X7 receptor causes the release of the 17 kDa form of IL- 
lp, while long stimulation causes the release of the 31 kDa form (Ferrari 
et al., 2006). The need for LPS for P2X7 receptor-induced IL-lp release 
is debatable (Ferrari et al., 2006). K+ efflux was reported to be important 
for its release in response to P2X7 receptor activation, but other 
intracellular ions such as Ca2+ might also be involved (Ferrari et al., 
2006). IL-lp release was inhibited after a mutation of the P2X7 receptor 
that prevented pore formation (Ferrari et al., 2006). Cell lysis is not 
necessary for IL-lp release as it was found that it occurred in the absence 
of cell lysis (Ferrari et al., 2006). While IL-lp and IL-10 release were 
found to be attenuated in knockout mice, IL-6 release was found to be 
enhanced, which is thought to be a potential compensatory mechanism 
(Hughes et al., 2007).
Murine mast cells were found to express the P2X7 receptor and, 
following its stimulation, proinflammatory cytokines, such as IL-4, IL-6, 
IL-13, and TNF-a were released. This release was blocked by the P2X7 
antagonists KN62 and oATP (Bulanova et al., 2005).
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In systemic lupus erythematosus (SLE), a polymorphism in the P2X7 
receptor gene was found in mice. Since the P2X7 receptor gene in both 
mice and humans was shown to be located in the lupus susceptibility 
loci, it was hypothesized that a polymorphism in the human P2X7 
receptor gene may be involved in SLE pathogenesis. This was also based 
on the role of P2X7 receptor in IL-lp secretion and apoptosis (Elliott et 
al., 2005).
Since P2X7 receptor expression and function in human osteoblasts were 
demonstrated in the preceeding chapters, the current chapter investigates 
its relevance to bone formation and the release of markers associated 
with osteoblast function.
5.2 Aims
To study the effects of P2X7 receptor activation and inhibition on aspects 
of osteoblast function using the SaOS2 and MG63 cell lines.
• To investigate the effect of P2X7 receptor activation and inhibition 
on ALP release.
• To investigate the effect of P2X7 receptor activation and 
inhibition on the release of the cytokines, IL-6 and IL-1 p.
• To investigate the effect of P2X7 receptor activation and inhibition 
on osteoblast mineralisation.
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5.3 Experimental protocols
The protocols used to study the effect of activation and blocking of P2X7 
receptors on the physiological actions of osteoblasts were described in 
detail in Chapter 2.
In all experiments involving BBG, the cells were incubated with the 
antagonist for one hour then the agonists (ATP or DBzATP) were added. 
These experiments are described in detail below.
5.3.1 ALP assay
An experiment was performed to determine the effect of blocking the 
P2X7 receptor with BBG on ALP activity induced by ATP and DBzATP. 
After 24 hours of plating, the cells were incubated with BBG at 37°C for 
one hour. Then the cells were treated with ATP or DBzATP, and ALP 
activity and cell number were measured after 2 days of treatment as 
described in chapter 2.
5.3.2 Cytokine release
SaOS2 cells were seeded in 24 well plates at 100,000 cells per well and 
incubated overnight. The next day, media was collected for baseline 
assay and cells were incubated with BBG at 37°C for one hour then the 
cells were treated with the vehicle, water, ATP or DBzATP. On day 4 
after plating media was collected for assay, and fresh DMEM containing 
the different compounds (ATP & DBzATP ± BBG) was added. On day 7 
after plating media was collected for the 6 day assay. Then, the IL-6 or 
IL-lp ELISA assay was performed as described in Chapter 2.
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5.3.3 Mineralisation
SaOS2 cells were seeded in 6 well plates at 500,000 cells per well and 
incubated overnight. The next day, DMEM was changed to one 
containing ascorbic acid (50 pg/ml). On the next day, the cells were 
incubated at 37°C for one hour with DMEM containing ascorbic acid (50 
pg/ml), p-glycerophosphate (8 mM), and BBG. Next the vehicle, water, 
ATP or DBzATP were added and the cells incubated at 37°C. This 
treatment was repeated twice weekly until day 15, when cells were 
stained with freshly prepared 1% alizarin red S as described in Chapter 2.
The mineralisation assay was not performed in MG63 cells because they 
do not form bone nodules in vitro (Hughes and Aubin, 1998).
5.4 Results
5.4.1 ALP
A ratio o f  alkaline buffer solution to phosphatase substrate o f  9:1 was 
used in SaOS2 cells, while this ratio was 1:1 in MG63 cells. However, 
basal ALP levels were found to be significantly (p value<0.0001 for 2 
day results) higher in SaOS2 cells (1.023 ± 0.021 OD corrected for cell 
number on day 2) compared to MG63 cells (0.052 ±0.012 OD corrected 
for cell number on day 2). In both cell lines these concentrations were 
found to decrease significantly from days 2 to 7. In SaOS2 cells basal 
ALP activity was found to decrease significantly by approximately 60 % 
and 75 % from day 2 to day 5 (p value<0.0001) and day 7 (p 
value<0.0001), respectively (Figure 5.1 A). In MG63 cells ALP activity 
decreased significantly by approximately 73 % and 79 % from day 2 to 
day 5 (p value<0.01) and day 7 (p value<0.001), respectively(Figure 
5 .IB).
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ATP 4xl0"5 M significantly stimulated ALP activity in both cell lines. 
This increase in SaOS2 cells on days 2 and 5 was 52 and 30 %, 
respectively (Figure 5.2). In MG63 cells an increase of 21 and 15 % was 
observed on days 5 and 7, respectively (Figure 5.3). Significant increases 
or decreases in ALP activity were also seen with other ATP 
concentrations but were not consistent between the cell lines (Figures 5.1 
and 5.2)
All the ATP concentrations used here were found to have no effect on 
the cell numbers except the 4x10‘5 M concentration, which significantly 
reduced SaOS2 cell numbers on day 2, and MG63 cell numbers on days 
5 and 7 (Figure 5.4).
Since the effect on ALP activity with ATP was most pronounced after 2 
days of incubation in SaOS2 cells, this time point was used for all future 
studies. An increase in ALP activity was also found with DBzATP 
(Figure 5.5). At lxlO'6 M DBzATP significantly increased ALP activity 
by 20 % in SaOS2 cells, while no significant changes were seen in 
MG63 cells. The increase in ALP activity seen with DBzATP (20 % 
increase with lxlO*6 M ) was significantly (p value=0.01) less than that 
seen with ATP (52 % increase by 4x10‘5 M) in SaOS2 cells. Higher 
DBzATP concentrations caused massive cell death (data not shown) and 
therefore the effect on ALP could not be determined. The concentrations 
of DBzATP used here did not show any significant effect on cell number 
(Figure 5.6).
To find the effect of blocking the P2X7 receptor on ALP activity, two 
antagonists, BBG and KN62 were studied. Preliminary experiments 
showed that KN62 could not be tested further because 10 % DMSO 
(KN62 vehicle) had a highly toxic effect on the cells, leading to cell
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death. Hence only BBG was tested. BBG was used at a concentration of 
5x1 O'6 M as this was the concentration which showed the maximum 
block in the YO-PRO 1 uptake assays (Chapter 4). Preliminary data 
showed that BBG at this concentration had no effect on ALP activity on 
its own (Figure 5.7).
In SaOS2 cells, BBG was found to decrease significantly the ALP 
activity induced by ATP by approximately 12 % (Figure 5.8A). ALP 
activity in response to the combination of DBzATP and BBG was 
significantly lower than DBzATP alone (Figure 5.8B). In MG63 cells, 
ATP significantly increased ALP activity by approximately 21 % (Figure 
5.9A), but BBG had no effect on this increase. Neither DBzATP alone 
nor in combination with BBG had any effect on ALP activity (Figure 
5.9B).
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Figure 5.1: Basal ALP activity in SaOS2 and MG63 cells.
SaOS2 (A) and MG63 (B) cells were grown for 2, 5, and 7 days then ALP (OD) and 
cell number (OD) were determined. ALP activity was corrected for cell number. Data 
are expressed as mean ± SEM. Statistical analyses were performed using Student’s t- 
Test. *P<0.01, #P< 0.001, **P<0.0001 vs. 2 days. (n=4-5)
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Figure 5.2: Effect of ATP on ALP activity in SaOS2 cells.
Cells were grown for 2(A), 5(B), and 7(C) days with ATP 1x10'®, 4x10-®, 1x10®, 4x10'5 
M or water (ATP vehicle) then ALP (OD) and cell number (OD) were determined. ALP 
activity was corrected for cell number. Data are expressed as mean percentage ± 
SEM of control containing vehicle. Statistical analyses were performed using one-way 
ANOVAwith Newman-Keuls post-hoc test. *P<0.05, **P<0.01 vs. control. (n=4)
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Figure 5.3: Effect of ATP on ALP activity in MG63 cells.
Cells were grown for 2(A), 5(B), and 7(C) days with ATP 1x1 O'6, 4x1c6, 1x105, 4x1 O'5 
M or water (ATP vehicle) then ALP (OD) and cell number (OD) were determined. ALP 
activity was corrected for cell number. Data are expressed as mean percentage ± 
SEM of control containing vehicle. Statistical analyses were performed using one-way 
ANOVA with Newman-Keuls post-hoc test. *P<0.05, **P<0.01 vs. control. (n=3-5)
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Figure 5.4: Effect of ATP on SaOS2 (A) and MG63 (B) cell number.
Cells were grown for 2, 5, and 7 days with ATP then cell numbers were determined by 
reading the absorbance at 490 nm (OD) using a Cell Titer 96 Non-Radioactive Cell 
proliferation assay. Statistical analyses were performed using one-way ANOVA with 
Newman-Keuls post-hoc test. Data are expressed as mean ± SEM. *P<0.05 vs. 
control. (n=3).
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Figure 5.5: Effect of DBzATP on ALP activity in SaOS2 (A) and MG63 (B) cells.
Cells were grown for 2 days with DBzATP 5x1O'7, 1x1 O'6, 5x1 O'6, 1x10"5 M or water 
(DBzATP vehicle) then ALP (OD) and cell number (OD) were determined. ALP activity 
was corrected for cell number. Data are expressed as mean percentage ± SEM of 
control containing vehicle. Statistical analyses were performed using one-way ANOVA 
with Newman-Keuls post-hoc test. *P<0.05 vs. control. (n=4-5)
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Figure 5.6: Effect of DBzATP on SaOS2 (A) and MG63 (B) cell number.
Cells were grown for 2 days with DBzATP then cell numbers were determined by 
reading absorbance at 490 nm (OD) using a Cell Titer 96 Non-Radioactive Cell 
proliferation assay. (n=3). Statistical analyses were performed using one-way ANOVA 
with Newman-Keuls post-hoc test. Data are expressed as mean ± SEM. *P<0.05 vs. 
control.
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Figure 5.7: Effect of BBG on ALP activity in MG63 (A) and SaOS2 (B) cells.
Cells were incubated with BBG 5x10"® M or water (BBG vehicle) for one hour then 
grown for 2 days then ALP (OD) and cell number (OD) were determined. ALP activity 
was corrected for cell number. Data are expressed as % of control containing vehicle. 
(n=1)
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Figure 5.8: Effect of BBG on blocking ALP activity induced by ATP (A) and 
DBzATP (B) in SaOS2 cells.
Cells were incubated with BBG 5x1 (T6 M or water (BBG vehicle) for one hour then 
grown for 2 days with ATP 4x10'5M, DBzATP 1x1 O'6 M or water (ATP and DBzATP 
vehicle) then ALP (OD) and cell number (OD) were determined. ALP activity was 
corrected for cell number. Data are expressed as mean percentage ± SEM of control 
containing vehicle. Statistical analyses were performed using one-way ANOVA with 
Newman-Keuls post-hoc test. **P<0.01, #P<0.001. (n=3-4)
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Figure 5.9: Effect of BBG on blocking ALP activity induced by ATP (A) and 
DBzATP (B) in MG63 cells.
Cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour then 
grown for 2 days with ATP 4x10 5M, DBzATP 1x10"® M or water (ATP and DBzATP 
vehicle) then ALP (OD) and cell number (OD) were determined. ALP activity was 
corrected for cell number. Data are expressed as mean percentage ± SEM of control 
containing vehicle. Statistical analyses were performed using one-way ANOVA with 
Newman-Keuls post-hoc test. *P<0.05 vs. control. (n=3-4)
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5.4.2 Cytokine release
Since ATP 4x10‘5 M and DBzATP lxlO'6 M gave the most significant 
increases in ALP release, these concentrations were used for all IL-6, IL- 
1(3 and mineralisation assays. BBG was used at a concentration of 5x1 O'6 
M, as this was the concentration which showed the maximum block in 
the YO-PRO 1 uptake assays (Chapter 4). These experiments were only 
performed in SaOS2 cells as they produced the largest changes in 
response to ATP and DBzATP.
IL-6
Basal IL-6 release in SaOS2 cells was 3.8 ± 0.8 pg/mg protein after 3 
days, while it was 2.9 ± 0.4 pg/mg protein after 6 days. ATP significantly 
increased IL-6 release from control after 3 and 6 days incubation by 
approximately 350 %. BBG alone had no effect on the release of IL-6 by 
SaOS2 cells at either time point. BBG significantly blocked the ATP- 
induced release after both periods of incubation (Figure 5.10).
DBzATP had no effect on IL-6 release after either period of incubation. 
Again no effect of BBG alone on the release of IL-6 by SaOS2 cells was 
seen. IL-6 release in response to BBG and DBzATP combined was 
significantly lower than DBzATP alone after 6 days (Figure 5.11).
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Figure 5.10: Effect of ATP and BBG on IL-6 release from SaOS2 cells.
Cells were incubated with BBG 5x10‘6 M or water (BBG vehicle) for one hour then 
grown for 3 (A) and 6 (B) days with ATP 4x10~5M or water (ATP vehicle) then media 
and cells were collected for the IL-6 and protein assays. IL-6 data were corrected for 
protein concentrations. Data are expressed as mean percentage ± SEM of control 
containing vehicle. Statistical analyses were performed using one-way ANOVA with 
Newman-Keuls Post-Hoc test. *P<0.05, **P<0.01. (n=3-4)
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Figure 5.11: Effect of DBzATP and BBG on IL-6 release in SaOS2 cells.
Cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour then 
grown for 3 (A) and 6 (B) days with DBzATP 1x1 O'6 M or water (DBzATP vehicle) then 
media and cells were collected for the IL-6 and protein assays. IL-6 data were 
corrected for protein concentrations. Data are expressed as mean percentage ± SEM 
of control containing vehicle. Statistical analyses were performed using one-way 
ANOVA with Newman-Keuls Post-Hoc test. *P<0.05 vs. control. (n=3-4)
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ILdfi
Basal IL-lp release in SaOS2 cells was 4.4 ± 0.57 pg/mg protein after 3 
days, while it was 4.1 ± 0.81 pg/mg protein after 6 days. Neither ATP 
nor DBzATP had any significant effect on IL-lp release from SaOS2 
cells after 3 or 6 days incubation (Figures 5.12 and 5.13). BBG alone had 
no effect on control cell IL-ip release at either time point (Figures 5.12 
and 5.13). The combination of ATP and BBG significantly increased IL- 
1 p release by approximately 62 % compared to control only after 3 days 
(Figure 5.12A). DBzATP and BBG together had no effect on IL-lp 
release at either time point (Figure 5.13).
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Figure 5.12: Effect of ATP and BBG on IL-1/3 release from SaOS2 cells.
Cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour then 
grown for 3 (A) and 6 (B) days with ATP 4x10‘5M or water (ATP vehicle) then media 
and cells collected for IL-1(3 and protein assay. IL-1 p data were corrected for protein 
concentrations. Data are expressed as  mean percentage ± SEM of control containing 
vehicle. Statistical analyses were performed using one-way ANOVA with Newman- 
Keuls Post-Hoc test. *P<0.05 vs. control. (n=3)
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Figure 5.13: Effect of DBzATP and BBG on IL-1/3 release in SaOS2 cells.
Cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour then 
grown for 3 (A) and 6 (B) days with DBzATP 1x1 O^M or water (DBzATP vehicle) then 
media and cells collected for IL-1(3 and protein assay. IL-1 p data were corrected for 
protein concentrations. Data are expressed as  mean percentage ± SEM of control 
containing vehicle. Statistical analyses were performed using one-way ANOVA with 
Newman-Keuls Post-Hoc test, but no significant differences were seen. (n=3)
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5.4.3 Mineralisation
SaOS2 cells were incubated for 15 days with ATP 4x10“5 M, DBzATP 
lxKT6 M, ATP with BBG 5x10^  M, or DBzATP with BBG 5x1c6 M, 
which were replenished twice weekly. None of the treatments used had 
any effect on the bone nodule formation (mineralisation) (Figures 5.14, 
5.15, and 5.16). A protein assay was performed (Tables 5.1 and 5.2), but 
no significant differences between treatments were observed.
173
P2X7 Receptors in Osteoblasts
Figure 5.14: Representative example of the effect of ATP and BBG on nodule 
formation (mineralisation) in SaOS2 cells.
Cells were incubated with BBG 5x1 (T6 M or water (BBG vehicle) for one hour then 
grown for 15 days with ATP 4x10'5M or water (ATP vehicle), which were replenished 
twice weekly. Cells were then stained with alizarin red S. Another identical plate was 
used for a protein assay. (n=3) A: ATP, B: ATP + BBG, C: Control.
Protein (mg/ml) ± SEM
Control 1.90 ±0.37
ATP 1.72 ±0.31
BBG + ATP 1.59 ±0.30
Table 5.1: Effect of ATP and BBG protein concentration.
SaOS2 cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour 
then grown for 15 days with ATP 4 x 1 0 ^  or water (ATP vehicle), which were 
replenished twice weekly. Cells were then removed for a protein assa. Another 
identical plate was stained with alizarin red S for mineralised nodule formation. Data 
are expressed as mean ± SEM. Statistical analyses were performed using one-way 
ANOVA with Newman-Keuls Post-Hoc test but no significant differences were seen. 
(n=3)
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Figure 5.15: Effect of DBzATP and BBG on nodule formation (mineralisation) in 
SaOS2 cells.
Cells were incubated with BBG 5x10-6 M or water (BBG vehicle) for one hour then 
grown for 15 days with DBzATP1x10'6 M or water (DBzATP vehicle), which were 
replenished twice weekly. Cells were then stained with alizarin red. Another identical 
plate was used for a protein assay. (n=3) A: DBzATP, B: DBzATP + BBG, C: Control.
Protein (mg/ml) ±  SEM
Control 1.89 ± 0 .2 6
DBzATP 1.77 ± 0 .2 0
BBG+DBzATP 1.80 ± 0 .2 5
Table 5.2: Effect of DBzATP and BBG on protein concentration.
SaOS2 cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour 
then grown for 15 days with DBzATPIxlO-6 M or water (DBzATP vehicle), which were 
replenished twice weekly. Cells were then removed for a protein assay for cell death. 
Another identical plate was stained with alizarin red S for mineralised nodule 
formation. Data are expressed as mean ± SEM. Statistical analyses were performed 
using one-way ANOVA with Newman-Keuls Post-Hoc test but no significant 
differences were seen. (n=3)
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Figure 5.16: Effect of ATP, DBzATP and BBG on nodule formation 
(mineralisation) in SaOS2 cells.
Cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour then 
grown for 15 days with ATP 4x10‘5M, DBzATP 1x1 O'6 M or water (ATP & DBzATP 
vehicle), which were replenished twice weekly. Cells were then stained with alizarin 
red. Data are expressed as mean percentage ± SEM of control containing vehicle. 
Another identical plate was used for a protein assay. Statistical analyses were 
performed using one-way ANOVA with Newman-Keuls Post-Hoc test but no significant 
differences were seen. (n=3)
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5.5 Discussion
This chapter investigated the effect of P2X7 receptor activation and 
inhibition on aspects of osteoblast physiological function i.e. ALP 
activity, cytokine release and mineralised nodule formation.
5.5.1 Effect of P2X? receptor activation and 
inhibition on ALP activity and mineralisation
The effect of ATP and DBzATP on ALP activity (corrected for cell 
number) in osteoblast-like cells was studied. It was found that ATP 
significantly increased ALP activity in a concentration-related manner 
after 2, 5 and 7 days incubation in SaOS2 and MG63 cells. SaOS2 cells 
are known to be more differentiated than MG63 cells (Hughes and 
Aubin, 1998), hence they have increased ALP production needed for 
bone formation, and this could explain why the effect of ATP was found 
to be greater in this cell line. ATP 4xl0"5 M significantly increased ALP 
activity in SaOS2 by approximately 52% on day 2, but only a 21 % 
increase was seen in the MG63 cells on day 5, may be reflecting the 
difference in stage of osteoblast differentiation in these two cell lines 
(Hughes and Aubin, 1998). An interesting finding was that basal and 
stimulated ALP activity was found to decrease sequentially significantly 
from day 2 to 7 in both cell lines in all groups. This decrease was greater 
than 75 % in some cases, and might be explained by increased stress 
associated with increased cell number reducing the ability of the cells to 
produce ALP. Another reason might be that a production on need 
mechanism exists, where the release of ALP is dependent on the actual 
need for it i.e. when the need decreases activity decreases, and the 
release might be more in the first days of bone formation or in this case 
cells in growth.
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DBzATP altered the ALP activity of SaOS2 cells as well, but this was 
found to be significantly less compared to ATP. At lxlO-6 M DBzATP 
significantly increased ALP activity by 20 % in SaOS2 cells only, while 
no effect was seen in MG63 cells. This suggests that the involvement of 
P2X7 receptors in ALP activity might be small. However, there does 
appear to be a P2X7 receptor component. BBG, a more potent antagonist 
on P2X7 receptors than other P2 receptors (Hibell et al., 2000; Jiang et 
al., 2000; Khakh et al., 2001b; Sperlagh et al., 2006), was found to block 
the ATP-induced ALP release. Another more likely explanation is that 
some of the serum constituents available in the medium might be binding 
DBzATP and reducing its potency on ALP production, while ATP- 
induced ALP release was not affected. This has been shown previously 
for ATP and DBzATP on ethidium bromide uptake (Michel et al., 2001). 
The difference in P2X7 receptor-induced ALP activity between MG63 
and SaOS2 cells might be due to the different stages of differentiation of 
these two cell types (Hughes and Aubin, 1998). In a previous study, ATP 
inhibited ALP activity in rat osteoblasts, an effect claimed to be via P2Y2 
receptors (Orriss et al., 2007). The difference with the results seen here 
might be due to the receptor involved and it might be species-dependent. 
The involvement of P2Yh receptors in the increased ALP activity seen 
here might be possible taking into consideration that DBzATP is active 
on this receptor (Ziganshin et al., 2002; Bumstock, 2007). However, the 
possibility of P2X7 receptor involvement is stronger as suggested by the 
inhibition of the ATP-induced ALP activity with BBG.
Since ALP is a bone formation marker (Bikle, 1997), the effect of P2X7 
receptor activation on its activity suggests a role for the P2X7 receptor on 
bone formation. The findings in the current project are in accordance 
with the previous findings of the effect of P2X7 receptor deletion on bone 
formation in mice (Ke et al., 2003). These P2X7 receptor knockout mice
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were found to have reduced bone formation compared to the wild-type 
(Ke et al., 2003).
Regarding the effect on cell number, ATP was used at concentrations 
that had a minimal effect on cell number in order to have a more accurate 
ALP assay. However, there was still a clear reduction in cell number, but 
only at one concentration. This reduction is most probably due to the 
action of ATP on P2X7 receptors, as it has been described to be a death 
receptor, as cell death resulting from its stimulation by either necrosis or 
apoptosis has been reported (Di Virgilio et al., 1998; Sluyter and Wiley, 
2002; Wang et al., 2004a; Elliott et al., 2005). The DBzATP 
concentrations used in this assay were lower than those of ATP 
(maximum concentration 40 pM) as DBzATP was found to be very 
toxic, causing death of almost all the cells at higher concentrations (data 
not shown). This might be an additional explanation for the small effect 
of DBzATP on ALP activity as its concentration (10 pM) may not have 
been high enough to activate P2X7 receptors sufficiently to increase ALP 
activity. This is supported by the DBzATP EC50 values for YO-PRO 1 
uptake which were found to be 0.5 mM ± 0.04 and 0.36 mM ± 0.04 for 
MG63 and SaOS2 cells, respectively, whilst they were 0.36 mM ± 0.03 
and 0.43 mM ± 0.04 respectively for ATP (see Chapter 4).
Mineralised bone nodules can be formed in vitro by using 13- 
glycerophosphate which acts as a substrate for ALP causing an increase 
in the concentration of inorganic phosphate and mineral deposition 
subsequently (Hughes and Aubin, 1998). Ascorbic acid is necessary for 
in vitro bone nodule formation as it promotes collagen maturation 
leading to extracellular matrix deposition (Hughes and Aubin, 1998). 
Neither ATP nor DBzATP were found to have any effect on 
mineralisation, an effect unlikely to be due to the assay as it was shown
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to be working previously (Davies et al., 2003). In a previous study, ATP 
inhibited bone nodule formation by rat osteoblasts, an effect claimed to 
be via P2 Y2 receptors (Orriss et al., 2007). The difference with the 
results seen here might be due to the receptor involved and the species 
used. These findings suggest that the role of P2X7 receptor on bone 
formation demonstrated previously (Ke et al., 2003) is not a direct 
action, but modulatory as indicated by the increase in ALP activity. 
Higher concentrations of ATP and DBzATP could not be tested due to 
their toxicity.
5.5.2 Effect of P2X? receptor activation and 
inhibition on cytokine release
Different cytokines (including IL-lp and 6) have been found to be 
involved in the RA inflammatory process (Andreakos et al., 2002; Boyce 
et al., 2005; Clark et al., 2005; Walsh et al., 2005). Additionally, IL-6 
was reported to be involved in the communication between osteoblasts 
and osteoclasts and its upregulation is involved in the pathogenesis of 
osteoporosis (Manolagas, 2000; Fini et al., 2004). Furthermore, 
stimulation of the P2X7 receptor has been reported to induce the release 
of many cytokines such as IL-ip, IL-4, IL-6, IL-13, and TNF-a (Ferrari 
et al., 1997; Bulanova et al., 2005; Di Virgilio, 2007; Hughes et al., 
2007) which led to its description as the cytokine release pore (Ferrari et 
al., 1997).
The effect of P2X7 receptor activation and inhibition on cytokine release 
was studied here and it was found that ATP significantly increased IL-6 
release from SaOS2 cells after 3 and 6 days of incubation. The effect of 
BBG on blocking this ATP-induced IL-6 release suggests that it is most 
probably due to P2X7 receptor activation. However, while DBzATP was
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found to produce no significant increase alone, BBG significantly 
reduced IL-6 release compared to DBzATP alone after 6 days 
incubation. The small DBzATP effect compared to ATP might be due to 
its lower concentration used (to reduce cell death), or its binding to 
serum constituents. Since IL-6 was reported to be involved in osteoblast- 
osteoclast signalling, this increase in IL-6 release is likely to stimulate 
osteoclastogenesis and hence resorption.
Adenosine receptors were reported to be involved in the release of IL-6 
from human osteoblast precursors (Evans et al., 2006) and osteoblastic 
cell lines (Russell et al., 2007). The involvement of adenosine receptors 
in the IL-6 release seen here from osteoblasts might be possible taking 
into consideration that adenosine is a metabolite of ATP (Lazarowski et 
al., 2003), and that any added ATP is degraded completely within a 
period of 2 hours (Buckley et al., 2003). Nonetheless, this involvement is 
most probably minimal due to the blocking effect of BBG on ATP- 
induced IL-6 release, since BBG has no effect on adenosine receptors 
(King and Townsend-Nicholson, 2003).
ATP was reported to have a concentration^ 10-100 pM) related effect on 
IL-6 release from human osteoblastic SAM-1 cells (Ihara et al., 2005). 
This release was claimed to be due to P2Y receptors, as it was blocked 
by suramin and the P2X7 receptor was thought not to be involved as it 
was not expressed by these cells (Ihara et al., 2005). Another study 
reported that ATP stimulated expression and release of IL-6 from human 
epidermal keratinocytes, an effect believed to be via P2Y receptors 
(Inoue et al., 2006). The involvement of P2Y receptors (if any) in the IL- 
6 release seen here is most probably very minimal due to the blocking 
effect of BBG on ATP-induced IL-6 release, since BBG has no effect on
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P2Y receptors (Ziganshin et al., 2002; King and Townsend-Nicholson, 
2003; Bumstock, 2006a; Bumstock, 2007).
P2X7 receptor activation was found to be involved in the release of IL-lp 
from microglial cells (Ferrari et al., 1997), leucocytes (Labasi et al., 
2002), and macrophages (Solle et al., 2001; Qu et al., 2007). IL-1 was 
reported to be involved in bone resorption (Canalis et al., 1991; 
Roodman, 1993) and it stimulates osteoblasts proliferation (Morioka et 
al., 2000). Additionally, IL-lp was found to have a role in the 
inflammation associated with RA (Andreakos et al., 2002; Boyce et al., 
2005; Clark et al., 2005; Walsh et al., 2005). IL-ip was studied here and 
no effect on its release was observed with any of the drugs used except 
when the cells were incubated with ATP and BBG together. The 
mechanism for this is not clear, but the involvement of the P2X7 receptor 
is unlikely as ATP and BBG alone had no effect on IL-lp release from 
osteoblasts. It is possible that the agonist concentrations used here are 
lower than those existing under physiological conditions needed to 
stimulate its release. Low extracellular concentrations of ATP are found 
naturally in tissues, but these may reach much higher levels after cell 
injuries such by hypoxia or ischemia (Liu and Rosenberg, 2001; Gartland 
et al., 2003a). Another potential reason might be the absence of LPS 
which was reported to be involved in IL-lp release from other cells 
(Ferrari et al., 1997), though this involvement is still debatable (Ferrari et 
al., 2006).
For ALP, IL-6, and IL-lp release, ATP and DBzATP were used at 
concentrations of 4x10‘5 and lx l O'6 M, respectively. These 
concentrations are lower than those which induce pore formation (see 
Chapter 4) demonstrating that pore formation is not necessary for ALP 
activity and IL-6 release. These actions are probably therefore related to
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opening of the ion channel formed by the P2X7 receptor in response to 
activation with lower concentrations of ATP and DBzATP leading to an 
increase in intracellular calcium. Alternatively, an unknown second 
messenger might be involved.
5.6 Conclusion
ALP activity and IL-6 release were found to increase in response to ATP. 
This effect is most probably via P2X7 receptor stimulation as suggested 
by the inhibition seen with BBG and the increase seen with DBzATP. No 
effect was seen on IL-ip release and mineralised nodule formation. 
These results suggest that the effect of the P2X7 receptor on bone 
formation is likely to be modulatory rather than direct.
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Chapter 6: Modulation of 
P2X7 receptor expression 
and function by 
oestrogen and 
glucocorticoids
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6.1 Introduction
6.1.1 Oestrogen receptors
Oestrogen receptors (ER) are widely distributed in the body (Moriarty et 
al., 2006). They exert either genomic effects through a nuclear receptor 
or non-genomic effects through a plasma membrane receptor (Deroo and 
Korach, 2006; Moriarty et al., 2006; Hammes and Levin, 2007). The 
nuclear receptor can enhance or repress genes either by direct binding to 
the target DNA or by interacting with co-activator or co-repressor 
proteins (Moriarty et al., 2006). The plasma membrane receptor can 
induce rapid responses (Moriarty et al., 2006; Wehling and Losel, 2006) 
via signalling pathways associated with G protein coupled-receptors such 
as inositol 1,4,5-triphosphate (IP3) production and endothelial nitric 
oxide synthase (eNOS) stimulation (Jacob et al., 2006). Additionally, 
oestrogen plasma membrane rapid responses were also reported to be 
generated via ion channel signalling pathways such as increasing the 
intracellular calcium concentration (Jacob et al., 2006). Protein kinase 
signalling pathways such as MAPK were also reported to be one of the 
rapid response mechanisms of oestrogen plasma membrane receptors 
(Jacob et al., 2006). Oestrogen plasma membrane receptors have also 
been found to have genomic actions (Jacob et al., 2006; Hammes and 
Levin, 2007). ER have been found to be expressed by many tissues such 
as reproductive (breast, uterine, and ovarian), bone, neuronal and 
cardiovascular (Ciana et al., 2006; Moriarty et al., 2006). Oestrogens can 
have anti-inflammatory or pro-inflammatory actions depending on many 
factors such as the cell type involved, concentration of oestrogen, and ER 
isoform expressed (Straub, 2007).
The ER exists as two isoforms, ERa and ERp, encoded by different 
genes (Bord et al., 2001; Deroo and Korach, 2006; Jacob et al., 2006;
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Moriarty et al., 2006; Straub, 2007). Both ERa and ERp are found in the 
plasma membrane in addition to the nucleus (Jacob et al., 2006; Hammes 
and Levin, 2007) and it is believed that ERp can heterodimerize with and 
inhibit ERa (Denger et al., 2001; McDonnell, 2004; DiSilvio et al., 
2006). The ERa consists of 595 amino acids and ERp consists of 485 
amino acids (Bord et al., 2001). A third plasma membrane receptor form 
named ER-X was also reported, but this is distinct from ERa and ERp 
(Jacob et al., 2006).
In bone both isoforms of the receptors (ERa and ERp) are expressed by 
osteoclasts and osteoblasts (Syed and Khosla, 2005; Deroo and Korach,
2006). Studies have shown that ER expression varies with age and bone 
type (cortical or cancellous) (Deroo and Korach, 2006). In osteoclasts 
oestrogen was found to suppress differentiation, inhibit activity and 
induce apoptosis, (Manolagas et al., 2002; Balasch, 2003; Cao et al., 
2003; Syed and Khosla, 2005; Jacob et al., 2006) thus inhibiting bone 
resorption (Robinson et al., 1997; Balasch, 2003; Vural et al., 2006; 
Straub, 2007). The ERa and ERp isoforms were both found to be 
expressed by osteoblasts (Bord et al., 2001; Denger et al., 2001; Waters 
et al., 2001; Wiren et al., 2002; Monroe et al., 2003). In cancellous bone 
ERa was found to be predominant compared to the p isoform, but the 
opposite was true in cortical bone (Bord et al., 2001). Oestrogen was 
shown to inhibit osteoblast apoptosis and hence increase their activity 
and lifespan (Manolagas et al., 2002; Balasch, 2003; Syed and Khosla, 
2005; Jacob et al., 2006) via a non-genomic mechanism (Syed and 
Khosla, 2005). The effect of oestrogen on osteoblast proliferation and 
differentiation seems controversial as some studies have reported 
stimulation and others inhibition (Robinson et al., 1997; O’Shaughnessy 
et al., 2000; Syed and Khosla, 2005). The source of this controversy is 
believed to be the osteoblastic model system studied, the ER isoform
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expressed and the oestrogen concentration. More recent studies of cells 
expressing ERa found an inhibitory action of oestrogen on osteoblast 
proliferation, but no effect was seen in cells expressing the ERp isoform 
(Syed and Khosla, 2005; DiSilvio et al., 2006). Additionally, it was 
found that 17p-oestradiol-mediated regulation of mineralisation, ALP 
activity, and cytokine release was more via ERa than ERp (Waters et al., 
2001). MG63 and SaOS2 cell lines were found to express ERa 
(Penolazzi et al., 2004; Miki et al., 2007) and ERp receptors (Miki et al.,
2007).
Interestingly, 17p-oestradiol has been found to exert non-genomic 
inhibition of human P2X7 receptor function in transfected CV-1 monkey 
kidney cells (Cario-Toumaniantz et al., 1998).
6.1.2 Glucocorticoid receptors
Glucocorticoids are the most potent anti-inflammatory agents and are 
used for the management of many inflammatory disorders such as 
asthma (Payne and Adcock, 2001; Valledor and Ricote, 2004; Barnes, 
2006) and RA (Valledor and Ricote, 2004; Barnes, 2006). Their anti­
inflammatory action arises from the suppression of many inflammatory 
mediators such as cytokines and chemokines by suppressing their genes. 
Furthermore, they activate certain genes responsible for the production of 
anti-inflammatory proteins. Additionally, glucocorticoids act at the 
cellular level by reducing the numbers of inflammatory cells such as 
eosinophils and T-lymphocytes (Barnes, 2006).
Glucocorticoid receptors (GR) are nuclear receptors (Bland, 2000; Yudt 
and Cidlowski, 2002; Valledor and Ricote, 2004; Duma et al., 2006) 
available in two isoforms GRa and GRP (Bland, 2000; Valledor and
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Ricote, 2004; Bames, 2006; Duma et al., 2006; Morand, 2007). GRp has 
much lower expression compared to GRa and is not activated by 
glucocorticoids (Bland, 2000; Bames, 2006; Morand, 2007).
Glucocorticoids cross the cell membrane and bind to a cytoplasmic GR 
(Payne and Adcock, 2001; Yudt and Cidlowski, 2002; Yukawa et al., 
2005; Bames, 2006; Morand, 2007). After this binding, the GR 
conformation changes and the GR-glucocorticoid complex enters the 
nucleus and binds to glucocorticoid response elements (GRE) leading to 
changes in gene transcription (Payne and Adcock, 2001; Yudt and 
Cidlowski, 2002; Bames, 2006; Morand, 2007). Some of the increase in 
gene transcription (trans-activation) causes the release of anti­
inflammatory proteins (Payne and Adcock, 2001; Valledor and Ricote, 
2004; Bames, 2006). While some of the decrease in gene transcription 
(trans-repression) is related to the anti-inflammatory action of 
glucocorticoids (cytokine transcription) (Payne and Adcock, 2001; 
Valledor and Ricote, 2004; Bames, 2006), part is related to the side 
effects of these drugs such as the effect on bone metabolism (Dovio et 
al., 2001; Bames, 2006).
Many studies have reported that GR exist in the cell membrane exerting 
rapid non-genomic actions (Andres et al., 1997; Borski, 2000; Evans et 
al., 2000), and it is believed that this is a GPCR (Borski, 2000; Evans et 
al., 2000).
Glucocorticoids were shown to inhibit ATP-induced intracellular 
calcium influx in mice neuroblastoma cell lines (Han et al., 2005). 
Conversely, another study found that glucocorticoids increase 
intracellular calcium in type I spiral ganglion neurons of the guinea-pig 
cochlea (Yukawa et al., 2005). It was believed that both effects were via
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non-genomic mechanisms as they occurred rapidly (within 5-10 
mniutes), and that the action of ATP was via P2X receptors (Han et al., 
2005; Yukawa et al., 2005).
In bone, glucocorticoids have been documented to increase bone 
resorption due to increased osteoclast lifespan and decrease bone 
formation due to decreased osteoblastogenesis and decreased osteoblast 
lifespan (Bland, 2000; Manolagas, 2000; Boling, 2004; Gregorio et al., 
2006; Kanis et al., 2007). Excess glucocorticoids lead to a reduction in 
BMD and consequently development of osteoporosis (Bland, 2000; 
Gregorio et al., 2006; Kanis et al., 2007). Expression of GRa mRNA and 
protein has been documented in human osteoblasts (Bland, 2000).
Since oestrogen and glucocorticoids are known to play a critical role in 
bone metabolism, and since 17p-oestradiol has been reported to have an 
antagonistic action on P2X7 receptors in other cells, the modulation of 
P2X7 receptor expression and function by 17p-oestradiol and 
dexamethasone has been studied as part of this thesis.
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6.2 Aims
To study the effects of an oestrogen (17p-oestradiol) and a
glucocorticoid (dexamethasone) which are known to affect bone
formation and P2X7 receptor function.
• To investigate the effect of 17p-oestradiol and dexamethasone on 
P2X7 receptor protein expression
• To investigate the effect of 17p-oestradiol and dexamethasone on 
YO-PRO 1 uptake induced by ATP
• To investigate the effect of 17p-oestradiol and dexamethasone on 
ALP release upon P2X7 receptor activation.
• To investigate the effect of 17(3-oestradiol and dexamethasone on 
cytokine release (IL-6  and IL-ip) upon P2X7 receptor activation.
• To investigate the effect of 17p-oestradiol and dexamethasone on 
bone mineralisation upon P2X7 receptor activation.
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6.3 Experimental protocols
The protocols used to study the effect of 17p-oestradiol and 
dexamethasone on the physiological actions of osteoblasts induced by 
P2X7 receptor activation were described in detail in Chapter 2. 17p- 
oestradiol and dexamethasone are referred to as oest. and dex. in the 
diagrams.
6.3.1 Effect of 17B-Qestradiol and dexamethasone on YO- 
PRO 1 uptake induced bv P2Xt receptor agonists
To determine the best incubation time for inhibition of YO-PRO 1 
uptake by 17|3-oestradiol and dexamethasone, approximately 100,000 
SaOS2 cells / well were pre-incubated in Greiner 96-well plates with 
17(5-oestradiol 5X10"6 M, dexamethasone lxlO*6 M, or ethanol 0.5 % 
(vehicle) and 1 pm YO-PRO 1 in the assay buffer-A (see Chapter 2) at 
37°C for 15-60 minutes followed by ATP 8x1 O'4 M for 5 minutes Then 
YO-PRO 1 uptake was measured. The concentrations of 17p-oestradiol 
and dexamethasone used were adapted from the literature (Cario- 
Toumaniantz et al., 1998; Yukawa et al., 2005).
To find if any effect was seen after short (30 minutes which might be a 
non-genomic effect) or long (2  days which might be a genomic effect) 
incubations, SaOS2 cells were grown in 25 cm flasks until confluent, 
and then incubated with 17p-oestradiol and dexamethasone for 30 
minutes or 2 days. The medium was then removed, cells trypsinized and 
counted. Cells were added to Greiner 96-well black plates (100,000 
cells/well) containing ATP and 1 pM YO-PRO 1 in assay buffer-A, and 
then the plate was incubated at 37°C for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation 
wavelength of 485 nm, and an emission wavelength of 520 nm. Data
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were expressed as % of maximum uptake of ATP in vehicle in the 
absence of 17p-oestradiol or dexamethasone. When ATP alone was used 
in these experiments, ethanol (0.5 % v/v) was added for comparison. 
This differs from work in Chapter 5 as ethanol was not included with 
ATP.
Since 17p-oestradiol lxlO ' 5 and dexamethasone 5x1 O^M gave the most 
significant block in the YO-PRO 1 uptake assays, these concentrations 
were used for all ALP, IL-6 , IL-lp, and mineralisation assays.
6.3.2 Effect of 17B-oestrad8ol and dexamethasone on ALP 
activity induced bv P2X7 receptor agonists
An experiment was performed to determine the effect of modulating the 
P2X7 receptor with 17P-oestradiol and dexamethasone on ALP activity 
induced by ATP and DBzATP. SaOS2 cells were seeded in 96 well 
plates at 1,500 cells per well and incubated overnight. Next day the 
medium was removed and cells were incubated with 17p-oestradiol, 
dexamethasone, or ethanol 0.5 % at 37°C for 30 minutes, and then with 
17p-oestradiol, dexamethasone, or ethanol and ATP or DBzATP for 2 
days. Next, ALP activity and cell number were measured as described in 
Chapter 2.
6.3.3 Effect of 17B-oestradiol and dexamethasone on 
cytokine release induced bv P2X7 receptor agonists
SaOS2 cells were seeded in 24 well plates at 100,000 cells per well and 
incubated overnight. Next day, cells were incubated with 17p-oestradiol, 
dexamethasone, or ethanol 0.5 % at 37°C for 30 minutes then water, ATP 
or DBzATP were added to the cells. On day 4 media were collected for
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the 3 day assay, and DMEM was changed to one containing different 
treatments (17p-oestradiol, dexamethasone, or ethanol 0.5 % with or 
without ATP or DBzATP) as above. On day 7 media was collected for 
the 6  day assay. Then, the IL-6  or IL-lp ELISA assay was performed as 
described in Chapter 2.
6.3.4 Effect of 17B-oestradiol and dexamethasone on 
mineralisation induced bv P2Xt receptor agonists
SaOS2 cells were seeded in 6  well plates at 500,000 cells per well and 
incubated overnight. The next day, DMEM was changed to one 
containing ascorbic acid (50 pg/ml). On the next day, the cells were 
incubated at 37°C for 30 minutes with DMEM containing ascorbic acid 
(50 pg/ml), p-glycerophosphate (8  mM), and 17p-oestradiol, 
dexamethasone, or ethanol 0.5%. Next, water, ATP or DBzATP were 
added and the cells incubated at 37°C. This treatment was repeated twice 
weekly until day 15, when cells were stained with freshly prepared 1% 
alizarin red S as described in Chapter 2.
6.4 Results
6.4.1 Modulation of P2X? receptor protein expression bv 
17B-oestradiol and dexamethasone
To investigate the effect of 17p-oestradiol and dexamethasone on the 
expression of the P2 X7 receptor protein, SaOS2 cells were incubated with 
these agents for either 30 minutes or 2 days. As can be seen in Figures 
6.1, 6.2, 6.3, and 6.4, the only apparent effect was on the 87 kDa (seen 
here at 92-103 kDa) band of the P2X7 receptor in the cells incubated with 
17P-oestradiol for 2 days, therefore these data were quantified. This
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band, and the 65 kDa band were quantified using densitometry, but no 
significant differences were observed (Figure 6.2 B and C).
6.4.2 Effect of 17B-oestradiol and dexamethasone on YO- 
PRO 1 Uptake
To find the best short incubation time to see any effect of 17p-oestradiol 
and dexamethasone on YO-PRO 1 uptake induced by ATP, SaOS2 cells 
were pre-incubated for different periods (15-60 minutes) with these 
agents and then the assay was performed as shown in Figure 6.5. Up to 
30 minutes incubation with either 17p-oestradiol or dexamethasone, 
inhibition of YO-PRO 1 uptake was seen, which was significant at 30 
minutes. However, after 30 minutes an increase was seen which was not 
significant. Therefore, a 30 minute incubation period was used 
subsequently.
The effect of 17p-oestradiol on the concentration-effect curves of ATP 
after 30 minutes and 2 days are illustrated in Figures 6 .6  and 6.7, 
respectively. After 30 minutes incubation, 17p-oestradiol at a 
concentration of 10 pM significantly inhibited the maximum YO-PRO 1 
uptake induced by ATP by approximately 23 % (Figure 6 .6 ). 
Additionally, after incubation for 2 days 17P-oestradiol was found to 
block the receptor to a greater extent compared to the 30 minutes 
incubation, as it significantly inhibited the maximum YO-PRO 1 uptake 
induced by ATP by approximately 37 % (Figure 6.7). However, the 
difference in inhibition between the two periods of incubation was not 
significant.
The effect of dexamethasone on the concentration-effect curves of ATP 
after 30 minutes and 2 days are illustrated in Figures 6 .8  and 6.9,
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respectively. Dexamethasone significantly reduced ATP-induced YO- 
PRO 1 uptake after 30 minutes incubation by approximately 18 % 
(Figure 6 .8). No significant effect was seen on YO-PRO 1 uptake after 2 
days incubation with dexamethasone (Figure 6.9).
EC50 values for ATP were not significantly altered by either 17p- 
oestradiol or dexamethasone (the values for the highest concentration of 
each compound used are shown in Table 6.1).
6.4.3 Effect of 17B-oestradiol and dexamethasone on ALP 
activity
A ratio of alkaline buffer solution to phosphatase substrate of 9:1 was 
used in SaOS2 cells, while this ratio was 1:1 in MG63 cells. However, 
basal ALP activity (OD corrected for cell number) in SaOS2 cells was 
significantly higher (1.44 ± 0.11, p value <0.01) compared to MG63 cells 
(0.026 ± 0.002). ATP significantly increased ALP activity by 
approximately 18 and 37 % compared to control in SaOS2 and MG63 
cells, respectively (Figures 6.10-A and 6.12). 17p-oestradiol alone had 
no effect on ALP activity in either cell line. The combination of ATP and 
17p-oestradiol significantly increased ALP activity by approximately 13 
and 32 % compared to control in SaOS2 and MG63 cells, respectively. 
There were no significant differences between ATP alone and the 
combination of ATP and 17(3-oestradiol (Figures 6.10 and 6.12). ATP- 
induced ALP activity was not significantly higher than control in the 
dexamethasone experiments (Figure 6.10B). Neither dexamethasone 
alone nor in combination with ATP had any significant effect on ALP 
activity in SaOS2 cells. The effect of dexamethasone on ATP-induced 
ALP activity was only studied in SaOS2 cells as they produced the 
largest changes in response to ATP and DBzATP (see Chapter 5). 
DBzATP increased ALP activity by approximately 10 % in SaOS2 cells,
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but this was not significant (Figure 6.11). No significant effects on ALP 
activity were seen with 17P-oestradiol or dexamethasone alone or in 
combination with DBzATP (Figure 6 .11).
6.4.4 Effect of 17B-oestradiol and dexamethasone on 
mineralisation
ATP alone and in combination with 17p-oestradiol significantly 
decreased mineralised bone nodule formation (Figures 6.13 and 6.15). In 
another set of experiments ATP alone and in combination with 
dexamethasone decreased mineralised bone nodule formation, but this 
effect was not significant (Figures 6.14 and 6.15). The combination of 
17p-oestradiol and ATP reduced the amount of protein in the cells, but 
this was not significant (Table 6.2). Neither ATP alone nor 
dexamethasone plus ATP had any significant effect on protein content 
(Table 6.2).
6.4.4 Effect of 17B-oestradiol and dexamethasone on IL-6 
release
Basal IL-6  release in SaOS2 cells was 2.04 ± 0.38 pg/mg protein after 3 
days, while it was 2.59 ± 0.67 pg/mg protein after 6  days. After 3 days of 
incubation of ATP (4x10‘5 M) with SaOS2 cells, there was a significant 
increase in IL-6  release by approximately 530 % compared to control, 
while the release increased significantly by approximately 760 % 
compared to control when ATP was combined with 17p-oestradiol 
(Figure 6.16A). 17p-oestradiol alone had no effect on IL-6  release 
compared to control. IL-6  release in response to 17p-oestradiol alone was 
significantly less than ATP alone, while the release in response to the
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combination of 170-oestradiol and ATP was significantly higher than 
17 0-oestradiol alone.
After 6  days of cells in growth, ATP increased IL-6  release by 
approximately 450 % compared to control, but this effect was not 
significant, while the release increased significantly by approximately 
1500 % compared to control when ATP was combined with 170- 
oestradiol (Figure 6.16B). The release in response to the combination of 
170-oestradiol and ATP was significantly higher than ATP and, 170- 
oestradiol. 170-oestradiol alone had no effect on IL-6  release compared 
to control.
DBzATP and 170-oestradiol alone or in combination had no significant 
effect on IL-6  release (Figure 6.17).
In another series of experiments, after 3 days of cells in growth, ATP 
significantly increased IL-6  release by approximately 500 % when 
compared with control, while the release in response to the combination 
of ATP and dexamethasone decreased significantly by approximately 
250 % when compared with ATP alone (Figures 6.18-A). The release in 
response to dexamethasone alone was significantly less than ATP but not 
different to control.
After 6  days of cells in growth, ATP increased IL-6  release by 
approximately 400 % compared to control, but this effect was not 
significant, while the release increased significantly by approximately 
640 % compared to control when ATP was combined with 
dexamethasone (Figure 6.18-B). The release in response to the 
combination of dexamethasone and ATP was significantly higher than
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dexamethasone alone. The release in response to dexamethasone alone 
was not different to control.
6.4.3 Effect of 17B-oestrad8ol and dexamethasone on IL- 
1B release
Basal IL-lp release in SaOS2 cells was 4.2 ± 0.79 pg/mg protein after 3 
days, while it was 7.1 ± 2.8 pg/mg protein after 6 days. After 3 days of 
SaOS2 cells in growth, ATP and 17p-oestradiol alone or in combination 
had no significant effect on IL-lp release (Figure 6.19A). DBzATP alone 
had no effect on IL -lp  release, but 17p-oestradiol alone significantly 
increased the release by approximately 18 % from control (Figure 
6.20A). The release in response to 17p-oestradiol alone and to its 
combination with DBzATP was significantly higher than DBzATP 
alone.
After 6 days of cells in growth, ATP significantly decreased IL-ip 
release by approximately 60 % from control (Figure 6.19B). The release 
in response to 17p-oestradiol alone and to its combination with ATP was 
significantly higher than ATP alone, but not different to control release. 
No significant effect was seen with DBzATP and 17p-oestradiol alone or 
in combination on IL-lp release (Figure 6.20B).
After 3 days of cells in growth, neither dexamethasone nor ATP alone or 
in combination had any significant effect on the release of IL-ip (Figure 
6.21A).
After 6 days of cells in growth ATP alone and dexamethasone alone 
significantly decreased IL-lp release by approximately 64 % and 54 %, 
respectively from control (Figure 6.21-B). IL-lp release in response to
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the combination of dexamethasone and ATP was significantly higher 
than ATP alone and dexamethasone alone, but not different from control.
199
P2X7 Receptors in Osteoblasts
17P-oestradiol
P2X7R (92) 
P2X7R (62) 
P2X7R (57)
P-actin (39)
Figure 6.1: Representative example of Western blotting of the effect of 
incubating SaOS2 cells with 17p-oestradiol for 30 minutes on P2X7 receptor 
expression.
SaOS2 cells were incubated with medium containing 17(3-oestradiol 1 * 10'5 M or 0.5 
% ethanol (17(3-oestradiol vehicle) at 37°C for 30 minutes, then trypsinized and lysed. 
Positive control (10 pg of HEK7 cell membrane in lane 1), and 25 pg of SaOS2 cell 
lysates were separated on 10 % gels. P2X7 receptor bands were seen at 57, 62 and 
92 kDa, while the (3-actin band was seen at 39 kDa. [n=3]
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Figure 6.2: Representative example of Western blotting of the effect of 
incubating SaOS2 cells with 17p-oestradiol for 2 days on P2X7 receptor 
expression.
SaOS2 cells were incubated with medium containing 17(3-oestradiol 1 x 10"5 M or 0.5 
% ethanol (17p-oestradiol vehicle) at 37°C for 2 days, then trypsinized and lysed. 
Positive control (10 pg of HEK7 cell membrane in lane 1), and 25 pg of SaOS2 cell 
lysates were separated on 10 % gels. P2X7 receptor bands were seen at 63, 74, and 
103 kDa, while the p-actin band was seen at 38 kDa. These bands were quantified 
using densitometry and the ratios of P2X7 receptor to p-actin bands are shown in B 
(90 kDa) and C (70 kDa) [n=3]
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P2X7R (67)
P2X7R (57)
P-actin (40)
Figure 6.3: Representative example of Western blotting of the effect of 
incubating SaOS2 cells with dexamethasone for 30 minutes on P2X7 receptor 
expression.
SaOS2 cells were incubated with medium containing dexam ethasone 5 * 10“® M or 
0.5 % ethanol (dexamethasone vehicle) at 37°C for 30 minutes, then trypsinized and 
lysed. Positive control (10 pg of HEK7 cell membrane in lane 1), and 25 pg of SaOS2 
cell lysates were separated on 10 % gels. P2X7 receptor bands were seen at 57 and 
67 kDa, while the p-actin band was seen at 40 kDa. [n=3J
+ve Ctrl Dexamethasone
+
P2X7R (93)
P2X7R (63)
P-actin (39)
Figure 6.4: Representative example of Western blotting of the effect of 
incubating SaOS2 cells with dexamethasone for 2 days on P2X7 receptor 
expression.
SaOS2 cells were incubated with medium containing dexamethasone 5 x  10"® M or 
0.5 % ethanol (dexamethasone vehicle) at 37°C for 2 days, then trypsinized and lysed. 
Positive control (10 pg of HEK7 cell membrane in lane 1), and 25 pg of SaOS2 cell 
lysates were separated on 10 % gels. P2X7 receptor bands were seen at 63 and 93 
kDa, while the p-actin band was seen at 39 kDa. [n=3]
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Figure 6.5: Effect of incubation time with 17(3-oestradiol and dexamethasone on 
ATP-induced YO-PRO 1 uptake in SaOS2 cells.
SaOS2 cells (approximately 100,000 cells / well) were incubated with 17(3-oestradiol 
SxlO"6 M, dexamethasone IxlO-6 M, or 0.5 % ethanol (17p-oestradiol and 
dexamethasone vehicle) and 1 pM YO-PRO 1 in the assay buffer at 37°C for 15-60 
minutes followed by ATP 8x10"4 M for 5 minutes. YO-PRO 1 fluorescence was 
monitored in a 96-well plate reader using an excitation wavelength of 485 nm, and an 
emission wavelength of 520 nm. The only significant inhibition of the ATP-induced YO- 
PRO 1 uptake was found to be with a 30 minutes incubation. Statistical analyses were 
performed using Student’s  t-test. *P<0.0005 vs. ATP, # P<0.005 vs. ATP. [n=3]. RFU: 
relative fluorescence unit.
203
P2X7 Receptors in Osteoblasts
120
100
oO
-5L2 -4.7 -4.2 -3.7 -3.2 -2.2
ATP Log (M)
ATP — ATP+ Oestradiol (1 e-6 M) -* -A T P  + Oestradiol (5e-6 M) ATP + Oestradiol (1e-5 M)
Figure 6.6: Effect of 30 minutes incubation with 17^-oestradiol on ATP 
concentration-effect curves in SaOS2 cells.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of 0.5 % ethanol (vehicle for 170-oestradiol), 1x10' 
6M, 5x1 O^M, or 1x10 5M of 170-oestradiol at 37°C for 30 minutes followed by ATP for 
5 minutes. YO-PRO 1 fluorescence was monitored in a 96-well plate reader using an 
excitation wavelength of 485 nm, and an emission wavelength of 520 nm. Data are 
expressed as % of maximum uptake of ATP in the absence of 170-oestradiol. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls post- 
hoc test. *P<0.05 vs. control. [n=5]
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Figure 6.7: Effect of 2 days incubation with 17^-oestradiol on ATP 
concentration-effect curves in SaOS2 cells.
SaOS2 cells were incubated with 0.5 % ethanol (vehicle for 17p-oestradiol), 1x1 O^M, 
5x1 O^M, or 1x10‘5M of 17p-oestradiol at 37°C for 2 days. The YO-PRO 1 uptake 
assay was performed where the cells (approximately 100,000 cells/well) were 
incubated with 1 pM YO-PRO 1 in the assay buffer and ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the absence of 17p-oestradiol. Statistical analyses were 
performed using one-way ANOVA with Newman-Keuls post-hoc test. **P<0.01 vs. 
control. [n=3]
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Figure 6 .8 : Effect of 30 minutes incubation with dexamethasone on ATP 
concentration-effect curves in SaOS2 cells.
SaOS2 cells (approximately 100,000 cells/well) were incubated with 1 pM YO-PRO 1 
in the assay buffer in the presence of 0.5 % ethanol (vehicle for dexamethasone), 
5x10~7M, 1x1 O^M, or 5x1 O^M of dexamethasone at 37°C for 30 minutes followed by 
ATP for 5 minutes. YO-PRO 1 fluorescence was monitored in a 96-well plate reader 
using an excitation wavelength of 485 nm, and an emission wavelength of 520 nm. 
Data are expressed as % of maximum uptake of ATP in the absence of 
dexamethasone. Statistical analyses were performed using one-way ANOVA with 
Newman-Keuls post-hoc test. *P<0.05 vs. control. [n=4]
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Figure 6.9: Effect of 2 days incubation with dexamethasone on ATP 
concentration-effect curves in SaOS2 cells.
SaOS2 cells were incubated with 0.5 % ethanol (vehicle for dexamethasone), 5x10' 
7M, 1x1 O^M, or 5x1 O^M of dexamethasone at 37°C for 2 days. The YO-PRO 1 uptake 
assay was performed where the cells (approximately 100,000 cells/well) were 
incubated with 1 pM YO-PRO 1 in the assay buffer and ATP for 5 minutes. YO-PRO 1 
fluorescence was monitored in a 96-well plate reader using an excitation wavelength 
of 485 nm, and an emission wavelength of 520 nm. Data are expressed as % of 
maximum uptake of ATP in the absence of dexamethasone. Statistical analyses were 
performed using one-way ANOVA with Newman-Keuls post-hoc test but no significant 
differences were seen. [n=4]
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30 Minutes 
incubation
ATP 0.38 mM
ATP+ 17p-oestradiol lxl(T* M 0.13 mM
ATP 0.43 mM
ATP+ Dexamethasone 5x10-6 M 0.23 mM
2 Days incubation ATP 0.51 mM
ATP+ 17p-oestradiol lx l0 ‘5 M 0.46 mM
ATP 0.48 mM
ATP+ Dexamethasone 5x1 O'6 M 0.5 M
Table 6.1: ECso values for ATP In the presence or absence of 17p-oestradiol and 
dexamethasone.
SaOS2 cells (approximately 100,000 cells/well) were pre-incubated with 0.5 % ethanol 
(vehicle), 17p-oestradiol 1x1 O' 5  M, or dexamethasone 5x1 O' 6  M at 37°C for 30 minutes 
or 2 days followed by 1 pM YO-PRO 1 in the assay buffer in the presence of ATP for 5 
minutes. YO-PRO 1 fluorescence was monitored in a 96-well plate reader using an 
excitation wavelength of 485 nm, and an emission wavelength of 520 nm. EC5 0  values 
were calculated using Prism. The data for the highest concentrations of 17p-oestradiol 
and dexamethasone are shown here, no differences were seen with the lower 
concentrations either. Statistical analyses were performed using Student’s t-tests, but 
no significant differences were seen. n=3-5
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Figure 6.10: Effect of 17^-oestradiol (A) and dexamethasone (B) on ALP activity 
induced by ATP in SaOS2 cells.
Cells were incubated with 17p-oestradiol 1x10‘5 M, dexamethasone 5x1c6 M or 0.5 % 
ethanol (17p-oestradiol and dexamethasone vehicle) for 30 minutes then grown for 2 
days with ATP 4x10'5M or water (ATP vehicle) then ALP and cell number were 
determined. ALP activity was corrected for cell number. Data are expressed as 
percentage of control containing vehicle. Statistical analyses were performed using 
one-way ANOVA with Newman-Keuls post-hoc test. **P<0.01, #P<0.001. (n=3)
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Figure 6.11: Effect of 17$-oestradiol (A) and dexamethasone (B) on ALP activity 
induced by DBzATP in SaOS2 cells.
Cells were incubated with 17p-oestradiol 1x10'5 M, dexamethasone 5x1c6 M or 0.5 % 
ethanol (17p-oestradiol and dexamethasone vehicle) for 30 minutes then grown for 2 
days with DBzATP 1x1 O'6 M or water (DBzATP vehicle) then ALP and cell number 
were determined. ALP activity was corrected for cell number. Data are expressed as 
percentage of control containing vehicle. Statistical analyses were performed using 
one-way ANOVA with Newman-Keuls post-hoc test, but no significant differences 
were seen. (n=3)
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Figure 6.12: Effect of 17p-oestradiol on ALP activity induced by ATP in MG63 
cells.
Cells were incubated with 17p-oestradiol 1x10"5 M or 0.5 % ethanol (170-oestradiol 
vehicle) for 30 minutes then grown for 2 days with ATP 4x10‘5M or water (ATP vehicle) 
then ALP and cell number were determined. ALP activity was corrected for cell 
number. Data are expressed as percentage of control containing vehicle. Statistical 
analyses were performed using one-way ANOVA with Newman-Keuls post-hoc test. 
*P<0.05 vs. control. (n=3)
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Figure 6.13: Representative example of the effect of ATP and 17(S-oestradio! on 
nodule formation (mineralisation) in SaOS2 cells.
Cells were incubated with 170-oestradiol IxlO"5 M, or 0.5 % ethanol (170-oestradiol 
vehicle) for 30 minutes then grown for 15 days with ATP 4x10'5M or water (ATP 
vehicle), which were replenished twice weekly. Cells were then stained with alizarin 
red. Another identical plate was used for a protein assay. A: Ethanol + ATP, B: ATP + 
170-Oestradiol, C: Control (Ethanol+Water). (n=3)
Protein (mg/ml) ± SEM
Control (Ethanol+Water) 1.81+0.49
ATP 1.63 + 0.93
170-oestradiol + ATP 1.00 + 0.74
Protein (mg/ml) ± SEM
Control (Ethanol+Water) 1.69 + 0.58
ATP 1.38 + 0.89
Dexamethasone + ATP 1.71+0.82
Table 6.2: Effect of ATP, DBzATP and BBG on SaOS2 cell protein concentration.
Cells were incubated with 170-oestradiol 1x10'5M, dexamethasone 5x10‘6M or 0.5 % 
ethanol (170-oestradiol or dexamethasone vehicle) for 30 minutes then grown for 15 
days with ATP 4x10‘5M or water (ATP vehicle), which were replenished twice weekly. 
Cells were then removed for a protein assay. Another identical plate was stained with 
alizarin red for mineralised nodule formation. Data are expressed as mean ± SEM. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls Post- 
Hoc test but no significant differences were seen. (n=3)
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Figure 6.14: Representative example of the effect of ATP and dexamethasone on 
nodule formation (mineralisation) in SaOS2 cells.
Cells were incubated with dexamethasone 5 x 1 0 ^  or 0.5 % ethanol (dexamethasone 
vehicle) for 30 minutes then grown for 15 days with ATP 4x10'5M or water (ATP 
vehicle), which were replenished twice weekly. Cells were then stained with alizarin 
red. Another identical plate was used for a protein assay. A: Ethanol + ATP, B: ATP + 
dexamethasone, C: Control (Ethanol+Water). (n=3)
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Figure 6.15: Effect of ATP, 17^-oestradiol and dexamethasone on nodule 
formation (mineralisation) in SaOS2 cells.
Cells were incubated with 17p-oestradiol 1x10'5M (A), dexamethasone 5x10"^  (B) or 
0.5 % ethanol (173-oestradiol and dexamethasone vehicle) for 30 minutes then grown 
for 15 days with ATP 4x10~5M or water (ATP vehicle), which were replenished twice 
weekly. Cells were then stained with alizarin red. Another identical plate was used for 
a protein assay for cell number. Data are expressed as mean percentage ± SEM of 
control containing vehicle. Statistical analyses were performed using one-way ANOVA 
with Newman-Keuls Post-Hoc test. #P<0.001 vs. control. (n=3)
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Figure 6.16: Effect o f  ATP and 17^-oestradio l on IL-6 release in SaOS2 cells.
Ceils were incubated with 170-oestradiol 1x10‘5 M or 0.5 % ethanol (170-oestradiol 
vehicle) for 30 minutes then grown for 3 (A) and 6 (B) days with ATP 4x10*5M or water 
(ATP vehicle) then media and cells were collected for IL-6 and protein assays. IL-6 
data were corrected for protein. Data are expressed as percentage of control. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls Post- 
Hoc test. *P<0.05, **P<0.01. (n=3)
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Figure 6.17: Effect o f  DBzATP and 17p-oestradiol on IL-6 release in SaOS2 cells.
Cells were incubated with 17p-oestradiol 1x1 O'5 M or 0.5 % ethanol (17p-oestradiol 
vehicle) for 30 minutes then grown for 3 (A) and 6 (B) days with DBzATP 1x1 O^M or 
water (DBzATP vehicle) then media and cells were collected for IL-6 and protein 
assays. IL-6 data were corrected for protein. Data are expressed as percentage of 
control. Statistical analyses were performed using one-way ANOVA with Newman- 
Keuls Post-Hoc test, but no significant differences were seen. (n=3)
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Figure 6.18: Effect o f  ATP and dexam ethasone on IL-6 release in SaOS2 cells.
Cells were incubated with dexamethasone 5x1 O'6 M or 0.5 % ethanol (dexamethasone 
vehicle) for 30 minutes then grown for 3 (A) and 6 (B) days with ATP 4x10'5M or water 
(ATP vehicle) then media and cells were collected for IL-6 and protein assays. IL-6 
data were corrected for protein. Data are expressed as percentage of control. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls Post- 
Hoc test. *P<0.05, **P<0.01. (n=3)
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Figure 6.19: Effect o f  ATP and 17^-oestradiol on IL-1f3 release in SaOS2 cells.
Cells were incubated with 17p-oestradiol 1x1 O'5 M or 0.5 % ethanol (17p-oestradiol 
vehicle) for 30 minutes then grown for 3 (A) and 6 (B) days with ATP 4x10 5M or water 
(ATP vehicle) then media and cells were collected for IL-1p and protein assays. IL-1p 
data were corrected for protein. Data are expressed as percentage of control. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls Post- 
Hoc test. #P<0.001. (n=3)
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Figure 6.20: Effect o f  DBzATP and 17p-oestradiol on IL-1p release in SaOS2 
cells.
Cells were incubated with 17p-oestradiol 1x10's M or 0.5 % ethanol (17p-oestradiol 
vehicle) for 30 minutes then grown for 3 (A) and 6 (B) days with ATP 1x10'6M or water 
(DBzATP vehicle) then media and cells were collected for IL-10 and protein assays. 
IL-1p data were corrected for protein. Data are expressed as percentage of control. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls Post- 
Hoc test. *P<0.05, **P<0.01. (n=3)
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Figure 6.21: Ef fect  o f  ATP and dexam ethasone on IL-1/3 release in SaO S2 cells.
Cells were incubated with dexamethasone 5x1 O'6 M or 0.5 % ethanol (dexamethasone 
vehicle) for 30 minutes then grown for 3 (A) and 6 (B) days with ATP 4x10'5M or water 
(ATP vehicle) then media and cells were collected for IL-1 p and protein assays. IL-1p 
data were corrected for protein. Data are expressed as  percentage of control. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls Post- 
Hoc test. *P<0.05, **P<0.01. (n=3)
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6.5 Discussion
This chapter investigated the modulation of expression and function of 
P2X7 receptors by 17p-oestradiol and dexamethasone in human 
osteoblasts. Additionally, the action of 17(3-oestradiol and 
dexamethasone on some of the effects of ATP on osteoblast function 
were also studied.
6.5.1 Modulation of P2Xt receptor expression and 
function (YO-PRO 1 uptake) bv 17B-oestradiol and 
dexamethasone
The results show that P2X7 receptor expression at the protein level is not 
modulated by 17(3-oestradiol or dexamethasone. Although the 87 kDa 
band seen in Western blotting appeared to be downregulated by 17(3- 
oestradiol after a 2  day incubation, the densitometric analysis did not 
show a significant difference. Therefore, any effect of 17(3-oestradiol and 
dexamethasone is not due to alterations in P2X7 receptor expression.
In relation to YO-PRO 1 uptake, efforts to generate concentration-effect 
curves for 17(3-oestradiol and dexamethasone in the presence of ATP 
failed, which may be due to the atypical pharmacology o f the receptor in 
these cells (discussed in detail in Chapter 4). Therefore, concentration- 
effect curves for ATP in the presence o f different concentrations of 17(3- 
oestradiol and dexamethasone were studied. The concentration-effect 
curves showed that the main action o f these agents was to reduce the 
maximum YO-PRO 1 uptake induced by ATP, while there was no shift 
in the EC30 values, suggesting they could be behaving as weak non­
competitive antagonists.
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The results obtained in this project confirm the finding of Cario- 
Toumaniantz et al. (1998) showing an effect of 17p-oestradiol on 
blocking the P2X7 receptor after a 30 minute incubation. This was 
claimed to be due to non-genomic ER inhibition of the P2X7 receptor.
Although glucocorticoids have been reported to have rapid non-genomic 
effect on ATP-induced intracellular calcium influx in guinea-pig and 
mouse, results have been conflicting (Han et al., 2005; Yukawa et al., 
2005). One explanation for this effect might be that it is species- 
dependent, especially since the homology in amino acid sequence 
between P2X receptors was found to be quite variable between species 
(North, 2002).
Both the effects of dexamethasone and 17p-oestradiol after 30 minutes of 
incubation must be mediated by a non-genomic mechanism as they 
occurred too quickly to be the result of a change in protein synthesis 
(Cario-Toumaniantz et al., 1998).
The inhibition o f ATP-induced YO-PRO 1 uptake after a 2 day 
incubation with 17p-oestradiol might be through a genomic mechanism, 
although no evidence exists to support this hypothesis. However, as there 
was no significant difference between results obtained for the 30 minute 
and 2 day incubation, another mechanism may be involved.
P2X7 receptor-induced pore formation is usually followed by cell death 
(Di Virgilio et al., 1998; Sluyter and Wiley, 2002; Wang et al., 2004a), 
therefore inhibition o f pore formation by 17p-oestradiol and 
dexamethasone might inhibit the cell death induced by P2X7 receptor 
activation. This might be another mechanism for the effect of these 
agents on osteoblasts.
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6.5.2 Effect of 17B-oestradiol and dexamethasone on 
ATP- and DBzATP-induced ALP activity and 
mineralisation
The only significant effect o f 17p-oestradiol on ALP activity was 
observed when it was used in combination with ATP. 17f}-oestradiol in 
combination with ATP significantly increased ALP activity compared to 
17p-oestradiol alone, suggesting that this effect is probably due to ATP.
No studies have been found investigating the effect o f 17p-oestradiol or 
dexamethasone on ATP- or DBzATP-induced ALP activity, but one 
study has reported an increase in activity with 17p-oestradiol alone in a 
human foetal osteoblastic cell line after 2 days o f cells in growth 
(Robinson et al., 1997). Another study reported that no effect on ALP 
activity was seen when SaOS2 cells were treated with 17[3-oestradiol 
alone for 3 days, but in combination with PTH the activity increased 
significantly (Nasu et al., 2000). 17^-oestradiol added intermittently but 
not continuously was found to increase ALP activity in SaOS2 cells (Rao 
et al., 2003). In post-menopausal women ALP activity was observed to 
increase in the first 4 weeks of treatment with 17p-oestradiol implants, 
but it dropped significantly after that (Pereda et al., 2002). Other studies 
reported an increase in ALP activity with 17p-oestradiol when the cells 
were grown for longer periods (O'Shaughnessy et al., 2000; Kanno et al., 
2004). One explanation for the difference in ALP activity in response to 
17f3-oestradiol seen here could be that it depends on the type of 
osteoblasts used (cell line or primary). In addition, 2 days of cells in 
growth might not be enough to see the effect of 17p-oestradiol.
The absence of effect of 17p-oestradiol on ATP-induced ALP activity 
supports the suggestion that its effect is not on osteoblast activity, but on
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their life span (Moriarty et al., 2006). This is supported by the 
observation that 17p-oestradiol blocks ATP-induced pore formation (as 
measured here by YO-PRO 1 uptake) which is reported to be followed 
by cell death (Virginio et al., 1999).
ATP alone and in combination with 17p-oestradiol showed a significant 
reduction in mineralisation by SaOS2 cells. Previous studies showed 
contradictory results with one study showing an increase in 
mineralisation in mouse osteoblasts (Kanno et al., 2004), while another 
study showed inhibition in a human foetal osteoblastic cell line (Waters 
et al., 2 0 0 1 ). In another study mineralisation was found to be higher in 
SaOS2 cells treated intermittently with 17p-oestradiol rather than 
continuously (Rao et al., 2003). Hence the difference in mineralisation 
might be species-dependent and timing of treatment might also be 
important. The significant decrease in mineralisation in response to ATP 
alone or in combination with 17p-oestradiol is unlikely to be due to cell 
death resulting from P2 X7 receptor activation as no significant 
differences in protein concentration were seen between different 
treatments. The data presented in Chapter 5 showed that ATP had no 
significant effect on mineralisation in SaOS2 cells, which are different to 
the results in this Chapter. An explanation might be the vehicle used here 
(ethanol for 17p-oestradiol). Ethanol was reported to inhibit or potentiate 
ATP-induced currents in P2X4 and P2X3 receptors, respectively, in a 
concentration-related manner (Davies et al., 2006). Overall, these results 
indicate that SaOS2 cells are probably not a good model for 
mineralisation assays.
Dexamethasone had no effect on ALP activity, either alone, or in 
combination with ATP or DBzATP. Previous studies reported a 
significant increase in ALP activity with dexamethasone alone following
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in vitro culture of human osteoblasts for 1 - 3 weeks (Yang et al., 2003; 
Jorgensen et al., 2004; Eijken et al., 2006). Again, a possible explanation 
for the discrepancy in ALP activity in this project compared to the 
literature might be due to insufficient period of treatment or type of 
osteoblast used (primary or cell line).
ATP alone or in combination with dexamethasone had no effect on 
mineralisation. A significant increase in mineralisation with 
dexamethasone alone was reported in a study in a human foetal 
osteoblastic cell line (Eijken et al., 2006) and in another study in HOB 
cells (Jorgensen et al., 2004). The difference in the results seen here to 
those reported in the literature might be due to an insufficient period of 
treatment here or the type o f osteoblast used (primary or cell line). The 
lack of effect of ATP and dexamethasone on mineralisation suggests that 
the role of the P2X7 receptor on mineralisation in these cells is minor and 
that dexamethasone does not have a direct effect cm bone formation.
6.5.3 Effect of 17B-oestradiol and dexamethasone on 
ATP- and DBzATP-induced cvtokine release
ATP alone significantly increased IL-6 release, a similar effect to that 
presented in Chapter 5. Although many studies have reported inhibition 
of IL-6 release in response to 17p-oestradiol (Waters et al., 2001; 
Manolagas et al., 2002; Straub, 2007), another study repented that there 
was no effect in MG63 and SaOS2 cells (Dovio et al., 2001). In the 
current study, I observed that 17f3-oestradiol had no effect on release 
after 3 and 6 days of cells in growth, but it enhanced ATP-induced 
release compared to control after 3 days and compared to control and 
ATP alone after 6 days o f cells in growth. There is no clear explanation 
for this enhancement, especially since 17p-oestradiol was observed to
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block ATP-induced YO-PRO 1 uptake. One possible explanation might 
be that a genomic effect of 17(3-oestradiol is involved as the cells are 
incubated for a relatively long period which would be enough for 
alteration of protein synthesis. Therefore, it is possible that pore 
formation is not necessary for ALP production and IL-6 release from 
osteoblasts as these effects were observed with lower concentrations of 
ATP than those which induce YO-PRO 1 uptake.
Neither DBzATP alone or in combination with 17p-oestradiol had any 
effect on IL-6 release. Similar to earlier results seen with DBzATP (see 
Chapter 5), the absence of a DBzATP effect compared to ATP might be 
due to its lower concentration, or its binding by serum constituents.
No significant effect in comparison to control was observed on IL-6 
release when dexamethasone alone was used, but in combination with 
ATP the release was decreased significantly after 3 days. This decrease is 
expected due to the potent anti-inflammatory action of dexamethasone 
(Payne and Adcock, 2001; Valledor and Ricote, 2004; Barnes, 2006), 
and IL-6 is one of the cytokines reported to be suppressed by 
glucocorticoids (Dovio et al., 2001; Payne and Adcock, 2001; Chen et 
al., 2005; Barnes, 2006). After 6 days dexamethasone significantly 
enhanced ATP-induced IL-6 release compared to control. This 
enhancement was unexpected, since dexamethasone is one of the most 
potent anti-inflammatory agents known, and the reason is not clear.
ATP significantly reduced IL-ip release after 6 days. This was 
significantly reversed when ATP was used in combination with 17(3- 
oestradiol. Similarly, in combination with DBzATP the release was 
significantly higher than DBzATP alone after 3 days, but decreased after 
6 days, but this was not significant A study found that IL-lp release
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increased in post-menopausal women, but this had decreased 
significantly after two months of treatment with hormone replacement 
therapy (HRT) (Vural et al., 2006). The results obtained here and those 
reported in the literature suggest that ATP could inhibit IL-lp release 
post-menopause, and that pre-menopause ATP and oestrogen should 
balance each other.
The above results suggest that die IL-6 and IL-ip release induced by 
P2X7 receptor activation could be modulated by 17p-oestradiol and 
dexamethasone. The effect o f dexamethasone might be due to it being 
anti-inflammatory, in which case this should be seen for both periods of 
incubation, but it was not. Therefore another unknown mechanism is 
probably involved. The absence of an effect of DBzATP compared to 
ATP might be due to its lower concentration, or its binding by serum 
constituents. The difference between the results obtained here and those 
reported in the literature, might be due to die cell type used, ER isoform 
expressed (a or p), and their density.
YO-PRO 1 uptake (see Chapter 4) is related to the formation of a pore in 
response to P2X7 receptor activation with high concentrations of 
agonists, but cytokine release is most probably due to channel opening as 
lower concentrations of agonists were used. It is likely to be due to a 
signalling pathway coupled to cation influx. Alternatively, an unknown 
second messenger might be involved.
The results presented in this chapter suggest that oestrogen and 
glucocorticoids may have a direct action on increasing osteoblast 
lifespan via inhibition o f P2X7 receptor-induced cell death. Additionally, 
they may have a modulatory action on some of the signalling pathways 
involving the P2X7 receptor.
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6.6 Conclusion
Both 17P-oestradiol and dexamethasone were found to have an inhibitory 
action on P2X7 receptor function. A non-classical, non-genomic 
mechanism might be responsible for the action of dexamethasone and 
17p-oestradiol, although a genomic mechanism might be responsible for 
some of the results.
Since the P2X7 receptor is known to be a death receptor, its blockade 
might be another mechanism through which 17p-oestradiol inhibits 
osteoblast apoptosis, and hence prolongs their life span. Apparently, as a 
result of 17p-oestradiol deficiency in menopause, osteoblast apoptosis 
increases, which predisposes to osteoporosis (Manolagas, 2000; Fini et 
al., 2004).
ALP activity and IL-6  and IL-lp release in response to P2X7 receptor 
activation were found to be modulated by 17p-oestradiol and 
dexamethasone. This modulation might play a role in the actions of 
oestrogen and glucocorticoids on bone cells and osteoporosis 
pathophysiology.
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Chapter 7: 
Characterisation of the 
expression andfunction 
of P2X7 receptors in 
primary human 
osteoblasts
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7.1 Introduction
When I started my project and in order to characterize P2 X7 receptors in 
osteoblasts, the options were: animal (mouse, rat, or guinea pig) 
osteoblasts, HOB cells, or human osteoblast-like cell lines. The animal 
option was very unfavourable due to the species differences in the amino 
acid sequence of the P2X7 receptor and receptor function (Hibell et al., 
2000; North and Suprenant, 2000b; Hibell et al., 2001a; North, 2002; 
Michel et al., 2006a; Bumstock, 2007). Therefore, I decided to 
concentrate on human osteoblasts. HOB cells were not preferred to start 
with for many reasons. These included limited availability of human 
primary cells due to the difficulties in obtaining them for ethical reasons, 
the cost if obtained from commercial sources, and die problems 
associated with only being able to use a limited number of passages. 
Additionally, it was reported in the literature that P2X7 receptor function 
in primary human osteoblasts might be different between one population 
and another (different individuals or sites) (Gartland et al., 2001). Based 
on the above I decided to start my project with two human osteoblast­
like cell lines, MG63 and SaOS2. An SaOS2 cell is closer to a well- 
differentiated osteoblast and has many of its features (Hughes and Aubin, 
1998). However, subsequently 1 decided to study primary human 
osteoblasts as a population o f these cells became available near the end 
of my PhD. 1 thought it possible that primary cells could behave 
differently to cell lines and they have the advantage of being more 
comparable physiologically to the in vivo situation (Hughes and Aubin, 
1998).
Due to the limited availability o f the primary cells, a detailed 
characterisation of P2X7 receptor expression and function in HOB cells
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could not be done. Therefore, key experiments were identified based on 
previous results with the MG63 and SaOS2 cells.
7.2 Aims
To characterise P2 X7 receptor expression and function in HOB.
• To study P2X7 receptor expression by HOB cells at the mRNA 
and protein levels.
• To compare the receptor expression at the protein level with that 
of SaOS2 and MG63 cells.
• To investigate the expression of other pore-forming P2X receptors 
(P2X2, P2 X4, and P2X5) by HOB cells at the mRNA and protein 
levels.
• To study the effect of P2X7 receptor agonists on YO-PRO 1 
uptake by HOB cells.
• To study the effect of P2X7 receptor agonists on IL-6  release in 
HOB cells.
• To study the effect of P2X7 receptor agonists on mineralisation 
(nodule formation) in HOB cells.
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7.3 Experimental protocols
The protocols used to study the expression and function of P2X7 
receptors in HOB cells were described in detail in Chapter 2.
7.3.1 Cell culture
Human primary osteoblasts referred to here as HOB were obtained from 
the knee of a 64 year-old Caucasian female. HOB cells (characterised by 
osteocalcin production) and all the solutions used for their growth were 
obtained from PromoCell (Heidelberg, Germany). The cells were grown 
in 25 cm flasks in osteoblast growth medium (containing 50 jig/ml 
gentamicin sulphate, 50 ng/ml amphotericin B and 0.62 ng/ml phenol 
red) supplemented with 10 % FCS. To passage the cells, they were 
washed with HepesBSS solution (Hepes, D-glucose, NaCl, KC1, sodium 
phosphate, phenol red), incubated with 1 ml detach kit (Trypsin/EDTA 
solution 0.04% / 0.03%) for 5 minutes at room temperature, then 2 ml 
trypsin neutralizing solution obtained from soybean (0.05%) was added, 
and the cells were counted and seeded at approximately 300,000 cells/25 
cm2 flask. The cells were incubated at 37°C in a humidified atmosphere 
of 95% air and 5% C 02, and the medium changed every three or four 
days.
7.3.2 RT-PCR
To study the expression of P2X2, P2 X4, P2X5, and P2X7 receptors at the 
mRNA level, RT-PCR was done using the primers described in Chapter 
3. MG63 cell cDNA was used as a positive control for P2 X4, P2X5, and 
P2X7 receptors, while human pancreas cell (BON-1) cDNA was used as 
a positive control for P2X2 receptors.
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7.3.3 Western Blotting
To study the expression of P2X2, P2X*, and P2X7 receptors at the protein 
level, Western blotting was carried out using the method and antibodies 
described in Chapter 2. Membranes of HEK7 cells were used as a 
positive control for P2X7 receptors, while rat brain membranes were used 
as a positive control for P2X2 and P2 X4 receptors.
In order to quantify the relative expression of P2X», and P2X7 receptors 
in HOB cells and to compare it to those of MG63 and SAOS2 cells, the 
OD of the bands for these receptors and a housekeeping gene ((3-actin) 
were analysed using densitometry in NIH Image software (see Chapters 
4 and 6 ).
It is important to note here that the batch of the P2X7 receptor antibody 
used for work in this chapter was different to that used in Chapter 3.
7.3.4 YO-PRO 1 uptake
The protocol described in Chapter 2 was followed exactly but using 
approximately 40,000 HOB cells/well.
7.3.5 IL-6 release
HOB cells were seeded in 96 well plates at 3,000 cells per well and 
incubated overnight. Next day, cells were incubated at 37°C with BBG 
for one hour or 17(3-oestradiol or dexamethasone for 30 minutes. Next, 
water, ATP or DBzATP were added to the cells. On day 4 media were 
collected for the assay. Then, the IL-6  ELISA assay was performed as 
described in Chapter 2. The vehicle for 17|3-oestradiol and 
dexamethasone, ethanol, was used at 0.5 % v/v.
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7.3.6 Mineralisation
HOB cells (passages 10 and 12) were seeded in 24 well plates at 40,000 
cells per well and incubated overnight. The next day, alpha-MEM was 
changed to media containing ascorbic acid (50 pg/ml), p- 
glycerophosphate (2 mM), dexamethasone (0.1 pM in 0.5% ethanol) and 
either water, ATP or DBzATP and the cells were incubated at 37°C. The 
solutions were replenished twice weekly for 3-4 weeks, then the cells 
were stained with freshly prepared 1% alizarin red S as described in 
Chapter 2.
7.4 Results:
7.4.1 Expression
RT-PCR for P2 X4, P2 X5, and P2 X7 receptors (Figure 7.1) in MG63 and 
HOB cell mRNA samples gave bands of the expected size (200 bp for 
the P2Xj and P2X5 receptors and 100 bp for the P2X7 receptor). Control 
samples (no AMV in the RT reaction) did not show any bands. No bands 
were seen using the P2X2 receptor primers in either MG63 or HOB cells, 
while in human pancreatic cell line mRNA (BON-1 cells), used as a 
positive control, the primers did amplify the expected product (2 0 0 bp, 
Figure 7.1 A).
In Western blotting membranes of HEK7 cells were used as a positive 
control for the P2X7 receptor, while rat brain membranes were used as a 
positive control for the P2X4 receptor. Using the rP2X7 receptor 
antibody, bands were seen in the positive control, HOB, MG63 and 
SaOS2 cell lysate samples at 53 ± 1.5 kDa (Figure 7.2). Figure 7.3 shows 
bands in the positive control, HOB, MG63 and SaOS2 cell lysate 
samples at 55 ± 1.4 kDa for the P2X* receptor. Using the p-actin
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antibody, bands were seen in all samples at 39 ± 1.7 kDa. Using the 
P2X2 receptor antibody, a band was only seen in the positive control, Rat 
brain cell membranes (data not shown).
In order to quantify P2 X4 and P2X7 receptor expression, the bands were 
compared to those for P-actin using densitometric analysis as shown in 
Figures 7.2-B and 7.3-B. Expression of both receptors was found to be 
significantly higher in HOB cells compared to MG63 cells, but compared 
to SaOS2 cells the expression was significantly higher only in the case of 
the P2X7 receptor.
7.4.2 YO-PR01 Uptake
Due to the limited availability of the cells, concentration-effect curves 
for ATP and DBzATP were constructed using fewer concentrations than 
for the SaOS2 and MG63 cells (see Chapter 4).
ATP and DBzATP were found to induce YO-PRO 1 uptake in HOB cells 
and their concentration-effect curves (Figure 7.4) gave EC50 values of 
0.53 mM ± 0.06 and 0.54 mM ± 0.04, respectively. Table 7.1 compares 
the EC50 values of ATP and DBzATP in HOB cells to those in MG63 
and SaOS2 cells. No significant differences were seen.
The results obtained in this project were compared with those reported 
by Gartland et al (2001) on HOB cells using the same concentrations of 
ATP and DBzATP. Figure 7.5A shows the YO-PRO 1 uptake obtained 
with lxlO ' 3 M and 5x1 O'4 M ATP and DBzATP by Gartland et al (2001). 
ATP and DBzATP at the same concentrations produced similar YO-PRO 
1 uptake in my HOB cells (Figure 7.5B).
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To compare YO-PRO 1 uptake in HOB cells with that in MG63 and 
SaOS2 cells, Figure 7.6 shows the YO-PRO 1 uptake obtained with 
lxlO ' 3 M and 5X10"4 M ATP and DBzATP in these cells corrected for 
cell number. The YO-PRO 1 uptake was found to be significantly higher 
(p value <0.001) in HOB cells compared to both MG63 and SaOS2 cells.
7.4.3 IL-6 Release
Basal IL-6  release in HOB cells was 10.277 ± 4.309 ng/mg protein after 
3 days of cells culture. The basal IL-6  release from HOB cells was found 
to be significantly higher than that in SaOS2 cells (3.8 ± 0.8 pg/mg 
protein, p value<0.05). ATP and DBzATP had no significant effect on 
IL-6  release, either alone or in combination with BBG or 17p-oestradiol 
(Figures 7.7-7.10). BBG and 17p-oestradiol alone had no effect on IL-6  
release.
In another series of experiments basal IL-6  release in HOB cells was 
11.292 ± 6.256 ng/mg protein. ATP significantly increased IL-6  release 
by approximately 40 % compared to control while dexamethasone 
significantly decreased release by 95 % compared to control. The effect 
of ATP was completely reversed by dexamethasone (Figure 7.11).
7.4.4 Mineralisation
Due to limited availability of the HOB cells, a qualitative experiment 
was performed to investigate the effect of P2X7 receptor activation on 
mineralised nodule formation. Both ATP and DBzATP were found to 
reduce mineralised nodule formation compared to control cells (Figure 
7.12). Analysis of the results could not be done as the experiment was
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only carried out twice. No data were obtained for protein content due to 
the limited availability of the cells.
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Figure 7.1: Representative exam ple on RT-PCR o f  FIX* P2X4, P2Xs, and P2X7 
receptor mRNA in HOB cells.
RT-PCR was performed on RNA extracted from HOB cells using primers for the 
human P2X7 (lanes 3 and 4), P2X5 (lanes 6  and 7), P2 X4 (lanes 10 and 11) and P2X2 
(lane 13) receptors. The marker ladder is shown in lanes 1 and 8 , and P2X7, P2X5) 
and P2X* receptor positive controls (MG63 cell cDNA) are shown in lanes 2, 5, and 9, 
respectively. The P2X2 receptor positive control used was pancreas cell cDNA and is 
shown in lane 12. A band of 100 bp was seen in lanes 2 and 3 for MG63 and HOB 
cells, respectively corresponding to the P2X7 receptor. Bands of 200 bp were seen in 
lanes 5 and 6  for MG63 and HOB cells corresponding to the P2X5 receptor and in 
lanes 9 and 10 for MG63 and HOB cells corresponding to the P2 X4 receptor. For 
P2X2 receptors the positive control shown in lane 12 gave a band of 200 bp, while no 
band was seen in the HOB cell sample (lane 13). No bands were seen in lanes 4, 7, 
and 11 when HOB cell RNA samples were incubated without the RT enzyme. [n=3]
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Figure 7.2: P2X7 receptor W estern blotting in HOB, MG63, and  SaOS2 cells.
A representative example of a Western blot for P2X7 receptors. Positive control (10 pg 
of HEK7 cell membrane on lane 1), and 25 pg of HOB (lane 2), MG63 (lane 3), and 
SaOS2 (lane 4) cell lysates were separated on 10% gels. The nitrocellulose 
membrane was probed with the rP2X7 antibody (1:1000). All the samples gave a P2X7 
receptor band at 53 kDa, and a p-actin band at 37 kDa. These bands were quantified 
using densitometry and the ratio of P2X7 receptor expression to p-actin expression is 
shown in B. Data are expressed as mean ± SEM. Statistical analyses were performed 
using one-way ANOVA with Newman-Keuls post-hoc test. *P<0.01, #P<0.001 vs. 
HOB samples. [n=4]
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Figure 7.3: P2X4 receptor W estern blotting in HOB, MG63, and SaOS2 cells.
A representative example of a Western blot for P2 X4 receptors. Positive control (60 pg 
of rat brain on lane 1), and 25 pg of HOB (lane 2), MG63 (lane 3), and SaOS2 (lane 4) 
cell lysates were separated on 10% gels. The nitrocellulose membrane was probed 
with the rP2X* antibody (1:1000). All the samples gave a P2)C* receptor band at 56 
KDa, and a p-actin band at 40 kDa. These bands were quantified using densitometry 
and the ratio of P2 X4 receptor expression to (3-actin expression is shown in B. Data 
are expressed as mean ± SEM. Statistical analyses were performed using one-way 
ANOVA with Newman-Keuls post-hoc test. *P<0.05 vs. HOB samples. [n=3]
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Figure 7.4: Concentration-effect curves for ATP and DBzATP in HOB cells.
HOB cells (approximately 40,000 cells/well) were incubated with each agonist and 1 
pM YO-PRO 1 in assay buffer-A at 37°C for 5 minutes. YO-PRO 1 fluorescence was 
monitored in a 96-well plate reader using an excitation wavelength of 485 nm, and an 
emission wavelength of 520 nm. Data were plotted as % maximum ± SEM YO-PRO 1 
uptake for each agonist. [n= 4],
Aaonist MG 63 SaOS2 HOB
EC an (mM) 
±SEM
EC on (mM) 
±SEM
EQgo
(mM)±SEM
ATP 0.36 ±0.03 0.43 ±0.02 0.53 ±0.03
DBzATP 0.5± 0.04 0.36± 0.04 0.54± 0.02
Table 7.1: ECso values for ATP and DBzATP in MG63, SaOS2, and HOB cells.
Statistical analyses were performed using one-way ANOVA with Newman-Keuls post- 
hoc test, but no significant differences were seen.
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Figure 7.5: YO-PRO 1 uptake induced by  1x10* M and 5x10 4 M ATP and DBzATP 
in HOB cells.
A comparison between the results obtained by Gartland et al (2001) for several 
populations of HOB cells using ethidium bromide and an hour incubation with the 
agonists (A) and the results obtained in this project (B) with the same concentrations 
of ATP and DBzATP. Data are expressed as % of control ± SEM. Statistical analyses 
were performed using Student’s t-test between each concentration of ATP and 
DBzATP for the data obtained here. No significant differences were seen. [n=4], A 
adapted from Gartland et al (2001).
242
P2X7 Receptors in Osteoblasts
>- w
DHOB 
BMG63 
□ SaOS2
Figure 7.6: Comparsiosn o f YO-PRO 1 uptake induced b y  1x1 CT3 M and 5x1 O'4 M 
ATP and DBzATP in HOB, MG63, and SaOS2 cells.
Approximately 40,000 HOB cells/well and 100,000 MG63 and SaOS2 cells/well were 
incubated with each agonist and 1 pM YO-PRO 1 in 0.5 mM assay buffer-A at 37°C 
for 5 minutes. YO-PRO 1 fluorescence was monitored in a 96-well plate reader using 
an excitation wavelength of 485 nm, and an emission wavelength of 520 nm. Data 
were corrected for cell number. Data are expressed as mean ± SEM. Statistical 
analyses were performed using one-way ANOVA with Newman-Keuls post-hoc test. # 
P<0.001 vs. HOB cells. [n=4 - 45].
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Figure 7.7; Effect o f  ATP and BBG on IL-6 release in HOB cells.
Cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour then ATP 
4x10'5M or water (ATP vehicle) were added and the cells were grown for 3 days. 
Media and cells were then collected for IL-6 and protein assays. IL-6 data were 
corrected for protein content. Data are expressed as percentage of control ± SEM. 
Statistical analyses were performed using one-way ANOVA with Newman-Keuls post- 
hoc test. No significant differences were seen.(n=3)
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Figure 7.8: Effect o f  DBzATP and BBG on IL-6 release in HOB cells.
Cells were incubated with BBG 5x1 O'6 M or water (BBG vehicle) for one hour then 
DBzATP 1x1 O'6 M or water (DBzATP vehicle) were added and the cells were grown for 
3 days. Media and cells were then collected for IL-6 and protein assays. IL-6 data 
were corrected for protein content. Data are expressed as percentage of control ± 
SEM. Statistical analyses were performed using one-way ANOVA with Newman-Keuls 
post-hoc test. No significant differences were seen. (n=3)
CTRL DBzATP BBG BBG+DBzATP
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Figure 7.9: Effect o f  ATP and 17^-oestradiol on IL-6 release in HOB cells.
Cells were incubated with 17p-oestradiol 1x10'5 M or 0.5 % ethanol (17p-oestradiol 
vehicle) for 30 minutes then ATP 4x10'5M or water (ATP vehicle) were added and the 
cells were grown for 3 days. Media and cells were then collected for IL-6 and protein 
assays. IL-6 data were corrected for protein content. Data are expressed as 
percentage of control ± SEM. Statistical analyses were performed using one-way 
ANOVA with Newman-Keuls post-hoc test. No significant differences were seen. (n=3)
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Figure 7.10: Effect o f  DBzATP and  17f3-oestradiol on IL-6 release in HOB cells.
Cells were incubated with 17p-oestradiol 1x10'5 M or 0.5 % ethanol (17p-oestradiol 
vehicle) for 30 minutes then ATP 4x10'5M or water (ATP vehicle) were added and the 
cells were grown for 3 days. Media and cells were then collected for IL-6 and protein 
assays. IL-6 data were corrected for protein content. Data are expressed as 
percentage of control ± SEM. Statistical analyses were performed using one-way 
ANOVA with Newman-Keuls post-hoc test. No significant differences were seen. (n=3)
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Figure 7.11: Effect o f  ATP and dexam ethasone on IL-6 release in HOB cells.
Cells were incubated with dexamethasone 5x1 O'6 M or 0.5 % ethanol (dexamethasone 
vehicle) for 30 minutes then ATP 4 x 1 0 ^  or water (ATP vehicle) were added and the 
cells were grown for 3 days. Media and cells were then collected for IL-6 and protein 
assays. IL-6 data were corrected for protein content. Data are expressed as 
percentage of control ± SEM. Statistical analyses were performed using one-way 
ANOVA with Newman-Keuls post-hoc test. **P<0.01, #P<0.001 vs. control or ATP. 
(n=3)
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Experiment 1
Experiment 2
Figure 7.12: Effect o f  ATP and DBzATP on m ineralised bone nodule formation in 
HOB cells.
Cells were grown for 3-4 weeks with ATP 4x10'5M, DBzATP 1x10"® M or water (ATP 
and DBzATP vehicle) replenished twice weekly, then cells were stained with alizarin 
red. (n=2) A: ATP, B: DBzATP, C: Control.
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7.5 Discussion
This chapter investigated the expression of P2X7 receptors in HOB cells 
at the mRNA and protein levels. Additionally, the effect of P2X7 receptor 
activation on YO-PRO 1 uptake, IL-6  release, and bone nodule 
formation were also studied.
7.5.1 P2Xt receptor expression
The results described in this chapter demonstrated expression of P2X7 
receptors by HOB cells at the mRNA and protein levels. Additionally, 
expression of two other pore-forming P2X receptors, i.e. P2 X4 and P2X5, 
was also seen.
In Western blotting bands were seen at 53 ± 1.5 kDa and 55 ± 1.4 kDa 
corresponding to P2 X4 and P2X7 receptors, respectively. The 85 kDa 
band claimed by some studies to be the mature and functional form of 
the receptor was absent in all the experiments performed. However, the 
60 kDa band, believed to be the mature and functional form of the 
receptor in MG63 and SaOS2 cells, was labelled clearly. These results 
suggest that the 60 kDa band of the P2X7 receptor is the functional form 
in the human primary osteoblasts in addition to the osteoblastic-like cell 
lines tested (MG63 and SaOS2 cells). The P2X7 receptor band was seen 
previously in MG63 and SaOS2 cells samples at 6 8  kDa and 54kDa. The 
54 kDa band corresponds to the deglycosylated form of the receptor and, 
due to a change in the batch of the primary antibody used, it only 
appeared to recognise this form of the receptor.
Densitometric analysis of the Western blotting bands when normalised 
using p-actin revealed that the expression of P2X7 receptors by HOB 
cells was significantly higher than in MG63 and SaOS2 cells. The reason
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for the difference in expression between these cell lines and primary cells 
is not clear, but may be due to higher synthesis of the receptor by the 
primary cells. Due to limited availability of the HOB cells, the 
subcellular localisation of the receptor could not be studied.
Neither P2X2 receptor mRNA nor protein (data not shown) were detected 
in HOB cells suggesting that the receptor is not expressed in these cells. 
Positive controls for the PCR primers and antibody demonstrated that the 
P2X2 receptor mRNA and protein could be detected by both methods. 
Similar results were found in MG63 and SaOS2 cells. However, P2X4 
receptor mRNA and protein were identified in HOB cells. Densitometric 
analysis of the Western blotting bands revealed that the expression of 
P2X4 receptors by HOB cells is also significantly higher than MG63 
cells, which might again due to greater synthesis of this receptor by the 
primary cells compared to cell lines. Additionally, expression of P2X5 
receptors was also examined following a study claiming it can also form 
a pore (Bo et al., 2003). Using RT-PCR, the presence of P2X5 receptor 
mRNA was identified.
Thus, to summarize, the results presented here confirm earlier findings in 
MG63 and SaOS2 cells that human osteoblasts do not express P2X2 
receptors. Therefore, primary human osteoblasts express three potential 
pore-forming purinergic receptors, P2 X4, P2X5 and P2X7. Additionally, 
the increased expression in the HOB cells compared to MG63 and 
SaOS2 cells, suggests that P2X* and P2X7 receptors have a role in these 
HOB cells.
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7.5.1 P2Xt receptor functional studies
Significantly higher expression of P2X7 receptors by HOB cells 
compared to MG63 and SaOS2 cells allowed the use of fewer HOB cells 
for the YO-PRO 1 uptake, IL-6 release, and mineralised bone nodule 
formation studies.
The YO-PRO 1 results demonstrated that ATP and DBzATP were weak 
agonists (EC5o values in the millimolar level). These results were similar 
to those obtained in MG63 and SaOS2 cells where DBzATP showed 
similar effects in opening the pore (Table 7.1) and was equipotent to 
ATP. A likely explanation for this is that the P2X7 receptor is behaving 
differently in cells expressing endogenous receptors compared to 
transfected cells in which most of the previous studies have been done. 
Interestingly, the similar EC50 values for the agonists in HOB cells and 
cell lines makes the possibility of the influence of high receptor number 
on potency less likely. This is based on the significantly higher 
expression of the receptor in the HOB cells which allowed the use of a 
lower number of cells for this assay. Alternatively, a P2X7 receptor 
heterodimer with other P2X receptors could be involved, a possibility 
that very recently been reported in other cells for P2 X4 and P2X7 
receptors (Guo et al., 2007). This would not occur in transfected cells. 
Additionally, Gartland et al. (2001) described inconsistencies in ethidium 
uptake between ATP and DBzATP in some populations of primary 
human osteoblasts. The atypical pharmacology of the P2X7 receptor 
identified in MG63 and SaOS2 cells (discussed in detail in Chapter 4) 
based on the low potency of DBzATP, also occurs in HOB ceils. The 
data obtained here were similar to those obtained by Gartland et al 
(2001) in several populations of HOB cells, strengthening the hypothesis 
about the atypical pharmacology of P2X7 receptors in osteoblasts. Thus, 
results in HOB cells confirm earlier findings in MG63 and SaOS2 cells.
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Although the results of P2X7 receptor activation on IL-6 release from 
HOB cells are preliminary, they suggest that the P2X7 receptor possibly 
does not play a role in IL-6 release from these cells. These results are 
opposite to those from SaOS2 cells, where ATP was found to play an 
important role in IL-6 release (see Chapters 5 and 6). The basal IL-6 
release from HOB cells was found to be significantly higher than SaOS2 
cells. An increase in IL-6 release from HOB cells with ATP was not seen 
when water was used as a vehicle (Figure 7.7), but an increase was seen 
when ethanol was used as a vehicle (Figure 7.11). Therefore the increase 
in IL-6 release might be due to an effect of ethanol on the cells. An effect 
of ethanol on ATP-induced currents in other P2X receptors was reported 
previously in the literature (Davies et al., 2006). A possible reason for 
the absence of an effect of ATP on IL-6 release from HOB cells is that 
the release from these cells is already maximal and can not be increased 
further. Further work is needed to confirm this.
The suppression of IL-6 release by dexamethasone was expected due to 
its potent anti-inflammatory action. The apparent reversal of the ATP 
effect is likely to be due to the strong dexamethasone anti-inflammatory 
effect (Payne and Adcock, 2001; Valledor and Ricote, 2004; Barnes, 
2006) and not direct inhibition. 17p-oestradiol did not show any effect on 
IL-6 release either alone or in combination with ATP in HOB cells. 
However, ATP-induced IL-6 release was enhanced in SaOS2 cells by 
17p-oestradiol. Again, the high basal release of EL-6 by HOB cells may 
explain these differences.
The effect of P2X7 activation on IL-ip release from HOB cells could not 
be performed due to limited availability of the cells, but preliminary 
experiments showed that the basal release of IL-ip from these cells is 
approximately 1-fold lower than SaOS2 cells (data not shown).
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The results of P2X7 receptor activation on mineralised nodule formation 
in HOB cells are preliminary, but very interesting as they suggest that the 
P2X7 receptor plays an important role in this physiological action of 
primary osteoblasts. Due to limited availability of the HOB cells, protein 
assays could not be performed in these experiments, but no toxicity of 
ATP and DBzATP was observed by visual examination of the cells. 
Inhibition of mineralised bone nodule formation in response to ATP has 
been observed previously in rat osteoblasts, but it was claimed to be via 
P2Y2 receptors (Hoebertz et al., 2002). This possibility can not be 
excluded here although the DBzATP results suggest it to be unlikely as 
DBzATP is not an agonist at P2Y2 receptors (Ziganshin et al., 2002; 
Bumstock, 2007). Again, the presence of ethanol as a vehicle raises a 
question as to its involvement in mineralization inhibition by ATP, 
which needs to be clarified.
The absence of any effect of DBzATP on IL-6 release might be due to its 
lower concentration, or its binding by the serum constituents. 
Conversely, the effect of DBzATP on mineralisation was clear which 
might be due to the increased length of treatment.
The IL-6 release and mineralised bone nodule formation data in HOB 
cells are different than those in SaOS2 cells. These differences suggest 
that P2X7 receptors modulate IL-6 release in SaOS2 cells but not 
mineralisation and vice versa in HOB cells. Therefore, SaOS2 cells do 
not appear to be a good model for some aspects of osteoblast function.
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7.6 Conclusion
The results presented in this chapter demonstrate that the P2X7 receptor 
is expressed and functional in HOB cells. The 60 kDa form of the 
receptor appears to be the mature and functional form of the receptor in 
the human osteoblast. Additionally, P2X7 receptor protein expression 
was found to be significantly higher in HOB cells compared to the cell 
lines MG63 and SaOS2, and this was translated into significantly higher 
YO-PRO 1 uptake. However, the EC50 values for ATP and DBzATP 
were found to be similar in the HOB cells and the cell lines, confirming 
the atypical pharmacology. Similarly to the MG63 and SaOS2 cell lines, 
HOB cells also express P2X$ and P2X5 receptors, but not P2X2 
receptors.
The P2X7 receptor appears to control IL-6 release in SaOS2 cells and 
mineralised bone nodule formation in HOB cells. However, my results 
generally suggest SaOS2 cells to be a reasonable model for HOB for the 
pharmacological assays of P2X7 receptors but not for the physiological 
functions.
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Chapter 8: General 
Discussion
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8.1 General discussion of results
The general aim of this project was to characterise the expression and 
function of P2X7 receptors in human osteoblasts. Additionally, the 
effects of P2X7 receptor activation on several physiological functions of 
osteoblasts were studied. The results obtained in this project indicate that 
human osteoblasts express P2X7 receptors. Furthermore, they are 
functional and probably play an important role in osteoblast function by 
increasing ALP activity and IL-6 release and decreasing mineralisaion.
8.1.1 Expression of P2X7 receptors bv human osteoblasts
In this study I have confirmed the expression of the P2X7 receptor in 
human osteoblasts both in primary human osteoblasts and in the MG63 
and SaOS2 osteosarcoma cell lines. I showed receptor expression at the 
mRNA level using RT-PCR and at the protein level using Western 
blotting and immunocytochemistry. With immunocytochemistry I found 
that the immunolabelling was stronger on the nucleus compared to the 
cytoplasm and cell membrane when the P2X7 receptor antibodies was 
used. A similar finding was observed in Western blotting as the band 
seen in the nuclear samples was stronger than that seen in the cell 
membranes or lysate. However, quantification could not be performed 
due to alterations in house-keeping gene protein (P-actin and GAPDH) 
expression with ceil density.
The fully functional form of all P2X receptors is believed to be the 
glycosylated form (North, 2002). The functional P2X7 receptor was 
claimed to be the 85 kDa form as it was reported to be the fully 
glycosylated form, and the 67 kDa form was said to be a deglycosylated 
form (Wang et al., 2005). However, all the results obtained in this project 
indicate that the 67 kDa form of the receptor is the functional state, and
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that the 85 kDa band was either absent or a minor state as it gave a faint 
band in the experiments performed. Deglycosylation of the P2X7 
receptor was carried out in membrane samples of MG63 and SaOS2 cells 
and it was found that the receptor band size (67 kDa) decreased by 
approximately 9 kDa to 58 kDa. It should be noted that all three bands 
observed (85, 67 and 58 kDa) disappeared when the primary antibody 
was incubated with peptide used to raise it, suggesting that they are 
indeed different forms of the P2X7 receptor. The 85 kDa band might be 
the extra protein needed for pore formation according to a hypothesis 
suggested in the literature (North, 2002; Faria et al., 2005; Liang and 
Schwiebert, 2005). An alternative explanation for this 85 kDa band 
might be that it is a P2 X4/P2 X7 heteromer, which was suggested in a 
recent study (Guo et al., 2007). Another possible explanation might be 
that the functional form of the receptor differs from one cell type to 
another and it is the 67 kDa form in human osteoblasts, but the 85 kDa 
form in CaSki cells (transformed cervical epithelial cells) (Wang et al., 
2005).
The expression of other pore-forming P2X receptors (P2X2, P2 X4 and 
P2X5) was studied to see whether other receptor subtypes could be 
responsible for the results obtained. Expression of P2 X4 and P2X5, but 
not P2X2 receptors was demonstrated in human primary osteoblasts, 
MG63 and SaOS2 cell lines. Presence of P2 X4 receptor supports the 
possibility of existence of P2 X4/P2 X7 heteromer that very recently been 
reported in other cells (Guo et al., 2007). Therefore, it is possible that 
these receptors could mediate some of the effects of the P2X receptor 
agonists described below.
Interestingly the expression of the P2X7 receptor protein by human 
primary osteoblasts was found to be significantly greater than MG63 and
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SaOS2 cells, suggesting that the primary cells synthesize higher amounts 
of the receptor compared to the cell lines. Similarly, expression of P2 X4 
receptor protein by human primary osteoblasts was also found to be 
significantly greater than MG63 cells only. These results suggest that 
both these receptor types play a role in human primary osteoblast 
functions.
8.1.2 Pharmacological characterisation of P2Xt receptors 
in human osteoblasts
Once P2X7 receptor expression had been confirmed in human 
osteoblasts, the pharmacological characterisation of the receptor was 
studied using the YO-PRO 1 uptake method. This method utilizes the 
pore-forming characteristic of the P2X7 receptor and YO-PRO 1, a dye 
which fluoresces after entering the cell through the pore and binding to 
nucleic acid. This assay is well known for the pharmacological study of 
the P2X7 receptor (Michel et al., 1999; Gartland et al., 2001; Michel et 
al., 2006b). Pore formation in human osteoblasts was found to occur 
within 5 minutes of incubating the cells with the agonist, in contrast to 
results from Gartland et al (2001) showing that an hour was needed for 
pore formation. These findings led these authors to suggest an atypical 
pharmacology of the P2X7 receptor in human osteoblasts. Based on 
different data, atypical pharmacology can also be applied to the P2X7 
receptors in this project as DBzATP was found to be equipotent to ATP. 
DBzATP is thought to be the best P2X7 receptor agonist based on results 
in the literature showing it to be at least 10-fold more potent compared to 
ATP on P2X7 receptors (Chessell et al., 1998; Michel et al., 1999; Lee et 
al., 2006). However, these studies were performed in transfected cells. 
Other studies performed in native cells have found DBzATP to be 
inactive (Cario-Toumaniantz et al., 1998) or equipotent to ATP
257
P2X7 Receptors in Osteoblasts
(Hickman et al., 1994; Gartland et al., 2001) at P2X7 receptors. Other 
agonists, 2Me-S-ATP and ATP-y-S were also tested and their EC5o 
values were found to be similar to those of ATP and DBzATP. The EC50 
values obtained suggest that the receptor involved in the YO-PRO 1 
uptake is P2X7 and not P2X2, P2Xj, or P2X5 receptors. The reason for 
the equipotency of these agonists might be the atypical pharmacology of 
the receptor in human osteoblasts as stated earlier. Another explanation 
might be a P2X4/P2 X7 receptor heteromer, suggested to exist in a recent 
study (Guo et al., 2007). However, the overall affinities of the agonists 
used in inducing pore formation and the lack of receptor desensitisation 
seen with ATP (3xl0‘ M) indicate that the P2X7 receptor is most likely 
to be responsible for YO-PRO 1 uptake.
This hypothesized atypical pharmacology of die osteoblast P2X7 receptor 
may also explain the results obtained with the antagonists BBG, KN62, 
oATP and PPADS on ATP- and DBzATP-induced YO-PRO 1 uptake. 
Although these antagonists were found to behave in a non-competitive 
manner, similar to data reported in die literature in other cell lines 
(Michel et al., 2000), their antagonist action in human osteoblasts was 
found to be weak. The effect of BBG here is most probably on P2X7 
receptors as it was reported to be more potent at P2X7 receptors 
compared to the other P2X receptor subtypes (Hibell et al., 2000; Jiang 
et al., 2000; Khakh et al., 2001b; Sperlagh et al., 2006). Although KN62 
is reported in the literature to be the most potent human P2X7 receptor 
antagonist (Sperlagh et al., 2006), that was not found here as it was very 
weakly active. Although the atypical pharmacology of the osteoblast 
P2X7 receptor is the most likely explanation for the data with the 
antagonists, a P2 X4/P2 X7 receptor heteromer could also be involved.
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8.1.3 Effect of P2X7 receptor activation on human 
osteoblast function
P2X7 receptor activation was found to increase ALP production and IL-6 
release from the SaOS2 cell line and these effects were blocked by BBG. 
The effect of DBzATP on ALP production and IL-6 release was either 
absent or weak. The absence of an effect with DBzATP on ALP and IL-6 
raises a question as to the involvement of the P2X7 receptor. However, 
the BBG inhibition of ATP-induced ALP production and IL-6 release 
suggests that the ATP effect is most likely to be via P2X7 receptors and 
not adenosine or P2Y receptors as BBG has no effect on these receptors. 
A possible explanation for the weak action of DBzATP might be the 
hypothesized atypical pharmacology of P2X7 receptors in human 
osteoblasts. However, low concentrations of DBzATP, below the EC50 
value obtained in the YO-PRO 1 assay which had to be used to avoid cell 
death might be a reason also. Another explanation might be that some of 
the serum constituents available in the medium might be binding 
DBzATP and reducing its potency, an effect reported previously for 
DBzATP on ethidium bromide uptake (Michel et al., 2001).
In contrast to previous studies reporting the involvement of P2X7 
receptors in IL-lp release in other cells (Ferrari et al., 1997; Solle et al., 
2001; Labasi et al., 2002; Qu et al., 2007), no effect was seen here. This 
suggests either that the P2X7 receptor is not involved in IL-ip release 
from osteoblasts, or that the agonist concentrations used here are lower 
than those found under physiological conditions which are needed to 
stimulate its release. However, the latter reason is unlikely as the agonist 
concentrations used here caused IL-6 release, unless IL-ip and IL-6 are 
released by different mechanisms. A more likely explanation might be 
that lipo-polysaccharide is needed for P2X7 receptor-induced IL-ip 
release, an effect which is still debatable (Ferrari et al., 2006). An effect
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on bone nodule formation was only observed with ATP when ethanol 
was used as the vehicle suggesting that this effect is probably not due to 
P2X7 receptor activation.
8.1.4 P2X7 receptor channel versus pore formation
Activation of the P2X7 receptor passes through two stages, channel 
opening and pore formation (North, 2002). The channel is permeable to 
small cations such as calcium (North, 2002; Dubyak, 2007) and opened 
by low concentrations of agonists (North, 2002; Bumstock, 2007; 
Dubyak, 2007). The pore, however, is opened by higher concentrations 
of agonists, is permeable to large cations (<900Da) and is the end stage 
leading to cell death unless the agonist is removed (Ferrari et al., 1997; 
North, 2002; Bumstock, 2007). Effects on the physiological actions 
(ALP production and IL-6 release) of osteoblasts were observed here 
with ATP at concentrations lower than those which induce YO-PRO 1 
uptake suggesting that pore formation is not necessary for these effects. 
Therefore, these actions are most probably related to the P2X7 receptor 
channel opening in response to lower concentrations of ATP and an 
increase in intracellular calcium. Alternatively, another unknown second 
messenger might be involved.
8.1.5 Effect of 17B-oestradiol and dexamethasone on 
P2Xt receptor expression and function in human 
osteoblast
17p-oestradiol and dexamethasone were found to affect P2X7 receptor 
function in the SaOS2 cell line, an effect likely to be via a non-genomic 
mechanism. They could be acting as weak, non-competitive antagonists 
in blocking YO-PRO 1 uptake with no effect on P2X7 receptor
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expression. Dexamethsone had no effect on ALP release, but decreased 
ATP-induced IL-6 release after 3 days incubation, probably as a 
consequence of its potent anti-inflammatory action. The unexpected 
increase in ATP-induced IL-6 release by dexamethasone after 6 days 
incubation might be due to an upregulation of P2X7 receptors (although 
this was not tested). The effect of dexamethasone on P2X7 receptors in 
osteoblasts is not conclusive and more work is needed. No effect of P2X7 
receptor activation on IL-lp release was seen except when ethanol was 
used as a vehicle with the agonists, demonstrating that this action is not 
P2X7 receptor induced. 17P-oestradiol was reported in the literature to 
increase ALP production (O’Shaughnessy et al., 2000; Rao et al., 2003; 
Kanno et al., 2004) and to decrease (Waters et al., 2001; Manolagas et 
al., 2002; Straub, 2007), or have no effect (Dovio et al., 2001) on IL-6 
release. Dexamethasone was reported to increase ALP production (Yang 
et al., 2003; Jorgensen et al., 2004; Eijken et al., 2006) and decrease IL-6 
release (Dovio et al., 2001; Payne and Adcock, 2001; Chen et al., 2005; 
Barnes, 2006). The results obtained in this project for 17p-oestradiol and 
dexamethasone are contradictory to those reported in the literature, 
which might be due to the cell type used (primary cells or cell lines), 
oestrogen receptor isoform expressed (a or p), and receptor density.
8.1.6 Expression and function of P2XZ receptors in 
primary human osteoblast
Altough preliminary, the results obtained with the primary human 
osteoblast cells supported the earlier findings with the SaOS2 and MG63 
cell lines in that the primary osteoblasts expressed functional P2X7 
receptors involved in many of the physiological actions of osteoblasts 
(IL-6 release and nodule formation). Additionally, the YO-PRO 1 assay 
results confirmed the hypothesis of atypical pharmacology of P2X7
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receptors in human osteoblasts. The P2X7 receptor-induced decrease in 
bone nodule formation in the primary cells was particularly interesting 
and unexpected.
8.1,7 Osteoblast model for the study of P2X? receptors
At the end of this project, it is possible to suggest which might be the 
best osteoblast model for studying P2X7 receptors. The MG63 cell line 
would be a good model for the pharmacological characterization of P2X7 
receptors using the YO-PRO 1 assay. However, these cells are not 
suitable for studying P2X7 receptor-mediated effects on ALP activity or 
bone nodule formation as it was reported that they don’t produce ALP or 
form nodules (Hughes and Aubin, 1998). Conversely, the SaOS2 cell 
line is considered to be the closest to the mature osteoblast (Hughes and 
Aubin, 1998) and most of the results I obtained with them were then 
confirmed in primary human osteoblasts, though the results with the 
latter were preliminary. I believe that the SaOS2 cell line represents a 
good model for die study of P2X7 receptors in human osteoblasts, 
although primary cells would clearly be the ideal choice. This is based on 
the following factors: the ease and low cost of growing die SaOS2 cells, 
and the possibility of growing them for a higher number of passages 
compared to the primary human osteoblasts and the similarity of my 
results in the SaOS2 and primary cell,
8.2 Role of P2X? receptors in bone formation
Figure 8.1 shows a summary of the effect of P2X7 receptor activation 
and inhibition on several physiological actions of osteoblasts. Activation 
of the P2X7 receptor with low concentrations of agonist opens a channel
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permeable to small cations such as calcium, which I believe results in the 
release of IL-6 and the production of ALP seen in this project. These two 
proteins are important factors in the pathophysiology of osteoporosis and 
RA. IL-6 is an inflammatory mediator involved in the pathophysiology 
of RA and in communication between osteoblasts and osteoclasts, where 
an imbalance results in osteoporosis. The increase in ALP production 
and release results in an increase in osteoblastic bone formation and a 
disturbance in ALP activity predisposes to osteoporosis. Activation of 
the P2X7 receptor with high concentrations of agonist or prolonged 
activation with low agonist concentrations leads to the formation of a 
pore permeable to large cations (<900 Da) such as YO-PRO 1 or 
ethidium bromide. The consequence of pore formation is usually cell 
death either by apotosis or necrosis, which led to die P2X7 receptor being 
described as a death receptor. All the above actions of P2X7 receptor 
activation are inhibited with BBG, an antagonist more potent on P2X7 
receptors compared to the other P2X receptors.
The results revealed in this project confirm the earlier findings in 
knockout mice reported in the literature on the role of the P2X7 receptor 
in bone formation (Ke et al., 2003). Bone formation in these knockout 
mice was found to be reduced compared to the wild-type animals (Ke et 
al., 2003). The increase in ALP release, a known bone formation marker 
(Bikle, 1997), seen here as a result of P2X7 receptor activation, supports 
the role proposed for P2X7 receptors in bone formation (Ke et al., 2003). 
The effect of P2X7 receptor activation on bone formation is probably 
indirect and this is supported by lack of clear effect on mineralisation in 
SaOS2 cells. The mineralisation results might be due to involvement of 
another purinergic receptor or a vehicle effect However, interestingly in 
HOB cells, preliminary data showed a decrease in nodule formation, 
opposite to the results with knockout mice and my ALP results, so the
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question remains: are P2X7 receptors involved in bone formation? The 
answer is that they most probably are involved, but have a modulatory 
role in bone formation capable of both increasing and decreasing it 
depending on the environment. Additionally, species variations may also 
occur as Ke et al. (2003) worked in mice and my project used human 
cells, but more work is needed to confirm this hypothesis.
17P-oestradiol blocked P2X7 receptor-induced pore formation, which I 
believe to be via a non-genomic mechanism as reported in a previous 
study in other cells (Cario-Toumaniantz et al., 1998). In the literature, the 
effect of oestrogen was reported to increase the activity and lifespan of 
osteoblasts by inhibiting their apoptosis (Manolagas et al., 2002; 
Balasch, 2003; Syed and Khosla, 2005; Jacob et al., 2006) via a non- 
genomic mechanism (Syed and Khosla, 2005). Therefore the reduction in 
pore formation seen here might be another mechanism underlying the 
action of 17p-oestradiol on osteoblast bone formation as pore formation 
is often followed by cell death (Virginio et al., 1999). In the menopause 
bone formation is affected due to oestrogen deficiency and the loss of its 
effect on inhibiting P2X7 receptor-induced osteoblast apoptosis which 
could contribute to osteoporosis.
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Figure 8.1: A diagram sum m arising  the resu lts  obtained in this thesis  showing 
the effect of P2X7 receptor activation and inhibition on the physiological actions of 
osteoblasts and bone formation. Extracellular ATP represents the exogenous and 
endogenous nucleotide. + Activation, - inhibition, t  increase. RA: rheumatoid arthritis.
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The consequences of the action of dexamethasone on P2X7 receptors in 
osteoblasts are less clear, but it is possible to explain some of the effects 
on IL-6. IL-6 is believed to act as a signalling pathway between 
osteoblasts and osteoclasts (Canalis et al., 1991; Lowik, 1992; 
Manolagas, 2000; Fini et al., 2004). IL-6 was shown to stimulate bone 
resorption by stimulating osteoclast differentiation and activity (Lowik, 
1992; Roodman, 1993; Connell and Mclnnes, 2006). Enhancing P2X7 
receptor-inducd IL-6 release by long exposure to dexamethasone will 
result in increasing bone resorption leading to bone loss as seen in 
osteoporosis, a problem seen with long-term steroid use (Manolagas, 
2000; Gregorio et al., 2006; Kanis et al., 2007). However, this finding is 
at odds with the expected result from short incubations where IL-6 
release was reduced by dexamethasone, probably due to its anti­
inflammatory effects. More studies are needed to address this question.
Figure 8.2 shows a summary of the effect of P2X7 receptor activation on 
the signalling pathways between osteoblasts and osteoclasts. The effect 
of ATP on IL-6 release was discussed earlier, and this raised the question 
as to what would happen to two other important osteoblast-derived 
mediators, RANKL and M-CSF. Unfortunately, there was not enough 
time to investigate these molecules further in this project. This is clearly 
an area for future work to address.
Any effect of P2X7 receptor stimulation on RA might be via the increase 
in IL-6 release. IL-6 release was reported to increase in RA and blocking 
its release would improve the disease. Inhibition of IL-6 release would 
inhibit osteoblast-osteoclast signalling pathways resulting in 
prevention/reduction of bone loss arising from osteoclast activity. 
Additionally, the increase in oseoblast apoptosis caused by P2X7 receptor 
activation would result in decreased bone formation. The net result of
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P2X7 receptor activation in RA would be an increase in bone damage 
resulting from increased osteoclastic resorption and decreased 
osteoblastic bone formation. These effects are definitely possible as there 
is a large increase in ATP release caused by inflammatory processes 
(Bours et al., 2006) such as in RA .
Overall, the results presented in this project suggest that oestrogen and 
glucocorticoids may have a direct action on increasing osteoblast 
lifespan via inhibition of P2X7 receptor-induced cell death. Additionally, 
they may have a modulatory action on some of the signalling pathways 
involving the P2X7 receptor.
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8.3 The P2X? receptor as a potential therapeutic 
target for bone diseases
My results suggest that a therapeutic agent acting on P2X7 receptors 
could have potential for the treatment of osteoporosis and RA. The 
importance of this has arisen from the characterisation of the expression 
of P2X7 receptors and their functions in osteoblasts. Additionally, this 
idea is supported by the effect of 17p-oestradiol and dexamethasone on 
P2X7 receptor function and their speculated role in the physiological 
actions of osteoblasts. Based on the results obtained in this project, it is 
possible that we could see a new group of anti-osteoporotic agents. 
Further studies are needed to decide whether a P2X7 receptor agonist or 
antagonist would be useful for treatment of osteoporosis and RA. From 
the current study a P2X7 receptor agonists (ATP and DBzATP) was 
found to increase ALP activity which would result in an increase in bone 
formation. On the other hand a P2X7 receptor antagonist (BBG) was 
found to decrease pore formation which will lead to a decrease in cell 
death and hence increase osteoblast lifespan resulting in an increase in 
bone formation. Additionally this antagonist decreased ATP-induced IL- 
6 release which is believed to be a potent inflammatory mediator and 
involved in osteoblast-osteoclast signalling, so the net effect would be a 
decrease in inflammation and osteoclastogenesis.
An anti-osteoporotic agent which induces osteoblastic bone formation by 
acting on purinergic P2X7 receptors would be novel, as it would be 
acting by a completely different mechanism than the currently available 
agents.
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8.4 Recommendations for future work
The results obtained in this thesis are preliminary in some areas, so need 
to be investigated further. These results also suggest further work to 
learn more about P2X7 receptors in osteoblasts.
• Study a time course for the effect of P2X7 receptor activation on 
IL-6 release in HOB cells.
• Generate concentration-effect curves for P2X7 receptor agonists 
on IL-6 release in HOB cells.
• Investigate the effect of BBG and other P2X antagonists (PPADS 
and oATP) on P2X7 receptor-induced IL-6 release in HOB cells.
• Study the effect of P2X7 receptor activation and inhibition on 
ALP production in HOB cells.
• Investigate further the effect of 17p-oestradiol and dexamethasone 
on P2X7 receptor-induced IL-6 release and ALP production in 
HOB cells.
• Investigate the effect of P2X7 receptor activation and inhibition on 
LPS-induced IL-6 and IL-lp release from SaOS2 and HOB cells.
• Investigate further the effect of P2X7 receptor activation and 
inhibition on mineralised bone nodule formation in HOB cells.
• Study the effect of P2X7 receptor activation and inhibition on 
RANKL and M-CSF release from SaOS2 and HOB cells.
• Study the expression and involvement of P2X4/P2X7 heteromer in 
osteoblast function
Longer-term future studies could include: characterisation of P2X7 
receptors in human osteoporotic osteoblasts, P2X7 receptor-coupled 
signal transduction mechanisms, and electrophysiology of P2X7 receptor 
channels.
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8.5 Conclusion
Bone diseases such as osteoporosis and RA are major risk factors for 
morbidity and mortality, therefore bone research has expanded recently 
as reflected by the many new potential treatments for these bone 
diseases.
In this project expression of functional P2X7 receptors in human 
osteoblasts was confirmed, and 17(3-oestradiol and dexamethasone were 
found to inhibit P2X7 receptor function probably via a non-genomic 
mechanism. Additionally, I found that P2X7 receptor activation increases 
ALP production and IL-6 release, an effect found to be modulated by 
both 17p-oestradiol and dexamethasone. These results suggest that the 
P2X7 receptor is playing a role in bone formation.
P2X7 receptors as targets look to be promising in the bone field generally 
and in the treatment of osteoporosis and RA in particular. The 
importance of this depended on the identification of P2X7 receptor 
expression and function in osteoblasts and the role of the agents known 
to have an effect in osteoporosis. Based on the results obtained in this 
project, the potential for P2X7 receptors as a target for a new group of 
anti-osteoporotic agents has been highlighted.
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